Cyclized 2-amino-3-cyanothiophenes and derivatives for cancer treatment
Cyclized 2-amino-3-cyanothiophenes and derivatives provide effective KRAS inhibition for treating cancers with KRAS mutations or wild-type amplification, addressing the inadequacies of current treatments by inhibiting KRAS activity and demonstrating anti-tumor efficacy with favorable pharmacological properties.
Patent Information
- Application Number
- JP2024532457
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-26
AI Technical Summary
Current treatments for cancers mediated by KRAS mutations or wild-type KRAS amplification are inadequate, and there is a need for compounds that effectively inhibit KRAS activity while possessing desirable pharmacological properties such as metabolic stability, plasma protein binding, and solubility.
Development of cyclized 2-amino-3-cyanothiophenes and derivatives that act as KRAS inhibitors, specifically targeting KRAS mutations at positions 12 or 13, including G12D, G12V, and G13D, or inhibiting amplified wild-type KRAS, with properties like metabolic stability, solubility, and permeability.
The compounds demonstrate anti-tumor activity by inhibiting uncontrolled cell proliferation in cancers with KRAS mutations or wild-type amplification, offering selective inhibition and desirable pharmacokinetic properties.
Smart Images

Figure 2024543967000001_ABST
Abstract
Description
[Technical Field]
[0001] FIELD OF THE INVENTION The present invention relates to a compound of formula (I) [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , Z, R 3 ~R 5 , A, p, U, V and W have the meanings given in the claims and the specification. and derivatives thereof, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use in medicinal / medical applications, in particular as drugs for treating and / or preventing cancer diseases, e.g., cancer.
[0002] Background of the Invention V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is a small GTPase of the Ras family, which exists intracellularly in either a GTP- or GDP-bound state (McCormick et al., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Nimnual et al., Sci. STKE., 2002, 2002(145):pe36). Binding of GTPase-activating proteins (GAPs), such as NF1, enhances the GTPase activity of Ras family proteins. Binding of guanine nucleotide exchange factors (GEFs), such as SOS1 (Son of Sevenless 1), promotes the release of GDP from Ras family proteins, allowing GTP binding (Chardin et al., Science, 1993, 260(5112):1338-43). In their GTP-bound state, Ras family proteins are active and associate with effector proteins, including c-RAF and phosphoinositide 3-kinase (PI3K), to promote the RAF / mitogen- or extracellular signal-regulated kinase (MEK / ERK) pathway, the PI3K / AKT / mammalian target of rapamycin (mTOR) pathway, and the RalGDS (Ral guanine nucleotide dissociation stimulator) pathway (McCormick et al., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Rodriguez-Viciana et al., Cancer Cell. 2005, 7(3):205-6). These pathways affect diverse cellular processes, such as proliferation, survival, metabolism, motility, angiogenesis, immunity, and growth (Young et al., Adv. Cancer Res., 2009, 102:1-17; Rodriguez-Viciana et al., Cancer Cell. 2005, 7(3):205-6).
[0003] Cancer-associated mutations in Ras family proteins suppress their intrinsic and GAP-induced GTPase activities, leading to an increase in the population of GTP-bound / active mutant Ras family proteins (McCormick et al., Expert Opin. Ther. Targets., 2015, 19(4):451-4; Hunter et al., Mol. Cancer Res., 2015, 13(9):1325-35). This, in turn, leads to sustained activation of effector pathways downstream of the mutant Ras family proteins (e.g., the RAF / MEK / ERK, PI3K / AKT / mTOR, and RalGDS pathways).
[0004] KRAS mutations (e.g., amino acids G12, G13, Q61, A146) are found in a variety of human cancers, including lung, colon, and pancreatic cancers (Cox et al., Nat. Rev. Drug Discov., 2014, 13(11):828-51). In addition, alterations in Ras family proteins / Ras genes (e.g., mutations, overexpression, gene amplification) have also been reported as a mechanism of resistance to anticancer drugs, such as the EGFR antibodies cetuximab and panitumumab (Leto et al., J. Mol. Med. (Berl). 2014 Jul;92(7):709-22) and the EGFR tyrosine kinase inhibitor osimertinib / AZD9291 (Ortiz-Cuaran et al., Clin. Cancer Res., 2016, 22(19):4837-47; Eberlein et al., Cancer Res., 2015, 7 5(12):2489-500).
[0005] In oncology indications, such as gastric cancer, gastroesophageal junction cancer, and a subset of esophageal cancers, significant amplification of the wild-type (WT) KRAS proto-oncogene acts as a driver alteration, and tumor models harboring this genotype are KRAS-addicted in vitro and in vivo (Wong et al. Nat Med., 2018, 24(7):968-977). In contrast, WT cell lines lacking KRAS amplification are KRAS-independent unless they contain secondary alterations in the gene that indirectly cause KRAS activation (Meyers et al., Nat Genet., 2017, 49:1779-1784). Based on these data, KRAS-targeting agents with activity targeting KRAS WT are expected to have a therapeutic window.
[0006] For example, genetic alterations affecting codon 12 of KRAS result in the replacement of the glycine residue normally present at this position with a different amino acid, such as aspartic acid (G12D mutation or KRAS G12D), cysteine (G12C mutation or KRAS G12C), or valine (G12V mutation or KRAS G12V). Similarly, mutations within codons 13, 61, and 146 of KRAS are commonly found in the KRAS gene. KRAS mutations are detectable in 35% of lung cancers, 45% of colon cancers, and up to 90% of pancreatic cancers (Herdeis et al., Curr Opin Struct Biol., 2021, 71:136-147).
[0007] In summary, degraders / inhibitors of wild-type or mutant KRAS (eg, G12D, G12V, and G12C) are expected to provide anti-cancer effects.
[0008] Thus, there is a need to develop novel compounds that are effective in treating cancers mediated by KRAS, particularly KRAS mutated at positions 12 or 13, and / or cancers mediated by amplification of wild-type KRAS, that also possess desirable pharmacological properties, including (but not limited to) metabolic stability, plasma protein binding, solubility, and permeability.
[0009] Detailed Description of the Invention Now, surprisingly, it has been found that the compound of formula (I) [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , Z, R 3 ~R 5 , A, p, U, V and W have the above mentioned meanings. It has been found that the compound of the formula: acts as an inhibitor of KRAS and is involved in the control of cell proliferation, and therefore the compound of the present invention can be used, for example, to treat diseases characterized by excessive or abnormal cell proliferation.
[0010] Surprisingly, it has been found that the compounds described herein have antitumor activity and are useful for inhibiting uncontrolled cell proliferation caused by malignant diseases. This antitumor activity is believed to be particularly due to the inhibition of KRAS mutated at position 12 or 13, preferably G12D, G12V or G13D mutant KRAS, or the inhibition of WT KRAS, particularly amplified KRAS WT. Advantageously, the compounds may be selective for a specific KRAS mutant, preferably KRAS G12D, or may be effective against a panel of KRAS mutants, including amplification of KRAS wild type.
[0011] In addition, compounds of the present invention advantageously possess desirable pharmacological properties including, but not limited to, metabolic stability, plasma protein binding, solubility, and permeability.
[0012] Thus, in a first aspect, the present invention provides a compound of formula (I) [ka] [In the formula, R 1a and R 1b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; R 2a and R 2b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; and / or In some cases, R 1a or R 1b One of the following and R 2a or R 2b are joined together with the carbon atom to which they are attached to form a cyclopropane ring, Z is -(CR 6a R 6b ) n - and Each R 6a and R 6b is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4Alkyl)2, C 3-5 independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; R 6a and R 6b together with the carbon atoms to which they are attached form a cyclopropane ring, n is selected from the group consisting of 0, 1 and 2; R 3 is a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -N3, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls may be substituted with one or more of the same or different R 7 and / or R 8 and optionally and independently substituted by Each R 7 is halogen, -CN, -OR 8 , -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and the divalent substituent =O; Each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls may be substituted with one or more of the same or different R 9 and / or R10 and optionally substituted by Each R 9 -OR 10 , -NR 10 R 10 and -C(O)NR 10 R 10 are independently selected from the group consisting of: Each R 10 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 Alkyl is C 1-6 C optionally substituted with alkyl 1-6 Alkoxy, C 3-10 optionally substituted with a substituent selected from the group consisting of cycloalkyl and 3- to 11-membered heterocyclyl; W is nitrogen (-N=) or -CH=; V is nitrogen (-N=) or -CH=; U is nitrogen (-N=) or -C(R 11 )=, R 11 is hydrogen, halogen and C 1-4 alkoxy; Ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and triazole; R 4 If there is, then each R 4 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, Cyano-C 1-6 Alkyl, halogen, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 alkyl)2, -CN, C 3-5 independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; p is selected from the group consisting of 0, 1, 2 and 3; R 5 is one or more of the same or different C 1-6 Alkyl, C 1-6 3- to 11-membered heterocyclyl optionally substituted by alkoxy or 5- to 6-membered heterocyclyl, wherein C 1-6 Alkyl is optionally substituted by cyclopropyl or R 5 is substituted by 3-11 membered heterocyclyl -OC 1-6 alkyl, wherein the 3- to 11-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted by Each R 12 is C 1-6 Alkyl, C 1-6 selected from the group consisting of alkoxy, halogen, and 3- to 11-membered heterocyclyl. or a salt thereof.
[0013] In another aspect, the present invention provides a compound comprising R 1a and R 1b are each independently hydrogen and C 1-4 The present invention relates to a compound of formula (I) or a salt thereof, wherein the compound is selected from the group consisting of alkyl.
[0014] In another aspect, the present invention provides a compound comprising R 2a and R 2b are each independently selected from the group consisting of hydrogen and halogen, or a salt thereof.
[0015] In another aspect, the present invention provides a compound comprising R 1a and R 1b are each independently selected from the group consisting of hydrogen and methyl, or a salt thereof.
[0016] In another aspect, the present invention provides a compound comprising R 2a and R 2bare each independently selected from the group consisting of hydrogen and fluorine, or a salt thereof.
[0017] In another aspect, the present invention provides a compound comprising R 1a , R 1b , R 2a and R 2b is hydrogen, or a salt thereof.
[0018] In another embodiment, the present invention relates to a compound of formula (I) or a salt thereof, wherein n is 0.
[0019] In another aspect, the present invention provides a compound according to the present invention, wherein n is 1 and each R 6a and R 6b is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The present invention relates to a compound of formula (I) or a salt thereof, wherein each of the aryl groups is independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl.
[0020] In another aspect, the present invention relates to compounds of formula (I) or salts thereof, wherein Z is -CH2-.
[0021] In another aspect, the present invention provides a compound according to the present invention, wherein n is 2 and each R 6a and R 6b is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The present invention relates to a compound of formula (I) or a salt thereof, wherein each of the aryl groups is independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl.
[0022] In another embodiment, the present invention relates to compounds of formula (I) or salts thereof, wherein p is 0.
[0023] In another aspect, the present invention provides a method for producing a pharmaceutical composition comprising: Formula (I * ) [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , Z, U, V, W, ring A and p are as defined herein above or below. or a salt thereof.
[0024] In another aspect, the present invention provides a compound of formula (Ia) [ka] [In the formula, A, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0025] In another aspect, the present invention provides a compound of formula (Ib) [ka] [In the formula, A, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0026] In another embodiment, the present invention relates to the compound of the present invention or a salt thereof, wherein ring A is a ring selected from the group consisting of imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and triazole.
[0027] In another embodiment, the present invention relates to the compound of the present invention or a salt thereof, wherein ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, isoxazole, isothiazole, and triazole.
[0028] In another aspect, the present invention provides a compound in which ring A is [ka] The present invention relates to a compound of the present invention or a salt thereof, selected from the group consisting of:
[0029] In another embodiment, the present invention relates to a compound of the present invention or a salt thereof, wherein ring A is isoxazole or isothiazole.
[0030] In another aspect, the present invention provides a compound in which ring A is [ka] The present invention relates to a compound of the present invention, or a salt thereof, selected from the following:
[0031] In another aspect, the present invention provides a compound in which ring A is [ka] The present invention relates to a compound of the present invention or a salt thereof, wherein
[0032] In another aspect, the present invention provides a compound of formula (Ic) [ka] [In the formula, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0033] In another aspect, the present invention provides a compound of formula (Id): [ka] [In the formula, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0034] In another aspect, the present invention provides a compound of formula (Ie): [ka] [In the formula, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0035] In another aspect, the present invention provides a compound of formula (If): [ka] [In the formula, V, U, W, R 3 and R 5 is defined herein] or a salt thereof.
[0036] In another aspect, the present invention provides a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0037] In another aspect, the present invention provides a compound wherein W is nitrogen (-N=), V is nitrogen (-N=), and U is ═C(R 11 )- and R 11 is hydrogen, halogen and C 1-4 alkoxy, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0038] In another aspect, the present invention provides a compound wherein W is —CH═, V is nitrogen (—N═), and U is ═C(R 11 )- and R 11 is hydrogen, halogen and C 1-4 alkoxy, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0039] In another aspect, the present invention provides a compound wherein V is —CH═, W is nitrogen (—N═), and U is ═C(R 11 )- and R 11 is hydrogen, halogen and C 1-4 alkoxy, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0040] In another aspect, the present invention provides a compound comprising R 11 is selected from hydrogen, fluorine, chlorine and —O—CH3, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0041] In another aspect, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0042] In another aspect, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0043] In another aspect, the present invention provides a compound represented by formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0044] In another aspect, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0045] In another aspect, the present invention provides a compound wherein W is nitrogen (-N=), V is nitrogen (-N=), and U is ═C(R 11 )- and R 11 is hydrogen, halogen and C 1-4 or wherein V is nitrogen (-N=), W is -CH=, and U is nitrogen (-N=), * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0046] In another aspect, the present invention provides a compound comprising R 5 There are one or more identical or different C 1-6 Alkyl, C 1-6 6- to 11-membered heterocyclyl optionally substituted by alkoxy or 5- to 6-membered heterocyclyl, wherein C 1-6 Formula (I), wherein alkyl is optionally substituted by cyclopropyl, (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0047] In another aspect, the present invention provides a compound comprising R 5 There are one or more identical or different C 1-4 7-membered heterocyclyl optionally substituted with alkyl, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0048] In another aspect, the present invention provides a compound comprising R 5 -OC is substituted by 5-8 membered heterocyclyl 1-6 alkyl, wherein the 5- to 8-membered heterocyclyl is one or more of the same or different R 12 and each R 12 C 1-6 Alkyl, C 1-6 alkoxy, halogen, and 5-membered heterocyclyl, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0049] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0050] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0051] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0052] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0053] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0054] In another aspect, the present invention provides a compound comprising R 5 but [ka] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0055] In another aspect, the present invention provides a compound comprising R 3 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -N3, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 1-6 Haloalkyl, C3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 are halogens, -CN, -OH, C 1-6 Alkoxy, -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, phenyl, and 5- to 10-membered heteroaryl, wherein C 1-6 All of the alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl are one or more of the same or different R 9 and / or R 10 and each R 9 -OR 10 and each R is independently selected from the group consisting of 10 is hydrogen, C 1-6 Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0056] In another aspect, the present invention provides a compound comprising R 3 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -N3, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 -OR 8 , -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10 and each R 9 -OR 10 and each R is independently selected from the group consisting of 10 is hydrogen, C 1-6 Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0057] In another aspect, the present invention provides a compound comprising R 3 is halogen, C 1-6 Alkyl, C 1-6 haloalkyl and -N3, selected from the group consisting of: *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0058] In another aspect, the present invention provides a compound comprising R 3 is selected from the group consisting of chlorine, methyl, -CF3 and -N3, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0059] In another aspect, the present invention provides a compound comprising R 3 is 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 are halogens, -CN, -OH, C 1-6 Alkoxy, -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10 and each R 9 -OR 10 , -NR10 R 10 and -C(O)NR 10 R 10 and each R is independently selected from the group consisting of 10 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 Alkyl is C 1-6 C optionally substituted with alkyl 1-6 Alkoxy, C 3-10 Optionally substituted by a substituent selected from the group consisting of cycloalkyl and 3- to 11-membered heterocyclyl, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0060] In another aspect, the present invention provides a compound comprising R 3 is 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 are halogens, -CN, -OH, C 1-6 Alkoxy, -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6Alkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10 and each R 9 OR 10 and each R is independently selected from the group consisting of 10 is hydrogen, C 1-6 Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0061] In another aspect, the present invention provides a compound comprising R 3 are selected from the group consisting of 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl, wherein the 3- to 11-membered heterocyclyl and the 5- to 10-membered heteroaryl are all selected from the group consisting of one or more of the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 is halogen, -CN, -OR 8 , -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10and each R 9 is -OH or C 1-6 alkoxy, and each R 10 C 1-6 Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0062] In another aspect, the present invention provides a compound comprising R 3 are selected from the group consisting of 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl, wherein the 3- to 11-membered heterocyclyl and the 5- to 10-membered heteroaryl are all selected from the group consisting of one or more of the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 are halogens, -CN, -OH, C 1-6 Alkoxy, -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10 and each R 9 is -OH or C 1-6 alkoxy, and each R 10 C 1-6Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0063] In another aspect, the present invention provides a compound comprising R 3 but [ka] and each of said groups is selected from the group consisting of the formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie), or (If), and one or more of the same or different R 7 and / or R 8 wherein each R 7 is halogen, -CN, -OR 8 , -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are each selected from the group consisting of one or more of the same or different R 9 and / or R 10 and each R 9 is -OH or C 1-6 alkoxy, and each R 10 C 1-6Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0064] In another aspect, the present invention provides a compound comprising R 3 but [ka] and each of said groups is selected from the group consisting of one or more of the same or different R 7 and / or R 8 wherein each R 7 is halogen, -CN, -OR 8 , -NR 8 R 8 , -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are each selected from the group consisting of one or more of the same or different R 9 and / or R 10 and each R 9 is -OH or C 1-6 alkoxy, and each R 10 C 1-6 Formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0065] In another aspect, the present invention provides a compound comprising R 3 but [ka] TIFF2024543967000024.tif246165 TIFF2024543967000025.tif235165 TIFF2024543967000026.tif248165 TIFF2024543967000027.tif231165 TIFF2024543967000028.tif180165 Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0066] In another aspect, the present invention provides a compound comprising R 3 There are one or more identical or different R 7 and / or R 8 and each R is a 3- to 11-membered heterocyclyl optionally substituted by 7 -OH, C 1-6 Alkoxy, -C(=O)R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.
[0067] In another aspect, the present invention provides a compound comprising R 3 There are one or more identical or different R 7and / or R 8 and each R is a 3- to 11-membered heterocyclyl optionally substituted by 7 -OH, C 1-6 Alkoxy, -C(=O)R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the compound and the salt is independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl.
[0068] In another aspect, the present invention provides a compound comprising R 3 There are one or more identical or different R 7 and / or R 8 and each R is a 5-membered nitrogen-containing heterocyclyl optionally and independently substituted by 7 -OH, C 1-6 Alkoxy, -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the group consisting of alkyl and 3- to 11-membered heterocyclyl is independently selected from the group consisting of alkyl and 3- to 11-membered heterocyclyl.
[0069] In another aspect, the present invention provides a compound comprising R 3 is 3-11-membered oxygen-containing heterocyclyl, or a salt thereof.
[0070] In another aspect, the present invention provides a compound comprising R 3 There are one or more identical or different R 7 and / or R 8wherein each R is selected from the group consisting of 5-10 membered heteroaryl optionally substituted by 7 is halogen, -OH, C 1-6 Alkoxy, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl are all one or more of the same or different R 10 and each R 10 C 1-6 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the group consisting of alkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl is independently selected from the group consisting of: alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl.
[0071] In another aspect, the present invention provides a compound comprising R 3 There are one or more identical or different R 7 and / or R 8 wherein each R is selected from the group consisting of 5-10 membered heteroaryl optionally substituted by 7 is halogen, -OH, C 1-6 Alkoxy, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6All of the alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl are one or more of the same or different R 10 and each R 10 is hydrogen, C 1-6 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the group consisting of alkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl is independently selected from the group consisting of: alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl.
[0072] In another aspect, the present invention provides a compound comprising R 3 -C(=O)NR 8 R 8 and optionally substituted 5-10 membered heteroaryl, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl and 3- to 11-membered heterocyclyl, wherein C 1-6 The present invention relates to a compound of formula (Ic), (Id), (Ie) or (If) or a salt thereof, wherein alkyl is optionally substituted with 3-11 membered heterocyclyl.
[0073] In another aspect, the present invention provides a compound comprising R 3 but [ka] and both are C 1-6 is optionally and independently substituted with alkyl, W is nitrogen (-N=), V is nitrogen (-N=), and U is -C(R 11 )=, where R 11 is hydrogen or fluorine, and R 5 but [ka] The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein:
[0074] In another aspect, the present invention provides a compound comprising R3 but [ka] wherein W is nitrogen (-N=), V is nitrogen (-N=), U is -CH=, and R 5 but [ka] The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein:
[0075] In another aspect, the present invention provides a compound comprising R 3 but [ka] wherein W is -N=, V is -N=, U is -CH=, and R 5 but [ka] The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein:
[0076] In another aspect, the present invention provides a compound comprising R 3 but [ka] and each 3- to 11-membered heterocyclyl is selected from the group consisting of one or more of the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 -OH, C 1-6 Alkoxy, -C(=O)R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C3-10 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the compound and the salt is independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl.
[0077] In another aspect, the present invention provides a compound comprising R 3 but [ka] and each of the 3- to 11-membered heterocyclyl and the 8- to 9-membered heteroaryl is selected from the group consisting of one or more of the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 -OR 8 , -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-11 membered heterocyclyl, C 6-10 independently selected from the group consisting of aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, 3-11 membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls are the same or different R 9 and / or R 10 and each R 9 is -OH or C 1-6 alkoxy, and each R 10 C 1-6The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the group consisting of alkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl is independently selected from the group consisting of: alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl.
[0078] In another aspect, the present invention provides a compound comprising R 3 but [ka] and each 5- to 10-membered heterocyclyl is selected from the group consisting of one or more of the same or different R 7 and / or R 8 and each R is optionally and independently substituted by 7 is halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 and a divalent substituent =O, wherein each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 All of the alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl are one or more of the same or different R 9 and each R 9 C 1-6 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein each of the group consisting of alkyl, 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl is independently selected from the group consisting of:
[0079] In another aspect, the present invention provides a compound comprising R 3 but [ka] TIFF2024543967000039.tif217165 TIFF2024543967000040.tif160165 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, selected from the group consisting of:
[0080] Preferred embodiments of the present invention are compounds I-1 to I61, II-1 to II-214 of the Examples and any subset thereof.
[0081] Particularly preferred embodiments of the present invention are compounds I-1 to I-45, II-1 to II-178 of the Examples and any subset thereof.
[0082] It is understood that any two or more aspects and / or preferred embodiments of formula (I) or subformulas thereof may be combined in any manner that results in a chemically stable structure to provide further aspects and / or preferred embodiments of formula (I) or subformulas thereof.
[0083] Furthermore, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof), hydrates, solvates, polymorphs, metabolites, derivatives, stereoisomers and prodrugs of the compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).
[0084] Furthermore, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).
[0085] Furthermore, the present invention provides a compound represented by formula (I), (I * The present invention relates to solvates of compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).
[0086] For example, the formula (I) having an ester group, *The compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof) are potential prodrugs in which the ester is cleaved under physiological conditions and are also part of the present invention.
[0087] Furthermore, the present invention provides a compound represented by formula (I), (I * The present invention relates to a pharmaceutically acceptable salt of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).
[0088] Furthermore, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof) with an inorganic or organic acid or base.
[0089] Pharmaceutical Composition A further object of the present invention is to provide a compound of formula (I), (I * and one or more pharmaceutically acceptable excipients.
[0090] In one embodiment, the pharmaceutical composition optionally comprises one or more other pharmacologically active substances, which may be pharmacologically active substances or combination partners as defined herein.
[0091] The compounds of the present invention represented by formula (I), (I * Pharmaceutical compositions suitable for administering a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, solutions, suspensions, in particular solutions, suspensions or other mixtures for injection (sc, iv, im) and infusion (injectable), elixirs, syrups, sachets, emulsions, inhalants or dispersible powders. *The content of the compound represented by (Ia), (Ib), (Ic), (Id), (Ie) or (If) should be in the range of 0.1 to 90 wt %, preferably 0.5 to 50 wt %, of the total composition, i.e., an amount sufficient to achieve the dose range specified below. The specified dose can be given several times a day as needed.
[0092] Suitable tablets may be prepared, for example, from the compound of formula (I), * The tablet may be obtained by mixing a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) with known pharmaceutically acceptable excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders, and / or lubricants. The tablet may also comprise multiple layers.
[0093] Coated tablets can be conveniently prepared by coating a core manufactured in the same way as a tablet with an excipient commonly used in tablet coating, such as Kollidon or shellac, gum arabic, talc, titanium dioxide, or sugar. The core may also consist of multiple layers to achieve delayed release or to prevent incompatibility. Similarly, tablet coatings may consist of multiple layers to achieve delayed release, and may use the excipients mentioned above for tablets.
[0094] Formula (I), (I * Syrups or elixirs containing one or more compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a combination with one or more other pharmaceutically active substances may further contain excipients such as sweeteners, e.g., saccharin, cyclamate, glycerol, or sugars, and flavor enhancers, e.g., flavorings, e.g., vanillin or orange extract. Syrups or elixirs may also contain excipients such as suspension adjuvants or thickeners, e.g., sodium carboxymethylcellulose, wetting agents, e.g., condensation products of fatty alcohols with ethylene oxide, or preservatives, e.g., p-hydroxybenzoates.
[0095] Solutions for injection and infusion are prepared by the usual method, for example, by adding excipients such as an isotonicity agent, a preservative, e.g., p-hydroxybenzoate, or a stabilizer, e.g., an alkali metal salt of ethylenediaminetetraacetic acid, and optionally using an emulsifier and / or dispersant, and when water is used as a diluent, for example, an organic solvent can be optionally used as a solvating agent or solubilizing aid, and then transferred into injection vials or ampoules or infusion bottles.
[0096] Formula (I), (I * Capsules containing one or more compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a combination with one or more other pharmaceutically active substances can be prepared, for example, by mixing the compounds / active substances with an inert excipient, such as lactose or sorbitol, and filling them into gelatin capsules.
[0097] Suitable suppositories can be prepared, for example, by mixing with excipients provided for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof.
[0098] Excipients that can be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), vegetable oils (e.g., peanut oil or sesame oil), monofunctional or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural mineral powders (e.g., kaolin, clay, talc, chalk), synthetic mineral powders (e.g., highly dispersed silicic acid and silicates), sugars (e.g., sucrose, lactose, and glucose), emulsifiers (e.g., lignin, spent sulfite liquor, methylcellulose, starch, and polyvinylpyrrolidone), and lubricants (e.g., magnesium stearate, talc, stearic acid, and sodium lauryl sulfate).
[0099] The pharmaceutical composition is administered by conventional methods, preferably orally or transdermally, most preferably orally.For oral administration, tablets may contain, apart from the above-mentioned excipients, additional excipients such as sodium citrate, calcium carbonate and dicalcium phosphate, together with various excipients such as starch, preferably potato starch, gelatin, etc.In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc can be used at the same time for the tableting process.For aqueous suspensions, the active substance can be combined with various flavor enhancers or colorants in addition to the above-mentioned excipients.
[0100] For parenteral use, solutions of the active substance and suitable liquid excipients can be used.
[0101] The applicable formula (I) per day, (I * The dosage range of the compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) is usually 1 mg to 2000 mg, preferably 250 mg to 1250 mg.
[0102] However, it may be necessary to deviate from the amounts specified, depending on the body weight, age, route of administration, severity of the disease, individual response to the drug, the nature of its formulation and the timing or interval at which the drug is administered (continuous or intermittent treatment with one or more doses per day). For this reason, in some cases it may be sufficient to use less than the minimum dose given above, while in other cases the upper limit may have to be exceeded. When administering larger amounts, it may be advisable to administer them in several smaller doses over the course of a day.
[0103] Therefore, in a further aspect, the present invention provides a compound comprising at least one (preferably one) compound of formula (I), (I * The present invention relates to a pharmaceutical composition comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
[0104] Formula (I), (I * Compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds and salts can also be co-administered, i.e., used in combination, with other pharmacologically active substances, such as other anti-neoplastic compounds (e.g., chemotherapy) (see further below under Combination Treatment).
[0105] The elements of such combinations, when used as monotherapy, can be administered in a manner conventional to those skilled in the art, for example, by oral, enteral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, transdermal or subcutaneous injection or implant), nasal, vaginal, rectal or topical routes of administration (whether subcombined or independent), and can be formulated, either alone or together, into suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable excipients appropriate for each route of administration.
[0106] The combination can be administered in a therapeutically effective single daily dose or in divided doses. The active ingredients of the combination can be administered in a therapeutically effective dose in monotherapy or in a dose lower than that used in monotherapy, but which, when combined, results in the desired (jointly) therapeutically effective amount.
[0107] However, when the combination of two or more active substances or principles produces a synergistic effect, it may be possible to reduce the amounts of one, more, or all of the substances or principles administered while still achieving the desired therapeutic effect. This may be useful, for example, to avoid, limit, or reduce any undesirable side effects associated with the use of one or more substances or principles when used in their normal amounts, while still obtaining the desired pharmacological or therapeutic effect.
[0108] Also for this reason, in a further aspect, the present invention provides a compound of formula (I), (I *The present invention relates to a pharmaceutical composition comprising a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, and one or more (preferably one or two, most preferably one) other pharmacologically active substances.
[0109] In a further aspect, the present invention provides a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, and one or more (preferably one or two, most preferably one) other pharmacologically active substances.
[0110] The co-administered or combined pharmaceutical compositions may also be provided in the form of a kit.
[0111] And therefore, in a further aspect, the present invention provides a method for producing a composition comprising: Formula (I), (I * a first pharmaceutical composition or dosage form comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) and optionally one or more pharmaceutically acceptable excipients; a second pharmaceutical composition or dosage form comprising another pharmacologically active substance and, optionally, one or more pharmaceutically acceptable excipients; The present invention relates to a kit comprising:
[0112] In one embodiment, such a kit further comprises a third pharmaceutical composition or dosage form comprising another pharmacologically active agent and, optionally, one or more pharmaceutically acceptable excipients.
[0113] Medical Use - Treatment Methods Indications-Patient Population The present invention is directed to compounds that inhibit KRAS, preferably KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A and KRAS G12R inhibitors, preferably inhibitors of KRAS G12C and / or KRAS G12D or inhibitors selective for KRAS G12D, as well as compounds that inhibit KRAS wild-type, preferably amplified, KRAS mutated at residue 13, such as KRAS G13D, or KRAS mutated at residue 61, such as KRAS Q61H. In particular, the compounds of formula (I), (I * Compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof) may be useful for the treatment and / or prevention of diseases and / or conditions mediated by KRAS, preferably KRAS mutated at residue 12, e.g., KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D or KRAS wild type amplification or KRAS mutated at residue 13, e.g., KRAS G13D or KRAS mutated at residue 61, e.g., KRAS Q61H.
[0114] Thus, in a further aspect, the present invention provides a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0115] In a further aspect, the present invention provides a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0116] In a further aspect, the present invention provides a compound of formula (I), (I ), (I ) or (I ) for use in treating and / or preventing diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, e.g., KRAS G12C, KRAS G12D, KRAS G12V, more preferably by G12D or by amplification of KRAS wild type or by KRAS mutated at residue 13, e.g., KRAS G13D. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0117] In a further aspect, the present invention provides a compound of formula (I), (I ), (I ) or (I ) in the manufacture of a medicament for treating and / or preventing diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, e.g., KRAS G12C, KRAS G12D, KRAS G12V, more preferably by G12D or by amplification of KRAS wild type or by KRAS mutated at residue 13, e.g., KRAS G13D. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0118] In a further aspect, the present invention provides a method for treating and / or preventing diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, e.g., KRAS G12C, KRAS G12D, KRAS G12V, more preferably by G12D or by amplification of KRAS wild type or by KRAS mutated at residue 13, e.g., KRAS G13D, comprising administering to a patient a therapeutically effective amount of a compound represented by formula (I), (I * The present invention relates to a method for treating a human breast cancer, comprising administering to a human a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0119] In a further aspect, the present invention provides a compound of formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0120] In a further aspect, the present invention provides a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0121] In a further aspect, the present invention relates to a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0122] In a further aspect, the present invention provides a method for treating and / or preventing cancer, comprising administering to a patient a therapeutically effective amount of a compound of formula (I), (I * The present invention relates to a method for treating a human breast cancer, comprising administering to a human a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0123] Preferably, the cancer defined herein (above or below) comprises a KRAS mutation. In particular, KRAS mutations include, for example, mutations of the KRAS gene and KRAS protein, such as overexpression of KRAS, amplification of KRAS or KRAS, KRAS mutated at residue 12, KRAS mutated at residue 13, KRAS mutated at residue 61, KRAS mutated at residue 146, in particular KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G13C, KRAS G13D, KRAS G13V, KRAS Q61H, KRAS Q61E, KRAS Q61P, KRAS A146P, KRAS A146T, KRAS A146V. KRAS may exhibit one or more of these mutations / alterations.
[0124] Preferably, the cancers defined herein (above or below) comprise, in addition to or alternatively to a KRAS mutation, a BRAF mutation, in particular a class III BRAF mutation as defined, for example, in Z. Yao, Nature, 2017, 548, 234-238.
[0125] Preferably, cancers as defined herein (above or below) comprise, in addition to or alternatively to KRAS mutations, mutations in receptor tyrosine kinases (RTKs), including EGFR, MET and ERBB2 mutations.
[0126] In a further aspect, the present invention relates to a compound of formula (I), (I ), for use in treating and / or preventing cancer, wherein the cancer comprises a KRAS mutation, said KRAS mutation being preferably selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D or KRAS wild type amplification, KRAS gene amplification or KRAS overexpression. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0127] In a further aspect, the present invention relates to the manufacture of a medicament for treating and / or preventing cancer, wherein the cancer comprises a KRAS mutation, said KRAS mutation preferably being selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D or KRAS wild type amplification, KRAS gene amplification or KRAS overexpression, comprising a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0128] In a further aspect, the present invention provides a method for treating and / or preventing cancer, comprising administering to a patient a therapeutically effective amount of a compound of formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof to a human, wherein the cancer comprises a KRAS mutation, and the KRAS mutation is preferably selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D or KRAS wild-type amplification, KRAS gene amplification or KRAS overexpression.
[0129] In a further aspect, the present invention relates to a compound of formula (I), (I) for use in treating and / or preventing cancer, wherein the cancer comprises a KRAS G12D mutation. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0130] In a further aspect, the present invention relates to a compound of formula (I), (I) for use in treating and / or preventing cancer, wherein the cancer comprises a KRAS G12V mutation. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0131] In a further aspect, the present invention relates to a compound of formula (I), (I) for use in treating and / or preventing cancer, wherein the cancer comprises a KRAS G13D mutation. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0132] In a further aspect, the present invention relates to a method for treating and / or preventing cancer, wherein the cancer comprises a KRAS wild-type amplification, comprising administering to a patient a therapeutically effective amount of a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0133] Another embodiment involves determining the KRAS status of a patient and the presence of a compound of formula (I), (I * The present invention is based on identifying a relationship between the potential sensitivity to treatment with a KRAS inhibitor, such as a compound of formula (I), (Ib), (Ic), (Id), (Ie), or (If). * Compounds of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) can be advantageously used to treat patients with KRAS-dependent diseases that may be resistant to other treatments. *
[0013] This invention provides opportunities, methods and tools for selecting patients, particularly cancer patients, for treatment with a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If). This selection is based on whether the tumor cells to be treated have a wild-type, preferably an amplified or mutated KRAS gene at residue 12, preferably a G12C, G12D or G12V gene, or a KRAS mutated at residue 13, preferably a G13D gene. Thus, the status of the KRAS gene can be determined by the formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If), may be advantageous to select treatment with a compound of formula (Ib).
[0134] According to one embodiment, the compound of formula (I), (I * A method for selecting a patient for treatment with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) is provided, the method comprising: providing a tumor cell-containing sample from the patient; determining whether the KRAS gene in the patient's tumor cell-containing sample encodes a wild-type (glycine at position 12) or mutant (cysteine, aspartic acid, valine, alanine, or arginine at position 12, aspartic acid at position 13, amplified and / or overexpressed) KRAS protein; Based on this, the formula (I), (I *selecting a patient for treatment with a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie), or (If); Includes:
[0135] The method may or may not include the step of isolating an actual patient sample.
[0136] According to another aspect, a compound of formula (I), (I) is provided for use in treating cancer having tumor cells with KRAS mutation or KRAS wild-type amplification. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0137] According to another aspect, a compound of formula (I), (I) for use in treating a cancer having tumor cells with amplification of a G12C mutant, a G12D mutant, a G12V mutant, a G12A mutant, a G13D mutant or a G12R mutant KRAS gene or a KRAS wild type is provided. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0138] According to another aspect, a compound of formula (I), (I) for use in treating cancer having tumor cells with amplification of a G12C mutant, a G12D mutant, a G12V mutant or a G13D mutant KRAS gene or a KRAS wild type is provided. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0139] According to another aspect, a compound of formula (I), (I) for use in treating cancer having tumor cells with a G12D mutant KRAS gene. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0140] According to another aspect, a compound of formula (I), (I) for use in treating cancer having tumor cells with a G12V mutant KRAS gene. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0141] According to another aspect, a compound of formula (I), (I) for use in treating cancer having tumor cells with a G13D mutant KRAS gene. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0142] According to another aspect, a compound of formula (I), (I) for use in treating cancer having tumor cells with KRAS wild-type amplification or KRAS overexpression is provided. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof.
[0143] According to another aspect, there is provided a method of treating cancer having tumor cells with a G12C mutant, a G12D mutant, a G12V mutant, a G12A mutant, a G13D mutant or a G12R mutant KRAS gene, or an amplification of the KRAS wild-type gene, comprising administering to a subject an effective amount of a compound of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof, is provided.
[0144] According to another aspect, there is provided a method of treating cancer having tumor cells with a G12C mutant, a G12D mutant, a G12V mutant, a G12A mutant or a G12R mutant KRAS gene, or an amplification of the KRAS wild-type gene, comprising administering to said cancer a therapeutically effective amount of a compound of formula (I), (I *(Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0145] Determining whether a tumor or cancer contains a G12C KRAS mutation can be performed by evaluating the nucleotide sequence encoding the KRAS protein, by evaluating the amino acid sequence of the KRAS protein, or by evaluating the characteristics of a putative KRAS mutant protein. The sequence of wild-type human KRAS is known in the art. Methods for detecting mutations in KRAS nucleotide sequences are known to those skilled in the art. These methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) assays, real-time PCR assays, PCR sequencing, mutant allele-specific PCR amplification (MASA) assays, direct sequencing, primer extension reactions, electrophoresis, oligonucleotide ligation assays, hybridization assays, TaqMan assays, SNP genotyping assays, high-resolution melting assays, and microarray analysis. In some embodiments, samples are evaluated for the G12C KRAS mutation by real-time PCR. Real-time PCR uses a fluorescent probe specific for the KRAS G12C mutation. If a mutation is present, the probe binds and fluorescence is detected. In some embodiments, the KRAS G12C mutation is identified using direct sequencing of a specific region in the KRAS gene (e.g., exon 2 and / or exon 3). This technique will identify all possible mutations in the sequenced region. Methods for detecting mutations in KRAS proteins are known to those skilled in the art. These methods include, but are not limited to, detection of mutant KRAS using binding agents (e.g., antibodies) specific to the mutant protein, protein electrophoresis, Western blotting, and direct peptide sequencing.
[0146] In some embodiments, the method for determining whether a tumor or cancer contains a G12C KRAS mutation can use a variety of samples. In some embodiments, the sample is taken from a subject with a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed, paraffin-embedded sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA. In some embodiments, the sample is a liquid biopsy, where a test is performed on a blood sample to look for cancer cells from the tumor circulating in the blood or for fragments of DNA from tumor cells present in the blood.
[0147] Similarly, it can be determined whether a tumor or cancer contains KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and KRAS G12R mutations or is KRAS wild-type, preferably amplified.
[0148] Preferably, in accordance with the methods and uses defined and disclosed herein (above and below), * The disease / condition / cancer / tumor / cancer cell to be treated / prevented by a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer, lung cancer, colon cancer, bile duct cancer, appendix cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, gastroesophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer and sarcoma.
[0149] Preferably, in accordance with the methods and uses defined and disclosed herein (above and below), *The disease / condition / cancer / tumor / cancer cell treated / prevented by a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer, lung cancer, ovarian cancer, colorectal cancer (CRC), gastric cancer, gastroesophageal junction cancer (GEJC) and esophageal cancer.
[0150] In another aspect, a compound of formula (I), (I * The disease / condition / cancer / tumor / cancer cell treated / prevented by a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer (preferably pancreatic ductal adenocarcinoma (PDAC)), lung cancer (preferably non-small cell lung cancer (NSCLC)), gastric cancer, bile duct cancer and colon cancer (preferably colon adenocarcinoma). Preferably, the pancreatic cancer, lung cancer, bile duct cancer, colon cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) or colon adenocarcinoma comprises a KRAS mutation, in particular a KRAS G12D or KRAS G12V mutation. Preferably (alternatively or in combination with the previous preferred embodiment), the non-small cell lung cancer (NSCLC) comprises a mutation (in particular a loss-of-function mutation) in the NF1 gene.
[0151] In another aspect, a compound of formula (I), (I * The disease / condition / cancer / tumor / cancer cell treated / prevented by a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is gastric cancer, ovarian cancer or esophageal cancer, and said gastric cancer or esophageal cancer is preferably selected from the group consisting of gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) and gastroesophageal junction cancer (GEJC). Preferably, said gastric cancer, ovarian cancer, esophageal cancer, gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) or gastroesophageal junction cancer (GEJC) comprises a KRAS mutation or amplification of wild-type KRAS.
[0152] Particularly preferably, compounds of formula (I), (I * The cancers treated / prevented by a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof are lung adenocarcinoma (preferably non-small cell lung cancer (NSCLC)) with a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation), a KRAS mutation at position 13 (preferably G13D) or an amplification of the KRAS wild type, colon adenocarcinoma with KRAS mutations at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutations), KRAS mutations at position 13 (preferably G13D) or KRAS wild type amplification, Pancreatic adenocarcinoma (preferably pancreatic ductal adenocarcinoma (PDAC)) with a RAS mutation at position 12 (preferably KRAS, preferably G12C, G12D, G12V, G12A, G12R mutation), a RAS mutation at position 13 (preferably G13D) or an amplification of the KRAS wild type. is selected from the group consisting of:
[0153] Preferably, as used herein (above or below), "cancer" includes drug-resistant cancers and cancers in which one, two or more lines of monotherapy or combination therapy with one or more anti-cancer agents have failed. In particular, "cancer" (and any embodiment thereof) refers to any cancer (particularly the cancer types defined above or below) that is resistant to treatment with a KRAS G12C inhibitor.
[0154] Various resistance mechanisms have already been reported. For example, the following papers describe resistance in patients after treatment with KRAS G12C inhibitors: (i) Awad MM, Liu S, Rybkin, II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med 2021;384:2382-93 and (ii) Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov 2021;11:1913-22.
[0155] In another aspect, a compound of formula (I), (I * The disease / condition / cancer / tumor / cancer cell to be treated / prevented by a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is preferably a RAS disease selected from the group consisting of neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Noonan syndrome with multiple lentigines (NSML) (also known as LEOPARD syndrome), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facio-cutaneous syndrome (CFC), Legius syndrome (also known as NF1-like syndrome) and hereditary gingival fibromatosis.
[0156] Furthermore, the following cancers, tumors and other proliferative diseases (including but not limited to) can be treated by the use of a compound of formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof. Preferably, the methods of treatment, methods, uses, compounds for use and pharmaceutical compositions for use disclosed herein (above and below) are applied to the treatment of diseases / conditions / cancers / tumors (i.e., respective cells) having a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation) or an amplification of KRAS wild type. Alternatively, they have been identified as having a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation) or an amplification of KRAS wild type as described and / or mentioned herein.
[0157] Cancers / tumors / carcinomas of the head and neck: for example, tumors / carcinomas of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity (including lips, gums, alveolar ridge, recurrent ridge, floor of mouth, tongue, hard palate, buccal mucosa), oropharynx (including base of tongue, tonsils, tonsillar foramen, soft palate, tonsillar fossa, pharyngeal wall), middle ear, larynx (including supraglottis, glottis, subglottis, vocal cords), hypopharynx, salivary glands (including minor salivary glands);
[0158] Lung cancers / tumors / carcinomas: e.g., non-small cell lung cancer (NSCLC) (squamous cell carcinoma, spindle cell carcinoma, adenocarcinoma, large cell carcinoma, clear cell carcinoma, bronchoalveolar carcinoma), small cell lung cancer (SCLC) (oat cell carcinoma, intermediate cell carcinoma, mixed oat cell carcinoma);
[0159] Mediastinal neoplasms: for example, neurogenic tumors (including neurofibroma, schwannoma, malignant schwannoma, neurosarcoma, ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, paraganglioma), germ cell tumors (including seminoma, teratoma, nonseminoma), thymic tumors (including thymoma, thymolipoma, thymic carcinoma, thymic carcinoid), mesenchymal tumors (including fibroma, fibrosarcoma, lipoma, liposarcoma, myxoma, mesothelioma, leiomyoma, leiomyosarcoma, rhabdomyosarcoma, xanthogranuloma, mesenchymoma, hemangioma, hemangioendothelioma, hemangiopericytoma, lymphangioma, lymphangiopericytoma, lymphangioleiomyoma);
[0160] Cancers / tumors / carcinomas of the gastrointestinal (GI) tract: e.g., tumors / carcinomas / cancer of the esophagus, stomach (gastric cancer), gastroesophageal junction cancer, pancreas, liver and biliary tract (including hepatocellular carcinoma (HCC), e.g., childhood HCC, fibrolamellar HCC, mixed HCC, spindle cell HCC, clear cell HCC, giant cell HCC, carcinosarcomatous HCC, sclerosing HCC, hepatoblastoma, cholangiocarcinoma, cholangiocellular carcinoma, hepatic cystadenocarcinoma, angiosarcoma, hemangioendothelioma, leiomyosarcoma, malignant schwannoma, fibrosarcoma, Klatskin's tumor), gallbladder, extrahepatic bile duct, small intestine intestine (including duodenum, jejunum, ileum), large intestine (including cecum, colon, rectum, anus; colorectal cancer, gastrointestinal stromal tumor (GIST)), genitourinary system (kidney, e.g., including renal pelvis, renal cell carcinoma (RCC), nephroblastoma (Wilms' tumor), renal epithelioma, Grawitz tumor, ureter, bladder, e.g., urinary tract carcinoma, urothelial carcinoma, urethra, e.g., distal, bulbomembranous, prostatic, prostate (androgen-dependent, androgen-independent, castration-resistant, hormone-independent, hormone-refractory), penis), stomach cancer;
[0161] Testicular cancer / tumor / carcinoma: e.g., seminoma, nonseminoma,
[0162] Gynecological cancers / tumors / carcinomas: for example, tumors / carcinomas / cancers of the ovaries, fallopian tubes, peritoneum, cervix, vulva, vagina, and uterine body (including endometrium and fundus);
[0163] Breast cancer / tumor / carcinoma: for example, breast cancer (invasive ductal carcinoma, colloid carcinoma, lobular infiltrating carcinoma, tubular carcinoma, adenocystic carcinoma, papillary carcinoma, medullary carcinoma, mucinous carcinoma), hormone receptor positive breast cancer (estrogen receptor positive breast cancer, progesterone receptor positive breast cancer), Her2 positive breast cancer, triple negative breast cancer, Paget's disease of the breast;
[0164] Cancers / tumors / carcinomas of the endocrine system: for example, tumors / carcinomas / cancers of the endocrine glands, thyroid gland (thyroid carcinoma / tumor; papillary, follicular, anaplastic, medullary), parathyroid gland (parathyroid carcinoma / tumor), adrenal cortex (adrenal cortical carcinoma / tumor), pituitary gland (including prolactinoma, craniopharyngioma), thymus, adrenal gland, pineal gland, carotid body, islet cell tumor, paraganglia, pancreatic endocrine tumors (PET; non-functioning PET, PPoma, gastrinoma, insulinoma, VIPoma, glucagonoma, somatostatinoma, GRFoma, ACTHoma), carcinoid tumor;
[0165] Sarcomas of soft tissues: e.g., fibrosarcoma, fibrous histiocytoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma, glomus tumor, hemangiopericytoma, synovial sarcoma, giant cell tumor of the tendon sheath, solitary fibrous tumor of the pleura and peritoneum, diffuse mesothelioma, malignant peripheral nerve sheath tumor (MPNST), granular cell tumor, clear cell sarcoma, melanocytic schwannoma, plexus sarcoma, neuroblastoma, ganglioneuroblastoma, neuroepithelioma, extraskeletal Ewing's sarcoma, paraganglioma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, mesenchymoma, alveolar soft part sarcoma, epithelioid sarcoma, extrarenal rhabdoid tumor, dysplastic small cell tumor;
[0166] Sarcomas of bone: e.g., myeloma, reticulum cell sarcoma, chondrosarcoma (including central, peripheral, clear cell, and mesenchymal chondrosarcomas), osteosarcoma (including parosteal, periosteal, high-grade superficial, small cell, radiation-induced osteosarcoma, and Paget's sarcoma), Ewing's tumor, malignant giant cell tumor, adamantinoma, (fibrous) histiocytoma, fibrosarcoma, chordoma, small round cell sarcoma, hemangioendothelioma, hemangiopericytoma, osteochondroma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, and chondroblastoma;
[0167] Mesothelioma: e.g., pleural mesothelioma, peritoneal mesothelioma;
[0168] Cancers of the skin: e.g., basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, melanoma (including cutaneous, superficial spreading, lentigo maligna, lentigo acuminata, nodular, and intraocular melanoma), actinic keratosis, and eyelid cancer;
[0169] Neoplasms of the central nervous system and brain: for example, astrocytomas (cerebral, cerebellar, diffuse, fibrous, anaplastic, pilocytic, protoplasmic, germ cell), glioblastoma, glioma, oligodendroglioma, oligoastrocytoma, ependymoma, ependymoblastoma, choroid plexus tumor, medulloblastoma, meningioma, schwannoma, hemangioblastoma, hemangioma, hemangiopericytoma, schwannoma, ganglioneuroma, neuroblastoma, retinoblastoma, schwannoma (e.g., acoustic), spinal axis tumor;
[0170] Lymphomas and leukemias: for example, B-cell non-Hodgkin's lymphoma (NHL) (including small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), and Burkitt's lymphoma (BL)), T-cell non-Hodgkin's lymphoma (including anaplastic large cell lymphoma (ALCL), adult T-cell leukemia / lymphoma) (ATLL), cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL)), lymphoblastic T-cell lymphoma (T-LBL), adult T-cell lymphoma, lymphoblastic B-cell lymphoma ( B-LBL), immunocytoma, chronic B-cell lymphocytic leukemia (B-CLL), chronic T-cell lymphocytic leukemia (T-CLL), B-cell small lymphocytic lymphoma (B-SLL), cutaneous T-cell lymphoma (CT LC), primary central nervous system lymphoma (PCNSL), immunoblastoma, Hodgkin's disease (HD) (including nodular lymphocyte-predominant HD (NLPHD), nodular sclerosing HD (NSHD), mixed cellularity HD (MCHD), lymphocyte-predominant HD, and lymphocyte-deficient HD (LDHD)), large granular lymphocytic leukemia (LGL), chronic myeloid leukemia (CML), acute myelogenous / myeloid (m yeloid) leukemia (AML), acute lymphocytic / lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), chronic lymphocytic / lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia, chronic myelogenous / myeloid leukemia (CML), myeloma, plasmacytoma, multiple myeloma (MM), plasmacytoma, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML);
[0171] carcinoma of unknown primary site (CUP);
[0172] All cancers / tumors / carcinomas referred to above that are characterized by a particular location / origin within the body are meant to include both the primary tumor and any metastatic tumors derived therefrom.
[0173] All of the above mentioned cancers / tumors / carcinomas can be further differentiated by histopathological classification.
[0174] Epithelial carcinomas, such as squamous cell carcinoma (SCC) (in situ, superficial invasive carcinoma, warty carcinoma, pseudosarcoma, anaplastic, transitional cell, lymphoepithelial), adenocarcinoma (AC) (well-differentiated, mucinous, papillary, pleomorphic giant cell, tubular, small cell, signet ring cell, spindle cell, clear cell, oat cell, colloid, adenosquamous, mucoepidermoid, adenoid cystic), mucinous cystadenocarcinoma, spiculated cell carcinoma, large cell carcinoma, small cell carcinoma, neuroendocrine tumors (small cell carcinoma, paraganglioma, carcinoid), oncocytic carcinoma;
[0175] Non-epithelial cancers, such as sarcomas (fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, giant cell sarcoma, lymphosarcoma, fibrous histiocytoma, liposarcoma, angiosarcoma, lymphangiosarcoma, neurofibrosarcoma), lymphoma, melanoma, germ cell tumors, hematological neoplasms, mixed and undifferentiated carcinomas.
[0176] The compounds of the invention may be used in treatment regimens for first line, second line or any further line of treatment.
[0177] The compounds of the present invention can be used for the prevention, short-term treatment or long-term treatment of the above mentioned diseases / conditions / cancers / tumours, optionally in combination with radiation therapy and / or surgery.
[0178] The methods of treatment, methods, uses and compounds for use disclosed herein (above and below) may be used in combination with compounds of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, and *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof (respectively represented by formula (I), (I * The present invention can be practiced using any pharmaceutical composition or kit comprising any individual embodiment or general subset of compounds represented by (Ia), (Ib), (Ic), (Id), (Ie), or (If).
[0179] Combination treatment In addition, the formula (I), (I * Compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds or salts can also be co-administered with other pharmacologically active substances, such as other anti-neoplastic compounds (e.g., chemotherapy), or used as adjuvants in combination with other treatments, such as radiation or surgical intervention, either pre- or post-operatively. Preferably, the pharmacologically active substance for co-administration is an anti-neoplastic compound.
[0180] Therefore, in a further aspect, the present invention relates to a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein said compound is administered before, after or together with one or more other pharmacologically active substances.
[0181] In a further aspect, the present invention relates to a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein said compound is administered in combination with one or more other pharmacologically active substances.
[0182] In a further aspect, the present invention provides a compound of formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein said compound is administered before, after or together with one or more other pharmacologically active substances.
[0183] In a further aspect, the present invention relates to a method (e.g. a method for treatment and / or prevention) as defined above, wherein the compound of formula (I), (I * A compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof, is administered before, after or together with a therapeutically effective amount of one or more other pharmacologically active substances.
[0184] In a further aspect, the present invention relates to a method (e.g. a method for treatment and / or prevention) as defined above, wherein the compound of formula (I), (I * A compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharmaceutically acceptable salt thereof, is administered in combination with a therapeutically effective amount of one or more other pharmacologically active substances.
[0185] In a further aspect, the present invention provides a method for treating and / or preventing cancer, comprising administering to a patient in need of said treatment and / or prevention a therapeutically effective amount of a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of one or more other pharmacologically active substances, wherein * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is administered simultaneously, concurrently, sequentially, consecutively, alternatingly or separately with one or more other pharmacologically active substances.
[0186] In a further aspect, the present invention relates to a method for treating and / or preventing cancer, comprising administering to a patient in need of said treatment and / or prevention a therapeutically effective amount of an inhibitor of KRAS mutated at residue 12 or 13, such as a KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and / or KRAS G12R inhibitor, preferably a KRAS G12C, KRAS G12D or selective KRAS G12D inhibitor or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of one or more other pharmacologically active substances, wherein the inhibitor or a pharmaceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.
[0187] In a further aspect, the present invention relates to a method for treating and / or preventing cancer, comprising administering to a patient in need of said treatment and / or prevention a therapeutically effective amount of an inhibitor of KRAS wild-type amplification or overexpression, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of one or more other pharmacologically active substances, wherein the inhibitor or a pharmaceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.
[0188] In a further aspect, the present invention relates to a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof is administered simultaneously, simultaneously, sequentially, consecutively, alternately or separately with one or more other pharmacologically active substances, * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof.
[0189] In a further aspect, the present invention relates to an inhibitor of KRAS mutated at residue 12 or 13, such as a KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and / or KRAS G12R inhibitor, preferably a KRAS G12C, KRAS G12D or selective KRAS G12D inhibitor or a pharmaceutically acceptable salt thereof, for use in treating and / or preventing cancer, wherein the inhibitor or pharmaceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.
[0190] In a further aspect, the present invention relates to an inhibitor of the amplification or overexpression of wild-type KRAS, or a pharmaceutically acceptable salt thereof, for use in treating and / or preventing cancer, wherein the inhibitor or the pharmaceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.
[0191] In a further aspect, the present invention provides a method for treating and / or preventing cancer, comprising: Formula (I), (I * a first pharmaceutical composition or dosage form comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients; a second pharmaceutical composition or dosage form comprising another pharmacologically active substance and, optionally, one or more pharmaceutically acceptable excipients; wherein the first pharmaceutical composition is administered simultaneously, simultaneously, sequentially, consecutively, alternatingly or separately from the second and / or additional pharmaceutical compositions or dosage forms.
[0192] In one embodiment, such kit for said use comprises a third pharmaceutical composition or dosage form comprising a third pharmaceutical composition or dosage form comprising a further pharmacologically active substance and optionally one or more pharmaceutically acceptable excipients.
[0193] In a further embodiment of the invention, the components (ie combination partners) and compounds for use of the combination, kit, use, method of the invention (including all embodiments) are administered simultaneously.
[0194] In a further embodiment of the invention, the components (i.e. combination partners) and compounds for use of the combination, kit, use, method of the invention (including all embodiments) are administered concurrently.
[0195] In a further embodiment of the invention, the components (ie combination partners) and compounds for use of the combination, kit, use, method of the invention (including all embodiments) are administered sequentially.
[0196] In a further embodiment of the invention, the components (ie combination partners) of the combination, kit, use, method and compounds for use according to the invention (including all embodiments) are administered sequentially.
[0197] In a further embodiment of the present invention, the components (ie combination partners) of the combination, kit, use, method and compound for use according to the present invention (including all embodiments) are administered alternately.
[0198] In a further embodiment of the invention, the components (ie combination partners) and compounds for use of the combination, kit, use, method of the invention (including all embodiments) are administered separately.
[0199] Formula (I), (I *The pharmacologically active substance used in conjunction with / in combination with a compound of the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof (including any individual embodiment or general subset of the compounds), or in the medical applications, uses, methods of treatment and / or prevention, pharmaceutical compositions defined herein (above and below), may be selected from any one or more of the following (preferably there are one or two additional pharmacologically active substances used in all these embodiments):
[0200] 1. Inhibitors of EGFR and / or ErbB2 (HER2) and / or ErbB3 (HER3) and / or ErbB4 (HER4) or any mutants thereof a. Irreversible inhibitors: for example, afatinib, dacomitinib, canatinib, neratinib, avitinib, poziotinib, AV412, PF-6274484, HKI357, olmutinib, osimertinib, almonertinib, nazartinib, lazertinib, pelitinib; b. Reversible inhibitors: for example, erlotinib, gefitinib, icotinib, sapitinib, lapatinib, varlitinib, vandetanib, TAK-285, AEE788, BMS599626 / AC-480, GW583340; c. Anti-EGFR antibodies: e.g., necitumumab, panitumumab, cetuximab, amivantamab; d. Anti-HER2 antibodies: for example, pertuzumab, trastuzumab, trastuzumab emtansine; e. Inhibitors of mutant EGFR; f. Inhibitors of HER2 with exon 20 mutations; g. Afatinib, the preferred irreversible inhibitor; h. The preferred anti-EGFR antibody is cetuximab.
[0201] 2. Inhibitors of MEK and / or its mutants a. For example, trametinib, cobimetinib, binimetinib, selumetinib, rifametinib; b. Preferably, trametinib c. MEK inhibitors disclosed in WO 2013 / 136249; d. MEK inhibitors disclosed in WO 2013 / 136254.
[0202] 3. Inhibitors of SOS1 and / or any mutants thereof (i.e., compounds that modulate / inhibit the GEF function of SOS1, for example, by binding to SOS1 and interfering with the protein-protein interaction between SOS1 and a (mutated) Ras protein, e.g., KRAS). a. For example, BAY-293; b. SOS1 inhibitors disclosed in WO 2018 / 115380; c. SOS1 inhibitors disclosed in WO 2019 / 122129; d. SOS1 inhibitors disclosed in WO 2020 / 180768, 2020 / 180770, 2018 / 172250 and 2019 / 201848.
[0203] 4. Inhibitors of YAP1, WWTR1, TEAD1, TEAD2, TEAD3 and / or TEAD4 a. Reversible inhibitors of TEAD transcription factors (e.g., those disclosed in WO 2018 / 204532); b. Irreversible inhibitors of TEAD transcription factors (e.g., those disclosed in WO 2020 / 243423); c. Protein-protein interaction inhibitors of the YAP / TAZ::TEAD interaction (e.g., those disclosed in WO 2021 / 186324); d. TEAD palmitoylation inhibitor.
[0204] 5. Oncolytic viruses
[0205] 6. RAS vaccine For example, TG02 (Targovax).
[0206] 7. Cell Cycle Inhibitors a. For example, inhibitors of CDK4 / 6 and / or any mutants thereof i. For example, palbociclib, ribociclib, abemaciclib, trilaciclib, PF-06873600; ii. Preferably, palbociclib and abemaciclib; iii. Most preferably, abemaciclib b. For example, vinca alkaloids i. For example, vinorelbine c. For example, an inhibitor of an Aurora kinase and / or any mutant thereof i. For example, alisertib, barasertib.
[0207] 8. Inhibitors of PTK2 (=FAK) and / or any mutants thereof a. For example, TAE226, BI853520.
[0208] 9. Inhibitors of SHP2 and / or any mutant thereof a. For example, SHP099, TNO155, RMC-4550, RMC-4630, IACS-13909.
[0209] 10. Inhibitors of PI3 kinase (=PI3K) and / or any mutants thereof a. For example, an inhibitor of PI3K alpha and / or any mutant thereof i. For example, alpelisib, selavelisib, GDC-0077, HH-CYH33, AMG511, bupallisib, dactolisib, pictilisib, taselisib.
[0210] 11. Inhibitors of FGFR1 and / or FGFR2 and / or FGFR3 and / or any mutants thereof a. For example, ponatinib, infigratinib, nintedanib.
[0211] 12. Inhibitors of AXL and / or any mutant thereof
[0212] 13. Taxanes a. For example, paclitaxel, nab-paclitaxel, docetaxel; b. Preferably, paclitaxel.
[0213] 14.Platinum-containing compounds a. For example, cisplatin, carboplatin, oxaliplatin b. Preferably, oxaliplatin.
[0214] 15. Antimetabolites a. For example, 5-fluorouracil, capecitabine, floxuridine, cytarabine, gemcitabine, pemetrexed, trifluridine in combination with tipiracil (=TAS102); b. Preferably, 5-fluorouracil.
[0215] 16. Immunotherapeutic agents For example, immune checkpoint inhibitors i. For example, anti-CTLA4 mAb, anti-PD1 mAb, anti-PD-L1 mAb, anti-PD-L2 mAb, anti-LAG3 mAb, anti-TIM3 mAb; ii. Preferably, an anti-PD1 mAb; iii. For example, ipilimumab, nivolumab, pembrolizumab, tislelizumab, atezolizumab, avelumab, durvalumab, pidilizumab, PDR-001 (= spartalizumab), AMG-404, ezabenlimab; iv. Preferably, nivolumab, pembrolizumab, ezabenlimab and PDR-001 (= spartalizumab); v. Most preferably, ezabenlimab, pembrolizumab, and nivolumab.
[0216] 17. Topoisomerase inhibitors a. For example, irinotecan, liposomal irinotecan (nal-IRI), topotecan, etoposide; b. Most preferably, irinotecan and liposomal irinotecan (nal-IRI).
[0217] 18. Inhibitors of A-Raf and / or B-Raf and / or C-Raf and / or any mutants thereof a. For example, encorafenib, dabrafenib, vemurafenib, PLX-8394, RAF-709 (= Example 131 in WO 2014 / 151616), LxH254, sorafenib, LY-3009120 (= Example 1 in WO 2013 / 134243), lifirafenib, TAK-632, agerafenib, CCT196969, RO5126766, RAF265.
[0218] 19. mTOR inhibitors a. For example, rapamycin, temsirolimus, everolimus, ridaforolimus, zotarolimus, sapanisertib, torin 1, dactolisib, GDC-0349, VS-5584, bistosertib, AZD8055.
[0219] 20. Epigenetic regulators For example, a BET inhibitor i. For example, JQ-1, GSK525762, OTX-015, CPI-0610, TEN-010, OTX-015, PLX51107, ABBV-075, ABBV-744, BMS986158, TGI-1601, CC-90010, AZD5153, I-BET151, BI894999.
[0220] 21. Inhibitors of IGF1 / 2 and / or IGF1-R and / or any mutants thereof a. For example, xentuzumab (antibody 60833 in WO 2010 / 066868), MEDI-573 (=dusigitumab), linsitinib.
[0221] 22. Inhibitors of Src family kinases and / or any mutants thereof a. For example, inhibitors of kinases of the SrcA subfamily and / or any mutants thereof, i.e., inhibitors of Src, Yes, Fyn, Fgr and / or any mutants thereof; b. For example, inhibitors of kinases of the SrcB subfamily and / or any mutants thereof, i.e., inhibitors of Lck, Hck, Blk, Lyn and / or any mutants thereof; c. For example, inhibitors of kinases of the Frk subfamily and / or any mutants thereof, i.e., inhibitors of Frk and / or any mutants thereof; d. For example, dasatinib, ponatinib, bosutinib, vandetanib, KX-01, saracatinib, KX2-391, SU6656, WH-4-023.
[0222] 23. Apoptosis regulators a. For example, an MDM2 inhibitor, such as an inhibitor of the interaction between p53 (preferably functional p53, most preferably wtp53) and MDM2 and / or any mutant thereof; i. For example, HDM-201, NVP-CGM097, RG-7112, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115; ii. Preferably, HDM-201, RG-7388 and AMG-232; iii. MDM2 inhibitors disclosed in WO 2015 / 155332; iv. MDM2 inhibitors disclosed in WO 2016 / 001376; v. MDM2 inhibitors disclosed in WO 2016 / 026937; vi. MDM2 inhibitors disclosed in WO 2017 / 060431; b. For example, PARP inhibitors; c. For example, MCL-1 inhibitors; i. For example, AZD-5991, AMG-176, AMG-397, S64315, S63845, A-1210477.
[0223] 24. Inhibitors of c-MET and / or any of its mutants a. For example, savolitinib, cabozantinib, foretinib; b. MET antibodies, e.g., emibetuzumab, amivantamab.
[0224] 25. Inhibitors of ERK and / or any mutant thereof a. For example, ulixertinib, LTT462.
[0225] 26. Inhibitors of farnesyltransferase and / or any mutant thereof For example, tipifarnib.
[0226] In a further embodiment of the (combined) uses and methods (e.g., methods for treatment and / or prevention) described above, one other pharmacologically active substance is a compound of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein said one other pharmacologically active substance is administered before, after or together with SOS1 inhibitors or MEK inhibitors or Trametinib or Anti-PD-1 antibody or Ezabenlimab or Cetuximab or afatinib or Standard of Care (SoC) for a given indication or PI3 kinase inhibitors or Inhibitors of TEAD palmitoylation or -YAP / TAZ::TEAD inhibitor.
[0227] In a further embodiment of the (combined) uses and methods (e.g., methods for treatment and / or prevention) described above, one other pharmacologically active substance is a compound of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein said one other pharmacologically active substance is SOS1 inhibitors or MEK inhibitors or Trametinib or Anti-PD-1 antibody or Ezabenlimab or Cetuximab or afatinib or Standard of Care (SoC) for a given indication or PI3 kinase inhibitors or Inhibitors of TEAD palmitoylation or -YAP / TAZ::TEAD inhibitor.
[0228] In a further embodiment of the (combined) uses and methods (e.g., methods for treatment and / or prevention) described above, the two other pharmacologically active substances are compounds of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein the two other pharmacologically active substances are administered before, after or together with MEK inhibitor and SOS1 inhibitor or Trametinib and SOS1 inhibitors or an anti-PD-1 antibody (preferably, ezabenlimab) and an anti-LAG-3 antibody, or Anti-PD-1 antibody (preferably ezabenlimab) and SOS1 inhibitor or an inhibitor selected from the group consisting of MEK inhibitors and EGFR inhibitors and / or ErbB2 (HER2) inhibitors and / or inhibitors of any mutants thereof; or an inhibitor selected from the group consisting of an SOS1 inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or MEK inhibitors and afatinib or MEK inhibitors and cetuximab or Trametinib and afatinib or Trametinib and cetuximab or SOS1 inhibitors and afatinib or SOS1 inhibitors and cetuximab or SOS1 inhibitors and TEAD palmitoylation inhibitors or -SOS1 inhibitor and YAP / TAZ::TEAD inhibitor.
[0229] In a further embodiment of the (combined) uses and methods (e.g., methods for treatment and / or prevention) described above, the two other pharmacologically active substances are compounds of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof, wherein the two other pharmacologically active substances are MEK inhibitor and SOS1 inhibitor or Trametinib and SOS1 inhibitors or an anti-PD-1 antibody (preferably, ezabenlimab) and an anti-LAG-3 antibody, or Anti-PD-1 antibody (preferably ezabenlimab) and SOS1 inhibitor or an inhibitor selected from the group consisting of MEK inhibitors and EGFR inhibitors and / or ErbB2 (HER2) inhibitors and / or inhibitors of any mutants thereof; or an inhibitor selected from the group consisting of an SOS1 inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or MEK inhibitors and afatinib or MEK inhibitors and cetuximab or Trametinib and afatinib or Trametinib and cetuximab or SOS1 inhibitors and afatinib or SOS1 inhibitors and cetuximab or SOS1 inhibitors and TEAD palmitoylation inhibitors or -SOS1 inhibitor and YAP / TAZ::TEAD inhibitor.
[0230] Formula (I), (I *), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof (formula (I), (I *Additional pharmacologically active substances that may also be used in conjunction with / in combination with the compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or in the medical applications, uses, methods of treatment and / or prevention, pharmaceutical compositions, kits defined herein (above and below) include hormones, hormone analogs and antihormones (e.g., tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglucan, thiazolinone ... Tethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g., anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g., goserelin acetate, leuprolide), growth factors and / or their corresponding receptors (growth factors, e.g., platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), inhibitors of epidermal growth factor (EGF), insulin-like growth factor (IGF), human epidermal growth factor (HER, e.g., HER2, HER3, HER4), and hepatocyte growth factor (HGF) and / or their corresponding receptors (e.g., (anti) growth factor antibodies, (anti) growth factor receptor antibodies, and tyrosine kinase inhibitors, e.g., cetuximab, gefitinib, afatinib, nintedanib, imatinib, lapatinib, bosutinib, bevacizumab, and trastuzumab), antimetabolites (e.g., folate antagonists, e.g., methotrexate, raltitrexed, pi imidine analogs such as 5-fluorouracil (5-FU), ribonucleoside and deoxyribonucleoside analogs, capecitabine and gemcitabine, purine and adenosine analogs such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (araC), fludarabine), antitumor antibiotics (e.g., anthracyclines such as doxorubicin, Doxil (pegylated liposomal doxorubicin hydrochloride, Myocet (non-pegylated liposomal doxorubicin), daunorubicin, epirubicin, and idarubicin,mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin), platinum derivatives (e.g., cisplatin, oxaliplatin, carboplatin), alkylating agents (e.g., estramustine, mechlorethamine, melphalan, chlorambucil, busulfan, dacarbazine, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas (e.g., carmustine and lomustine, thiotepa, etc.), antimitotic agents (e.g., vinca alkaloids (e.g., vinblastine, vindesine, vinorelbine, vincristine, etc.) and taxanes (e.g., paclitaxel, docetaxel), angiogenesis inhibitors (e.g., tasquinimod), tubulin inhibitors, DNA synthesis inhibitors, PARP inhibitors, topoisomerase inhibitors (e.g., epipodophyllotoxins, e.g., etoposide and etopophos, teniposide, amsacrine, topotecan, irinotecan, mitoxantrone, etc.), serine / threonine kinase inhibitors (e.g., PDK1 inhibitors, Raf inhibitors, A-Raf inhibitors, B-Raf inhibitors, C-Raf inhibitors, mTOR inhibitors, mTORC1 / 2 inhibitors, PI3K inhibitors, PI 3Kα inhibitors, dual mTOR / PI3K inhibitors, STK33 inhibitors, AKT inhibitors, PLK1 inhibitors, CDK inhibitors, Aurora kinase inhibitors), tyrosine kinase inhibitors (e.g., PTK2 / FAK inhibitors), protein-protein interaction inhibitors (e.g., IAP inhibitors / SMAC mimetics, Mcl-1, MDM2 / MDMX), MEK inhibitors, ERK inhibitors, FLT3 inhibitors, BRD4 inhibitors, IGF-1R inhibitors, TRAILR2 agonists, Bcl-xL inhibitors, Bcl-2 inhibitors (e.g., venetoclax), Bcl-2 / Bcl-xL inhibitors , ErbB receptor inhibitors, BCR-ABL inhibitors, ABL inhibitors, Src inhibitors, rapamycin analogs (e.g., everolimus, temsirolimus, ridaforolimus, sirolimus), androgen synthesis inhibitors, androgen receptor inhibitors, DNMT inhibitors, HDAC inhibitors, ANG1 / 2 inhibitors, CYP17 inhibitors, radiopharmaceuticals, proteasome inhibitors (e.g., carfilzomib), immunotherapeutic agents, for example, immune checkpoint inhibitors (e.g., CTLA4, PD1, PD-L1, PD-L2, LAG3, TIM3 binding molecules / immunoglobulins,These include, but are not limited to, antibodies against CD33, CD37, CD3xCD19, PSMAxCD3, and the like), immunomodulators such as ipilimumab, nivolumab, pembrolizumab, etc., anti-CDCC (antibody-dependent cell-mediated cytotoxicity) enhancers (e.g., anti-CD33 antibodies, anti-CD37 antibodies, anti-CD20 antibodies), T cell engagers (e.g., bispecific T cell engagers (BiTE®), e.g., CD3xBCMA, CD3xCD33, CD3xCD19, PSMAxCD3, etc.), tumor vaccines, immune modulators such as STING agonists, and various chemotherapeutic agents such as amifostine, anagrelide, clodronat, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole, mesna, mitotane, pamidronate, and porfimer.
[0231] It is to be understood that the combinations, compositions, kits, methods, uses, pharmaceutical compositions for use or compounds of the present invention may contemplate simultaneous, concurrent, sequential, consecutive, alternating or separate administration of the active ingredients or components. * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof and one or more other pharmacologically active substances can be administered in combination, either dependently or independently. For example, a compound of formula (I), (I * It will be understood that a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof and one or more other pharmacologically active substances may be administered either as part of the same pharmaceutical composition / dosage form or, preferably, in separate pharmaceutical compositions / dosage forms.
[0232] In this context, "combination" or "combined" in the sense of the present invention includes, but is not limited to, products resulting from the mixing or combining of two or more active ingredients, and includes both fixed and non-fixed (e.g., free) combinations (including kits) and uses, such as simultaneous, concurrent, sequential, consecutive, alternating or separate use of the ingredients or components. The term "fixed combination" means that the active ingredients are administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients are administered to a patient simultaneously, simultaneously or sequentially as separate entities without any specific time limit, whereby such administration provides therapeutically effective levels of the compounds in the patient's body.
[0233] Formula (I), (I * The administration of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof and one or more other pharmacologically active substances can be achieved by co-administering the active ingredients or components, for example, by administering them simultaneously or simultaneously in a single or two or more separate formulations or dosage forms. Alternatively, a compound of formula (I), (I * The administration of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharmaceutically acceptable salt thereof and one or more other pharmacologically active substances can be carried out by administering the active ingredients or components sequentially or alternately, for example, by administering them in two or more separate formulations or dosage forms.
[0234] For example, co-administration includes administering substantially simultaneously. Such an administration form can also be referred to as "simultaneous" administration. Co-administration includes administering the active agent within the same general period, for example, on the same day, but does not necessarily have to be simultaneous. Alternate administration includes administering one agent over a period, for example, several days or one week, and subsequently administering the other agent over a subsequent period, for example, several days or one week, and then repeating this pattern for one or more cycles. Sequential or continuous administration includes administering one agent during a first period (e.g., over several days or one week) using one or more doses, and subsequently administering the other agent during a second and / or additional period (e.g., over several days or one week) using one or more doses. A repeated schedule can also be utilized, which does not necessarily have to follow a regular order and includes administering the active agent on different days over the treatment period. For example, depending on the agent used and the condition of the subject, these general guidelines can be modified and utilized.
[0235] Definitions Terms not specifically defined herein should be given the meaning that would be ascribed to them by one of ordinary skill in the art in light of the present disclosure and context. However, when used herein, unless otherwise specified, the following terms have the indicated meanings and the following conventions are adhered to.
[0236] Prefix C x-y (where x and y each represent positive integers (x < y)) is used in direct reference and indicates that the chain or ring structure or combination of chain and ring structures as a whole being referred to may consist of a maximum of y and a minimum of x carbon atoms.
[0237] The member count indication of a group containing one or more heteroatoms (e.g., heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl) relates to the sum of the atoms of all ring members or the sum of all ring members and carbon chain members.
[0238] The number of carbon atoms in groups consisting of a combination of a carbon chain and a carbon ring structure (e.g., cycloalkylalkyl, arylalkyl) refers to the total number of carbon atoms in all the carbon ring and carbon chain members. Obviously, the ring structure has at least three members.
[0239] Generally, for groups containing two or more subgroups (e.g., heteroarylalkyl, heteroarylalkyl, cycloalkylalkyl, arylalkyl), the last subgroup in the name is the point of attachment of the group, e.g., the substituent aryl-C 1-6 Alkyl is C 1-6 It refers to an aryl group attached to an alkyl group, which in turn is attached to a core or group to which the substituent is attached.
[0240] For groups such as HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, etc., one skilled in the art may be able to determine the point of attachment of the group to the molecule from the free valence of the group itself.
[0241] The phrase "compounds of the invention" and grammatical variations thereof refer to compounds of formula (I), (I * The compounds of the present invention include compounds of formula (I), (Ib), (Ic), (Id), (Ie) and (If), including all salts, aspects and preferred embodiments thereof as defined herein. * Any reference to compounds designated (Ia), (Ib), (Ic), (Id), (Ie) and (If) is intended to include a reference to each (sub) aspect and embodiment.
[0242] Alkyl refers to a univalent saturated hydrocarbon chain, which may exist in both straight (unbranched) and branched forms. When alkyl is substituted, the substitution may occur independently at each and every hydrogen-bearing carbon atom, by mono- or polysubstitution.
[0243] "C 1-5The term "alkyl" includes, for example, HC-, HC-CH-, HC-CH-CH-, HC-CH(CH)-, HC-CH-CH-CH-, HC-CH(CH)-, HC-CH(CH)-CH-, HC-C(CH)-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH(CH)-, HC-CH-CH(CH)-, HC-CH-CH(CH)-CH-, HC-CH-C(CH)-, HC-C(CH)-CH-, HC-CH(CH)-CH(CH)- and HC-CH-CH(CHCH)-.
[0244] Further examples of alkyl are methyl (Me; -CH3), ethyl (Et; -CH2CH3), 1-propyl (n-propyl; n-Pr; -CH2CH2CH3), 2-propyl (i-Pr; isopropyl; -CH(CH3)2), 1-butyl (n-butyl; n-Bu; -CH2CH2CH2CH3), 2-methyl-1-propyl (isobutyl; i-Bu; -CH2CH(CH3)2), 2-butyl (sec-butyl; sec-Bu; -CH(CH3)CH2CH3), 2-methyl-2-propyl (tert-butyl; t-Bu; -C(CH3)3), 1-pentenyl (n-butyl; n-Bu; -CH2CH2CH2CH3), 2-methyl-3-propyl (tert-butyl; t-Bu; -C(CH3)3), 2-pentenyl (n-butyl; n-Bu; -CH2 ... ethyl (n-pentyl; -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 3-methyl-1-butyl (isopentyl; -CH2CH2CH(CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 2,2-dimethyl-1-propyl (neopentyl; -CH2C(CH3)3), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (n-hexyl;-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH( CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), 2,3-dimethyl-1-butyl (-CH2C H(CH3)CH(CH3)CH3), 2,2-dimethyl-1-butyl (-CH2C(CH3)2CH2CH3), 3,3-dimethyl-1-butyl (-CH2CH2C(CH3)3), 2-methyl-1-pentyl (-CH2CH(CH3)CH2CH2CH3), 3-methyl-1-pentyl (-CH2CH2CH(CH3)CH2CH3), 1-heptyl (n-heptyl) , 2-methyl-1-hexyl, 3-methyl-1-hexyl, 2,2-dimethyl-1-pentyl, 2,3-dimethyl-1-pentyl, 2,4-dimethyl-1-pentyl, 3,3-dimethyl-1-pentyl, 2,2,3-trimethyl-1-butyl, 3-ethyl-1-pentyl, 1-octyl (n-octyl), 1-nonyl (n-nonyl), 1-decyl (n-decyl), etc.;
[0245] The terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc., without further definition, refer to saturated hydrocarbon groups having the corresponding number of carbon atoms, whereby all isomers are included.
[0246] Also, the above definition of alkyl does not apply to alkyl when it is part of another (linked) group, e.g., C x-y Alkylamino or C x-y This also applies to alkyloxy and the like.
[0247] The term alkylene can also be derived from alkyl. Unlike alkyl, alkylene is divalent and requires two binding partners. Formally, it becomes divalent by removing a hydrogen atom from alkyl. Corresponding groups are, for example, -CH3 and -CH2-, -CH2CH3 and -CH2CH2-, or >CHCH3.
[0248] "C 1-4 The term "alkylene" refers to, for example, -(CH2)-, -(CH2-CH2)-, -(CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(CH(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH(CH3)-C H2-CH2)-, -(CH2-CH(CH3)-CH2)-, -(CH2-C(CH3)2)-, -(C(CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2- CH(CH2CH3))-, -(CH(CH2CH3)-CH2)-, -(CH(CH2CH2CH3))-, -(CH(CH(CH3))2)- and -C(CH3)(CH2CH3)-.
[0249] Other examples of alkylene are methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, hexylene, and the like.
[0250] The generic terms propylene, butylene, pentylene, hexylene, etc., without further definition, refer to all possible isomers with the corresponding number of carbon atoms, i.e. propylene includes 1-methylethylene, butylene includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.
[0251] The above definition of alkylene does not apply to alkylene when it is part of another (linked) group, e.g., HO-C x-y Alkyleneamino or H2N-C x-y This also applies to alkyleneoxy and the like.
[0252] Unlike alkyl, alkenyl consists of at least two carbon atoms, where at least two adjacent carbon atoms are connected by a C—C double bond, and a carbon atom may be part of only one C—C double bond. In the above-defined alkyl having at least two carbon atoms, when two hydrogen atoms on adjacent carbon atoms are formally removed to saturate the free valences and form a second bond, the corresponding alkenyl is formed.
[0253] Examples of alkenyl are vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, 1-methyl-prop-1-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl , 3-methyl-but-1-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3-methylbutyl, 2,3-dimethyl-but-1-enyl, hexa-1,3-dienyl, hexa-1,4-dienyl, penta-1,4-dienyl, penta-1,3-dienyl, buta-1,3-dienyl, 2,3-dimethylbuta-1,3-dienyl, and the like.
[0254] The generic terms propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl, etc., without further definition, refer to all possible isomers with the corresponding number of carbon atoms, i.e. propenyl includes prop-1-enyl and prop-2-enyl, butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, etc.
[0255] The alkenyl may optionally be in the cis or trans or E or Z orientation about the double bond(s).
[0256] The above definition of alkenyl also applies when the alkenyl is part of another (linked) group, e.g., C x-y Alkenylamino or C x-y This also applies to the case of alkenyloxy and the like.
[0257] Unlike alkyl, alkynyl consists of at least two carbon atoms, where at least two adjacent carbon atoms are joined by a C-C triple bond; in an alkyl as defined above having at least two carbon atoms, when two hydrogen atoms on each of the adjacent carbon atoms are formally removed to saturate the free valences and form two additional bonds, the corresponding alkynyl is formed.
[0258] Examples of alkynyl are ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, and the like.
[0259] The generic terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc., without further definition, refer to all possible isomers with the corresponding number of carbon atoms, i.e. propynyl includes prop-1-ynyl and prop-2-ynyl, butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl, 1-methyl-prop-2-ynyl, etc.
[0260] If the hydrocarbon chain has both at least one double bond and at least one triple bond, then by definition it belongs to the alkynyl subgroup.
[0261] The above definition of alkynyl also applies when alkynyl is part of another (linked) group, e.g., C x-y Alkynylamino or C x-y This also applies to the case of alkynyloxy.
[0262] Unlike alkylene, alkynylene consists of at least two carbon atoms, where at least two adjacent carbon atoms are joined by a C—C triple bond. In the above-defined alkylene having at least two carbon atoms, when two hydrogen atoms on each of the adjacent carbon atoms are formally removed to saturate the free valences and form two additional bonds, the corresponding alkynylene is formed.
[0263] Examples of alkynylene are ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene, and the like.
[0264] The generic terms propynylene, butynylene, pentynylene, hexynylene, etc., without further definition, refer to all possible isomers with the corresponding number of carbon atoms, i.e. propynylene includes 1-methylethynylene, butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.
[0265] The above definition of alkynylene also applies when alkynylene is part of another (linked) group, e.g., HO-C x-y Alkynyleneamino or H2N-C x-y This also applies to the case of alkynyleneoxy.
[0266] Heteroatoms means oxygen, nitrogen and sulfur atoms.
[0267] A haloalkyl (haloalkenyl, haloalkynyl) is derived from an alkyl (alkenyl, alkynyl) as defined above by independently replacing one or more hydrogen atoms of the hydrocarbon chain with halogen atoms, which may be the same or different. If a haloalkyl (haloalkenyl, haloalkynyl) is further substituted, the substitutions may occur independently at each and every hydrogen-bearing carbon atom, in the form of mono- or polysubstitutions.
[0268] Examples of haloalkyl (haloalkenyl, haloalkynyl) are -CF3, -CHF2, -CH2F, -CF2CF3, -CHFCF3, -CH2CF3, -CF2CH3, -CHFCH3, -CF2CF2CF3, -CF2CH2CH3, -CF=CF2, -CCl=CH2, -CBr=CH2, -C≡C-CF3, -CHFCH2CH3, -CHFCH2CF3, and the like.
[0269] The terms haloalkylene (haloalkenylene, haloalkynylene) are also derived from the haloalkyl (haloalkenyl, haloalkynyl) defined above. Haloalkylene (haloalkenylene, haloalkynylene) differs from haloalkyl (haloalkenyl, haloalkynyl) in that it is divalent and requires two binding partners. Formally, the divalent form is formed by removing a hydrogen atom from a haloalkyl (haloalkenyl, haloalkynyl).
[0270] Corresponding groups are, for example, -CH2F and -CHF-, -CHFCH2F and -CHFCHF- or >CFCH2F, etc.
[0271] The above definitions also apply when the corresponding halogen-containing group is part of another (linked) group.
[0272] Halogen denotes fluorine, chlorine, bromine and / or iodine atoms.
[0273] Cycloalkyl is made up of the subgroups monocyclic cycloalkyl, bicyclic cycloalkyl and spirocycloalkyl. The ring systems are saturated and formed by linked carbon atoms. In bicyclic cycloalkyl, the two rings are connected so that they share at least two carbon atoms. In spirocycloalkyl, one carbon atom (spiroatom) belongs to both rings.
[0274] If a cycloalkyl is substituted, the substitutions may occur independently at each and every hydrogen-bearing carbon atom in the form of mono- or polysubstitutions. The cycloalkyl itself may be linked to the molecule as a substituent via any suitable position on the ring system.
[0275] Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthyl), bicyclo[2.2.1]heptyl (norbornyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo[3.1.1]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl, and the like.
[0276] The above definition of cycloalkyl also applies when cycloalkyl is part of another (linked) group, e.g., C x-y Cycloalkylamino, C x-y Cycloalkyloxy or C x-y This also applies to the case where cycloalkyl is alkyl.
[0277] If the free valence of a cycloalkyl is saturated, an alicyclic is obtained.
[0278] Thus, the term cycloalkylene can be derived from cycloalkyl as defined above. Cycloalkylene, unlike cycloalkyl, is bivalent and requires two binding partners. Formally, bivalency is obtained by removing a hydrogen atom from cycloalkyl. Corresponding groups include, for example, cyclohexyl and [ka] is.
[0279] Also, the above definition of cycloalkylene does not apply to cycloalkylene when it is part of another (linked) group, e.g., HO—C x-y Cycloalkyleneamino or H2N-C x-y This also applies to the case of cycloalkyleneoxy and the like.
[0280] Cycloalkenyl is comprised of the subgroups monocyclic cycloalkenyl, bicyclic cycloalkenyl, and spirocycloalkenyl, provided that the ring system is unsaturated, i.e., at least one C-C double bond is present, but an aromatic system is not. In the cycloalkyl defined above, two hydrogen atoms at adjacent ring carbon atoms are formally removed to saturate the free valences and form a second bond to give the corresponding cycloalkenyl.
[0281] If a cycloalkenyl is substituted, the substitutions may occur independently at each and every hydrogen-bearing carbon atom in the form of mono- or polysubstitutions. The cycloalkenyl itself may be linked to the molecule as a substituent via any suitable position on the ring system.
[0282] Examples of cycloalkenyl include cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2-enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobut-1,3-dienyl, cyclopenta- -1,4-dienyl, cyclopenta-1,3-dienyl, cyclopenta-2,4-dienyl, cyclohexa-1,3-dienyl, cyclohexa-1,5-dienyl, cyclohexa-2,4-dienyl, cyclohexa-1,4-dienyl, cyclohexa-2,5-dienyl, bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl), bicyclo[2.2.1]hept-2-enyl (norbornenyl), spiro[4,5]dec-2-enyl, and the like.
[0283] The above definition of cycloalkenyl also applies when the cycloalkenyl is part of another (linked) group, e.g., C x-y Cycloalkenylamino, C x-y Cycloalkenyloxy or C x-yThis also applies to the case of cycloalkenylalkyl, etc.
[0284] If the free valence of the cycloalkenyl is saturated, an unsaturated cycloaliphatic is obtained.
[0285] Thus, the term cycloalkenylene can be derived from the previously defined cycloalkenyl. Cycloalkenylene, unlike cycloalkenyl, is divalent and requires two binding partners. Formally, divalency is obtained by removing a hydrogen atom from cycloalkenyl. Corresponding groups include, for example, cyclopentenyl and [ka] is.
[0286] Also, the above definition of cycloalkenylene does not apply to cycloalkenylene when it is part of another (linked) group, e.g., HO—C x-y Cycloalkenyleneamino or H2N-C x-y This also applies to the case of cycloalkenyleneoxy and the like.
[0287] Aryl denotes a mono-, bi- or tri-carbocycle having at least one aromatic carbocycle. Preferably, it denotes a monocyclic group having 6 carbon atoms (phenyl) or a bicyclic group having 9 or 10 carbon atoms (two 6-membered rings or one 6-membered ring with a 5-membered ring), where the second ring may also be aromatic or, alternatively, partially saturated.
[0288] When an aryl is substituted, the substitution may occur independently at each and every hydrogen-bearing carbon atom in the form of mono- or polysubstitution. The aryl itself may be linked to the molecule as a substituent via any suitable position of the ring system.
[0289] Examples of aryl are phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2-dihydronaphthyl), fluorenyl, etc. Phenyl is most preferred.
[0290] The above definition of aryl also applies when aryl is part of another (linked) group, such as arylamino, aryloxy or arylalkyl.
[0291] If the free valence of an aryl is saturated, an aromatic group results.
[0292] The term arylene can also be derived from aryl, as defined above. Arylene, unlike aryl, is bivalent and requires two binding partners. Formally, the bivalent is formed by removing a hydrogen atom from aryl. Corresponding groups include, for example, phenyl and [ka] , naphthyl and [ka] is.
[0293] The above definition of arylene also applies when arylene is part of another (linked) group, such as, for example, HO-aryleneamino or H2N-aryleneoxy.
[0294] Heterocyclyl refers to a ring system derived from the previously defined cycloalkyl, cycloalkenyl, and aryl by independently replacing one or more -CH2- groups in the hydrocarbon ring with -O-, -S-, or -NH- groups, or by replacing one or more =CH- groups with =N- groups. Here, a total of up to five heteroatoms may be present, and at least one carbon atom must be present between two oxygen atoms and two sulfur atoms or between an oxygen atom and a sulfur atom, so that the ring as a whole is chemically stable. Heteroatoms may optionally be present in all possible oxidation states (sulfur → sulfoxide -SO2-, sulfone -SO2-; nitrogen → N-oxide). In heterocyclyl, there is no heteroaromatic ring, i.e., the heteroatoms are not part of the aromatic system.
[0295] A direct consequence of the cycloalkyl, cycloalkenyl, and aryl derivatives is that heterocyclyl is comprised of monocyclic heterocyclyl, bicyclic heterocyclyl, tricyclic heterocyclyl, and spiroheterocyclyl subsubstrates, which may exist in saturated or unsaturated form.
[0296] Unsaturated means that the ring system contains at least one double bond, but does not form a heteroaromatic system. In a bicyclic heterocyclyl, the two rings are connected by sharing at least two (hetero)atoms. In a spiroheterocyclyl, one carbon atom (spiroatom) belongs to both rings.
[0297] If a heterocyclyl is substituted, the substitutions may occur independently at each and every hydrogen-bearing carbon and / or nitrogen atom in the form of mono- or polysubstitutions. The heterocyclyl itself may be linked to the molecule as a substituent via any suitable position on the ring system. Substituents on a heterocyclyl are not counted in the member count of the heterocyclyl.
[0298] Examples of heterocyclyl are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-dioxide. Oxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [1,4]-oxazepanyl, tetrahydrothienyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide, tetrahydrothienyl-S,S-dioxide, homothiomorpholinyl-S-oxide Cid, 2,3-dihydroazet, 2H-pyrrolyl, 4H-pyranyl, 1,4-dihydropyridinyl, 8-aza-bicyclo[3.2.1]octyl, 8-aza-bicyclo[5.1.0]octyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo[2.2.1]heptyl, 1-aza-bicyclo[2.2.2]octyl, 3,8-diaza -bicyclo[3.2.1]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl, 2,6-diaza-bicyclo[3.2.2]nonyl, 1,4-dioxa-spiro[4.5]decyl, 1-oxa-3,8-diaza-spiro[4.5]decyl, 2,6-diaza-spiro[3.3]heptyl, 2,7-diaza-spiro[4.4]nonyl, 2,6-diaza-spiro[3.4]octyl, 3,9-diaza-spiro[5.5]undecyl, 2,8-diaza-spiro[4,5]decyl, and the like.
[0299] Further examples are the structures illustrated below, which may be attached via (exchanging with) each hydrogen-carrying atom.
[0300] [ka] TIFF2024543967000046.tif229165 TIFF2024543967000047.tif234165 TIFF2024543967000048.tif207165
[0301] Preferred monocyclic heterocyclyls are 4 to 7 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur.
[0302] Preferred monocyclic heterocyclyls are piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl and azetidinyl.
[0303] Preferred bicyclic heterocyclyls are 6-10 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
[0304] Preferred tricyclic heterocyclyls are nine-membered and have one or two heteroatoms independently selected from oxygen, nitrogen, and sulfur.
[0305] Preferred spiroheterocyclyls are 7-11 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
[0306] The above definition of heterocyclyl also applies when heterocyclyl is part of another (linked) group, such as, for example, heterocyclylamino, heterocyclyloxy or heterocyclylalkyl.
[0307] If the free valence of a heterocyclyl is saturated, a heterocyclic ring is obtained.
[0308] The term heterocyclylene is also derived from the heterocyclyl defined above, which, unlike heterocyclyl, is bivalent and requires two binding partners. Formally, bivalency is obtained by removing a hydrogen atom from a heterocyclyl. Corresponding groups include, for example, piperidinyl and [ka] , 2,3-dihydro-1H-pyrrolyl and [ka] is.
[0309] The above definition of heterocyclylene also applies when heterocyclylene is part of another (linked) group, such as, for example, HO-heterocyclyleneamino or H2N-heterocyclyleneoxy.
[0310] Heteroaryl refers to a monocyclic heteroaromatic ring or a polycyclic ring having at least one heteroaromatic ring, and compared to the corresponding aryl or cycloalkyl(alkenyl), it contains one or more identical or different heteroatoms independently selected from nitrogen, sulfur and oxygen instead of one or more carbon atoms, where the resulting group must be chemically stable. The prerequisite for the existence of heteroaryl is the heteroatom and heteroaromatic system.
[0311] When a heteroaryl is substituted, the substitution may occur independently at each of all hydrogen-bearing carbon atoms and / or nitrogen atoms in the form of mono- or polysubstitution. The heteroaryl itself may be linked to the molecule as a substituent through both carbon and nitrogen at any suitable position of the ring system. Substituents on a heteroaryl are not counted in the number of members of the heteroaryl.
[0312] Examples of heteroaryl are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyridyl-N-oxide, pyrrolyl-N-oxide, pyrimidinyl-N-oxide, pyridazinyl-N-oxide, pyrazinyl-N-oxide, imidazolyl-N-oxide, isoxazolyl-N-oxide, oxazolyl-N-oxide, thiazolyl-N-oxide, oxadiazolyl-N-oxide, thiadiazolyl-N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, indolyl, isoindolyl, benzofuryl, benzothienyl, benzoxazolyl, benzophenone ... Benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzotriazinyl, indolizinyl, oxazolopyridyl, imidazopyridyl, naphthyridinyl, benzoxazolyl, pyridopyridyl, pyrimidopyridyl, purinyl, pteridinyl, benz Examples of the benzothiazolyl-N-oxide include benzothiazolyl, imidazopyridyl, imidazothiazolyl, quinolinyl-N-oxide, indolyl-N-oxide, isoquinolyl-N-oxide, quinazolinyl-N-oxide, quinoxalinyl-N-oxide, phthalazinyl-N-oxide, indolizinyl-N-oxide, indazolyl-N-oxide, benzothiazolyl-N-oxide, and benzimidazolyl-N-oxide.
[0313] Further examples are the structures illustrated below, which may be attached via (exchanging with) each hydrogen-carrying atom.
[0314] [ka] TIFF2024543967000052.tif117165
[0315] Preferably, the heteroaryl is a 5- to 6-membered monocyclic or a 9- to 10-membered bicyclic ring, each having 1 to 4 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
[0316] The above definition of heteroaryl also applies when heteroaryl is part of another (linked) group, such as heteroarylamino, heteroaryloxy, or heteroarylalkyl.
[0317] If the free valence of a heteroaryl is saturated, a heteroaromatic group results.
[0318] The term heteroarylene is also derived from heteroaryl as defined above. Heteroarylene, unlike heteroaryl, is bivalent and requires two binding partners. Formally, bivalency is achieved by removing a hydrogen atom from heteroaryl. Corresponding groups include, for example, pyrrolyl and [ka] is.
[0319] The above definition of heteroarylene also applies when heteroarylene is part of another (linked) group, such as, for example, HO-heteroaryleneamino or H2N-heteroaryleneoxy.
[0320] Substituted means that a hydrogen atom directly bonded to the atom in question has been replaced by another atom or group of atoms (substituents). Depending on the starting conditions (number of hydrogen atoms), mono- or polysubstitutions may occur on an atom. Substitution with a specific substituent is only possible if the allowed valences of the substituent and the atom to be substituted correspond to each other and the substitution results in a stable compound (i.e., a compound that does not spontaneously transform, for example, by rearrangement, cyclization, or elimination).
[0321] Divalent substituents such as =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N2, etc. may be substituents on carbon atoms only, while the divalent substituents =O and =NR may be substituents on sulfur atoms. Generally, substitution by a divalent substituent can only occur on a ring system and requires the replacement of two geminal hydrogen atoms, i.e., hydrogen atoms attached to the same carbon atom that is saturated before substitution. Thus, substitution by a divalent substituent can only occur on the -CH2- group or sulfur atom of the ring system (only =O or =NR groups, one or two =O groups are possible, or, for example, one =O and one =NR group are possible, each group replacing a free electron pair).
[0322] It is to be understood that all disclosure of atoms or compounds of the invention includes all suitable isotopic variations, particularly reference to hydrogen also includes deuterium.
[0323] Stereochemistry / Solvates / Hydrates: Unless otherwise specified, throughout this specification and the appended claims, a given chemical formula or name is intended to include tautomers and all stereoisomers, optical isomers, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) thereof, as well as racemates and mixtures of different proportions of separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms, and also to include salts and solvates thereof, including pharmaceutically acceptable salts thereof, where such isomers and enantiomers exist, such as hydrates and solvates of the free compound or of a salt of said compound.
[0324] Generally, substantially pure stereoisomers can be obtained according to synthetic principles known to those skilled in the art, for example, by separation of corresponding mixtures, by using stereochemically pure starting materials and / or by stereoselective synthesis. Methods for preparing optically active forms are known in the art, for example, by separation of racemic forms or, for example, by synthesis starting from optically active starting materials and / or by use of chiral reagents.
[0325] Enantiomerically pure compounds or intermediates of the invention can be prepared, for example, by asymmetric synthesis by preparation and subsequent separation of suitable diastereomeric compounds or intermediates which can be separated by known methods (e.g., by chromatographic separation or crystallization) and / or by using chiral reagents, e.g., chiral starting materials, chiral catalysts, or chiral auxiliaries.
[0326] Furthermore, methods for preparing enantiomerically pure compounds from the corresponding racemic mixture are known to those skilled in the art, for example by chromatographic separation of the corresponding racemic mixture on a chiral stationary phase or by resolution of the racemic mixture using a suitable resolving agent, for example by forming diastereomeric salts of the racemate with an optically active acid or base and subsequently resolving the salts and releasing the desired compounds from the salts, or by derivatizing the corresponding racemate with an optically active chiral auxiliary reagent and subsequently separating the diastereomers and removing the chiral auxiliary, or by dynamic resolution of the racemate (for example by enzymatic resolution), enantioselective crystallization from a collection of mirror image crystals under suitable conditions or (partial) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.
[0327] Salts: As used herein, the phrase "pharmaceutically acceptable" is used to refer to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0328] As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds, wherein the parent compound is modified by forming acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues, such as amines, alkali or organic salts of acidic residues, such as carboxylic acids, etc.
[0329] For example, such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid.
[0330] Further pharmaceutically acceptable salts can be formed with cations from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane.
[0331] The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of the appropriate base or acid in water or an organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
[0332] For example, salts of acids other than those mentioned above (eg, trifluoroacetates) that are useful for purifying or isolating the compounds of the invention also form part of this invention.
[0333] for example, [ka] In expressions such as the above, the letter A functions as a ring designator, for example, to more easily show the attachment of the ring to other rings.
[0334] For divalent groups where it is important to determine which adjacent group is bonded to which valency, the following notation may be used where necessary for clarification: [ka] or (R2 )-C(=O)NH- or (R 2 )-NHC(=O)-, the corresponding binding partner is shown in brackets.
[0335] In the absence of such specification, divalent groups may be attached in both directions, i.e., -C(=O)NH- also includes -NHC(=O)- and vice versa.
[0336] Groups or substituents are often referred to by the corresponding group designation (e.g., R a , R b It is noted that when such a group is used repeatedly in defining a compound of the invention in different parts of the molecule, the various uses are considered to be entirely independent of each other.
[0337] For purposes of this invention, a therapeutically effective amount means that amount of substance that is capable of avoiding symptoms of the disease or preventing or alleviating these symptoms or prolonging the survival of the treated patient.
[0338] List of Abbreviations [Table 1] TIFF2024543967000057.tif224161 TIFF2024543967000058.tif44161
[0339] Example The features and advantages of the present invention will become apparent from the following detailed examples which illustrate, by way of example, the principles of the invention without limiting its scope.
[0340] Preparation of Compounds of the Invention General Unless otherwise stated, all reactions are carried out with commercially available equipment using methods commonly used in chemical laboratories. Air- and / or moisture-sensitive starting materials are stored under protective gas, and the corresponding reactions and manipulations thereon are carried out under protective gas (nitrogen or argon).
[0341] When a compound is represented by both a structural formula and its nomenclature, in the event of a conflict, the structural formula takes precedence.
[0342] Microwave reactions are carried out in an initiator / reactor from Biotage or an Explorer from CEM or a Synthos 3000 or Monowave 3000 from Anton Paar in a closed vessel (preferably 2, 5 or 20 mL), preferably with stirring.
[0343] Chromatography Thin layer chromatography is performed on Merck pre-made glass-on-glass silica gel 60 TLC plates (with fluorescent indicator F-254).
[0344] Preparative high performance chromatography (RPHPLC) of the example compounds of the present invention is carried out on an Agilent or Gilson system equipped with a Waters column (designation: SunFire™ Prep C18, OBD™ 10 μm, 50 × 150 mm, or SunFire™ Prep C18, OBD™ 5 μm, 30 × 50 mm, or XBridge™ Prep C18, OBD™ 10 μm, 50 × 150 mm, or XBridge™ Prep C18, OBD™ 5 μm, 30 × 150 mm, or XBridge™ Prep C18, OBD™ 5 μm, 30 × 50 mm) and a YMC column (designation: Actus-Triart Prep C18, 5 μm, 30 × 50 mm).
[0345] Compounds were eluted using various gradients of HO / ACN, whereas for the Agilent system, 5% acidity modifier (20 mL HCOOH per 1 L HO / ACN (1 / 1)) was added to water (acidic conditions), and for the Gilson system, 0.1% HCOOH was added to water.
[0346] For chromatography under basic conditions on the Agilent system, a HO / ACN gradient is also used, while the water is made alkaline by adding a 5% basic modifier (50 g NH4HCO3 + 50 mL NH3 (25% in HO) to 1 L with HO). For the Gilson system, the water is made alkaline as follows: 5 mL of NH4HCO3 solution (158 g in 1 L HO) and 2 mL of NH3 (28% in HO) are added and the volume is made up to 1 L with HO.
[0347] Supercritical fluid chromatography (SFC) of the intermediates and example compounds of the present invention is carried out on a JASCO SFC system using the following columns: Chiralcel OJ (250×20 mm, 5 μm), Chiralpak AD (250×20 mm, 5 μm), Chiralpak AS (250×20 mm, 5 μm), Chiralpak IC (250×20 mm, 5 μm), Chiralpak IA (250×20 mm, 5 μm), Chiralcel OJ (250×20 mm, 5 μm), Chiralcel OD (250×20 mm, 5 μm), Phenomenex Lux C2 (250×20 mm, 5 μm).
[0348] Analytical HPLC (reaction control) of intermediates and final compounds is carried out using a Waters column (XBridge™ C18, 2.5 μm, 2.1 × 20 mm or XBridge™ C18, 2.5 μm, 2.1 × 30 mm or Aquity UPLC BEH C18, 1.7 μm, 2.1 × 50 mm), a YMC column (Triart C18, 3.0 μm, 2.0 × 30 mm), and a Phenomenex column (Luna C18, 5.0 μm, 2.0 × 30 mm). Each analytical instrument is also equipped with a mass detector.
[0349] HPLC-Mass Spectrometry / UV Spectroscopy Retention Time / MS-ESI for Characterizing Example Compounds of the Invention + is generated using an HPLC-MS system (high performance liquid chromatography with mass detection). Compounds eluting with the injection peak are identified with retention times t Ret =0.00.
[0350] Method A HPLC Agilent 1100 system MS 1200 Series LC / MSD (API-ES + / -3000V, quadrupole, G6140) MSD signal setting scan positive / negative 120~900m / z Detection signal 315 nm (bandwidth 170 nm, reference off) Spectral range: 230-400nm Peak width <0.01 min Column: Waters, XBridge C18, 2.5 μm, 2.1 × 20 mm column Column temperature: 60°C Solvent A: 20mM NH4HCO3 / NH3 aqueous solution, pH 9 B: ACN HPLC grade Flow rate 1.00mL / min Gradient 0.00-1.50 min 10% to 95% B 1.50~2.00 minutes 95% B 2:00-2:10 min 95% to 10% B
[0351] Method B HPLC Agilent 1260 Series MS 1200 Series LC / MSD (MM-ES+APCI + / -3000V, Quadrupole, G6130) Detection UV: 254 nm (bandwidth 8, reference off) UV: 230 nm (bandwidth 8, reference off) UV spectrum range: 190~400nm, step: 4nm MS: positive and negative modes Mass range: 100-800 m / z Column: Waters; Part Number 186003389; XBridge BEH C18, 2.5 μm, 30 x 2.1 mm Column temperature: 45°C Solvent A: 5 mM NH4HCO3 / 19 mM NH3 in H2O; B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00-1.00 min: 5% B to 100% B 1.00~1.37 minutes: 100% B 1.37-1.40 min: 100% B to 5% B
[0352] Method C HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range 100~750m / z Column: Waters X-Bridge BEH C18, 2.5 μm, 2.1 x 30 mm XP Column temperature: 45°C Solvent A: 20 mM NH4HCO3 / 30 mM NH3 in H2O; B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.0~1.00 min 15% to 95% B 1.0~1.30 minutes 95% B
[0353] Method D HPLC Agilent 1100 / 1200 system MS 1200 Series LC / MSD (MM-ES+APCI + / -3000V, quadrupole, G6130B) MSD Signal Settings Scan Positive 150~750 Detection signal: UV 254 nm, 230 nm, 214 nm (bandwidth 8, reference off) Spectral range: 190~400nm; slit: 4nm Peak width >0.0031 min (response time 0.063 sec, 80 Hz) Column: Waters, part number 186003389, XBridge BEH C18, 2.5 μm, 2.1 x 30 mm column Column temperature: 45°C Solvent A: 5 mM NH4HCO3 / 18 mM NH3 in H2O (pH = 9.2) B: ACN (HPLC grade) Flow rate 1.4mL / min Gradient 0.0-1.0 min 15% to 95% B 1.0~1.1 minutes 95% B Downtime: 1.3 minutes
[0354] Method E HPLC Agilent 1100 / 1200 system MS 1200 Series LC / MSD (MM-ES+APCI + / -3000V, quadrupole, G6130B) MSD Signal Settings Scan Positive / Negative 150~750 Detection signal: UV 254 nm, 230 nm, 214 nm (bandwidth 8, reference off) Spectral range: 190~400nm; slit: 4nm Peak width >0.0031 min (response time 0.063 sec, 80 Hz) Column: Waters, part number 186003389, XBridge BEH C18, 2.5 μm, 2.1 x 30 mm column Column temperature: 45°C Solvent A: 5 mM NH4HCO3 / 18 mM NH3 in H2O (pH = 9.2) B: ACN (HPLC grade) Flow rate 1.4mL / min Gradient 0.0-1.0 min 15% to 95% B 1.0~1.1 minutes 95% B Downtime: 1.3 minutes
[0355] Method F HPLC Agilent 1100 / 1200 system MS 1200 Series LC / MSD (API-ES + / -3000 / 3500V, quadrupole, G6140A) MSD Signal Settings Scan Positive / Negative 150~750 Detection signal: UV 254 nm, 230 nm, 214 nm (bandwidth 10, reference off) Spectral range: 190~400nm; slit: 4nm Peak width >0.0031 min (response time 0.063 sec, 80 Hz) Column: YMC; Part Number TA12S03-0302WT; Triart C18, 3 μm, 12 nm; 30 x 2.0 mm column Column temperature: 45°C Solvent A: H2O + 0.11% formic acid B: ACN + 0.1% formic acid (HPLC grade) Flow rate 1.4mL / min Gradient 0.0-1.0 min 15% to 95% B 1.0~1.1 minutes 95% B Downtime 1.23 minutes
[0356] Method G UPLC-MS Waters Acquity-UPLC-SQ Detector-2 MSD signal setting scan positive / negative 100~1500, Source voltage: Capillary voltage (kV) -3.50, Cone (V): 50 Source Temp: Desolvation Temp (℃): 350 Source gas flow rate: Desolvation (L / Hr): 750, Cone (L / Hr): 50 Detection signal Diode array Spectral range: 200~400nm; resolution: 1.2nm Sampling rate: 10 points / second Column: AQUITY UPLC BEH C18 1.7 μm, 2.1 x 50 mm Column temperature: 35°C Solvent A: 0.07% formic acid in ACN B: 0.07% formic acid in water Flow rate 0.6mL / min Gradient 0.0-0.30 min 97% B 0.30-2.20 min 97% to 2% B 2.20~3.30 minutes 2% B 3:30-4:50 min 2% to 97%B 4.50~4.51 minutes 97% B
[0357] Method H UPLC-MS Waters Acquity - Binary Solvent Manager - UPLC-SQ Detector - 2 MSD Signal Settings Scan Positive & Negative 100~1500 Source voltage: Capillary voltage (kV) -3.50, Cone (V): 50 Source Temp: Desolvation Temp (℃): 350 Source gas flow rate: Desolvation (L / Hr): 750, Cone (L / Hr): 50 Detection signal Diode array Spectral range: 200~400nm; resolution: 1.2nm Sampling rate: 10 points / second Column: AQUITY UPLC BEH C18 1.7 μm, 2.1 x 50 mm Column temperature: 35°C Solvent A: 0.07% formic acid in ACN B: 0.07% formic acid in water Flow rate 0.6mL / min Gradient 0.0-0.40 min 97% B 0.40-2.50 min 97% to 2% B 2.50~3.40 minutes 2% B 3.40-3.50 min 2% to 97%B 3.50~4.0 minutes 97% B
[0358] Method I LC-MS Waters Arc-HPLC-SQ Detector-2 MSD signal settings ESI scan positive & negative Capillary voltage 3.50kV, cone voltage 30V, desolvation gas 750L / Hr, desolvation temperature 350℃ Column: X-Bridge C18, 4.6 x 75 mm, 3.5 μm Column temperature: 35°C Solvent A: 10 mM ammonium acetate in water B:ACN Flow rate 1.0mL / min Gradient 0.0-0.75 min 5% B 0.75-1.50 min 5% to 40% B 1.50-5.0 min 40% to 98% B 5.0~7.0 minutes 98% B
[0359] Method J LC-MS Waters Acquity-UPLC-SQ Detector-2 MSD signal settings ESI scan positive & negative Capillary voltage 3.50kV, cone voltage 50V, desolvation gas 750L / Hr, desolvation temperature 350℃ Column: Waters Acquity-UPLC-SQ Detector-2 Column temperature: 35°C Solvent A: 0.05% TFA in ACN B: 0.05% TFA in water Flow rate 0.6mL / min Gradient 0.0-0.3 min 97% B 0.3-2.2 min 97% to 2% B 2.2~3.3 minutes 2% B
[0360] Method K LC-MS Waters Arc-HPLC-SQ Detector-2 MSD signal settings ESI scan positive & negative Capillary voltage 3.50kV, cone voltage 30V, desolvation gas 750L / Hr, desolvation temperature 350℃ Column: X-Bridge C18, 4.6 x 75 mm, 3.5 μm Column temperature: 35°C Solvent A: 10 mM ammonium acetate in water B:ACN Flow rate 2.0mL / min Gradient 0.0-0.2 min 10% B 0.2-2.50 min 10% to 75% B 2.50-3.0 min 75% to 100% B 3.0~4.8 minutes 100% B
[0361] Method L HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range: 550-1200 m / z Column: Waters X-Bridge BEH C18, 2.5 μm, 2.1 x 30 mm XP Column temperature: 45°C Solvent A: 20 mM NH4HCO3 / 30 mM NH3 in HO; B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00 to 1.50 min: 50% B to 95% B 1.50~2.00 minutes: 95% B
[0362] Method M HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range: 550-1200 m / z Column: Waters X-Bridge BEH C18, 2.5 μm, 2.1 x 30 mm XP Column temperature: 45°C Solvent A: 20 mM NH4HCO3 / 30 mM NH3 in HO; B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00-1.00 min: 50% B to 95% B 1.00~1.30 minutes: 95% B
[0363] Method N HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range 100~750m / z Column: YMC-Triart C18, 3 μm, 12 nm, 2.0 × 30 mm Column temperature: 45°C Solvent A: H2O + 0.11% formic acid, B: ACN (HPLC grade) + 0.1% formic acid Flow rate 1.40mL / min Gradient 0.00-1.00 min: 15% B to 95% B 1.00~1.30 minutes: 95% B
[0364] Method O HPLC Waters-Alliance 2996 Detection signal PDA detector Spectral range: 200~400nm; resolution: 1.2nm Sampling rate 1 point / sec ELSD parameters: Gas pressure: 50 PSI, Drift tube temperature: 50°C, Gain: 500 Column: Atlantis T3 (4.6 x 250 mm) 5.0 μm Column temperature Ambient temperature Solvent A: 10mM ammonium acetate B:ACN Flow rate 0.7mL / min Gradient 0.0-1.20 min 2% B 1.2-10.0 min 2% to 98% B 10.0~12.0 minutes 98% B 12.0-14.0 min 97 to 2% B 14.0~16.0 minutes 2% B
[0365] Method P UPLC-MS Waters Acquity-UPLC-SQ Detector-2 MSD Signal Settings Scan Positive / Negative 100~1500 Source voltage: Capillary voltage (kV) -3.50, Cone (V): 50 Source Temp: Desolvation Temp (℃): 350 Source gas flow rate: Desolvation (L / Hr): 650 Detection signal Diode array Spectral range: 200~400nm; resolution: 1.2nm Sampling rate: 10 points / second ELSD parameters: Gas: 2.0 SLM, Nebulizer Temp: 40°C, Evaporation Temp: 45°C Column: AQUITY UPLC BEH C18 1.7 μm, 2.1 x 50 mm Column temperature: 50°C Solvent A: 0.05% formic acid in water B: 0.05% formic acid in ACN Flow rate 0.6mL / min Gradient 0.0-2.20 min 3% to 98% B 2.20~3.20 minutes 98% B 3:20-3:50 min 98% to 3% B 3.50~4.20 minutes 2% B
[0366] Method Q HPLC-MS 2998 Waters Arc-HPLC equipped with PDA detector and SQ detector-2 MSD Signal Settings Scan Positive & Negative 100~1500 Source voltage: Capillary voltage (kV) -3.50, Cone (V): 30 Source Temp: Desolvation Temp (℃): 350 Source gas flow rate: Desolvation (L / Hr): 750 Detection signal PDA detector Spectral range: 200~400nm; resolution: 1.2nm Sampling rate: 10 points / second Column: X-Bridge C18, 4.6 x 50 mm, 3.5 μm Column temperature: 35°C Solvent A: 10 mM ammonium acetate in water B:ACN Flow rate 1.0mL / min Gradient 0.0-0.75 min 5% B 0.75-1.50 min 5% to 40% B 1.50-5.0 min 40% to 98% B 5.0~7.0 minutes 98% B 7.0-9.0 min 98% to 5% B 9.0~10.01 minutes 5% B
[0367] Method R HPLC Agilent 1200 System Column: Chiralpak IE, 5.0 μm, 2.1 x 150 mm column Column temperature: 40°C Solvent: EtOH / heptane 1:1 + 0.1% diethylamine (isoconcentrated) Flow rate 0.60mL / min
[0368] GCMS Method U Agilent Technologies-7890B GC system equipped with a GC 7693 autosampler and a 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 ml / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 100°C / 1 min, 20°C / min / 310°C / 5 min Total running time: 16 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column and column dimensions: ZB-5MS (30 m x 0.32 mm; 1 μm) MSD scan range 50~900
[0369] Method V Agilent Technologies-7890B GC system equipped with a GC 7693 autosampler and a 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 mL / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 40°C / 2 min, 15°C / min / 200°C / 1 min, 25°C / min / 310°C / 0 min Total running time: 18 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column and column dimensions: ZB-5MS (30 m x 0.32 mm; 1 μm) MSD scan range 50~900
[0370] Method W Agilent Technologies-7890B GC system equipped with a GC 7693 autosampler and a 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 ml / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 60°C / 3 min, 20°C / min / 310°C / 2 min Total running time: 18 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column and column dimensions: ZB-5MS (30 m x 0.32 mm; 1 μm)
[0371] Method SFC-1 Make Waters UPC 2 -MS Software Empower3 MS QDa Column: CHIRALCEL OX-3 (4.6 * 150MM)3μm A-solvent CO2 B - Solvent ACN Total flow rate 3g / min % Cosolvent 15 ABPR 1500psi Column temp 30℃ PDA range: 200nm~400nm Resolution 1.2nm MS parameters - QDa MS scan range 100Da~1000Da Cone Voltage Positive scan 20V Negative scan 15V
[0372] Method SFC-2 Make Waters UPC 2 -MS Software Empower3 MS QDa Column (R,R) WHElk-01 (4.6 x 150 mm) 3.5 μm A-solvent CO2 B-Solvent 0.5% isopropylamine in isopropanol Total flow rate 3g / min % Cosolvent 40 ABPR 1500psi Column temp 30℃ PDA range: 200nm~400nm Resolution 1.2nm MS parameters - QDa MS scan range 100Da~1000Da Cone Voltage Positive scan 20V Negative scan 15V
[0373] The compounds and intermediates of the present invention are prepared by the synthetic methods described below. In the synthetic methods, the substituents of the general formulae have the meanings given above. These methods are intended to be illustrative of the present invention, without limiting the scope of the subject matter and the claimed compounds to these examples. Where the preparation of starting compounds is not described, they are commercially available, or their synthesis is described in the prior art, or they can be prepared analogously to known prior art compounds or methods described herein, i.e., it is within the skill of an organic chemist to synthesize these compounds. Substances described in the literature can be prepared according to published synthetic methods. If the following chemical structures are shown without the exact configuration of stereocenters, for example, of asymmetrically substituted carbon atoms, both configurations are included in such representations and are considered to be disclosed. The representation of a stereocenter in a racemate is always considered to include and disclose both enantiomers (if no other defined stereocenter exists) or all other possible diastereomers and enantiomers (if additional defined or undefined stereocenters exist).
[0374] Synthesis of spiro ketone intermediate A Experimental procedure for the synthesis of A-2a [ka] To a suspension of 5-chloropentanenitrile (22.9 g, 195 mmol, 1.00 equiv) in EtOH (136 mL) was added acetyl chloride (111 mL, 1.56 mol, 8.00 equiv) dropwise at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. The mixture was concentrated under reduced pressure, washed with EtO, and the crude product A-2a was used directly as the HCl salt in the next step without further purification (HPLC method: A; t ret =1.03 minutes; [M+H] + =164).
[0375] Experimental procedure for the synthesis of A-3a [ka] Crude A-2a (HCl salt) (28.0 g, 140 mmol, 1.00 equiv.) and ethylene glycol (7.38 g, 119 mmol, 0.90 equiv.) were dissolved in DCM (300 mL) and stirred at room temperature for 6 days. The resulting suspension was concentrated under reduced pressure, diluted with EtO (200 mL), and filtered. The filtrate was concentrated under reduced pressure, dissolved in DCM (200 mL), and treated with KOH solution (2 M in water, 150 mL). The mixture was stirred at room temperature overnight, maintaining phase integrity. The phases were separated, the aqueous phase was extracted with DCM (2×), and the combined organic phases were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude orthoester A-3a was used in the next step without further purification (HPLC method: A; t ret =1.37 minutes; [M+H] + =163).
[0376] Experimental procedure for the synthesis of A-4a [ka] Crude A-3a (22.3 g, 107 mmol, 1.00 equiv.), 1-cyclohexenyloxytrimethylsilane (16.4 mL, 82.3 mmol, 0.80 equiv.), and zinc chloride (10.2 g, 74.8 mmol, 0.70 equiv.) were dissolved in DCM (120 mL) and stirred at room temperature for 5 h. The reaction mixture was treated with saturated sodium bicarbonate solution. The organic phase was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by NP-chromatography to give the desired compound A-4a (HPLC method: A; t ret =1.25 minutes; [M+H] + =283).
[0377] Experimental procedure for the synthesis of A-5a [ka] A-4a (14.9 g, 57.1 mmol, 1.00 equiv.) and sodium iodide (25.9 g, 171 mmol, 3.00 equiv.) were dissolved in acetone (120 mL) and stirred under reflux for 16 h. The reaction mixture was concentrated under reduced pressure, diluted with DCM, and washed with saturated sodium thiosulfate solution. The organic phase was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product A-5a was used in the next step without further purification.
[0378] Experimental procedure for the synthesis of A-6b [ka] A-5a (30.0 g, 85.0 mmol, 1.00 equiv.) was dissolved in THF. The mixture was treated with potassium tert.-butoxide (28.7 g, 256 mmol, 3.0 equiv.) at 0° C. and stirred at room temperature overnight. The reaction mixture was quenched by the addition of water (2 mL) and diluted with EtO and saturated sodium bicarbonate solution. The organic phase was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by NP-chromatography to give (racemic) compound A-6a (HPLC method: A; t ret =1.17 minutes; [M+H] + =225).
[0379] The reaction sequence A-1a→A-6a is based on Marko et al., THL 2003, 44, 3333-3336 and Maulide et al., Eur. J. Org. Chem. 2004, 19:3962-3967.
[0380] Enantiomer A-6b then eluted as the second peak after the other enantiomers (HPLC method: A; t ret =1.17 minutes; [M+H] + =225 / SFC method:SFC-1; t ret=2.99 min) can be obtained after chiral separation by SFC (Lux Cellulose-4 column (250 x 30 mm, 5 μm), 30 °C column temperature, using 90% CO2, 10% ACN as co-solvent).
[0381] Alternative procedure for the synthesis of A-6b Process 1 [ka] A dry, clean reactor was charged with toluene (234 L) under nitrogen (Note: 2.5 V total toluene was used in this reaction). Water (1.56 kg, 85.5 mol, holding 160:1 HO:Pd) was added, followed by a nitrogen rinse of 1,1,3,3-tetramethylguanidine (175.5 kg, 1527.6 mol, 2.0 equiv.) and then toluene (13 L). A-7a (130.0 kg, 763.8 mol) was added under nitrogen, followed by a toluene rinse (13 L). Allyl acetate (98.8 kg, 992.9 mol, 1.3 equiv.) was added under nitrogen, followed by a toluene rinse (13 L). The mixture was cooled to 10°C over 0.5 hours with stirring. The batch was degassed by sparging nitrogen through the solution for approximately 30 minutes. (S,S)-DACH-Ph Trost ligand (0.429 kg, 0.619 mol, 0.081 mol%) in degassed toluene (13 L) (Note: Pd:ligand = 1:1.15) was added, followed by a degassed toluene (13 L) rinse. Allylpalladium(II) chloride dimer (97.5 g, 267 mol, 0.035 mol%) in degassed toluene (13 L) was added, followed by a degassed toluene (13 L) rinse. The batch was held at 10-15 °C for at least 8 h. After the reaction was complete by HPLC, a solution of N-acetyl-L-cysteine (3.9 kg, 22.9 mol, 0.03 equiv.) in water (260 L) below 25 °C was added. The resulting solution was warmed to 20-25 °C and held at 20-25 °C for at least 1 h. After cutting the phases and discarding the bottom aqueous layer, 10 wt% aqueous NH4Cl (260 L) was added. The mixture was stirred for 10 minutes, after which the bottom aqueous layer was drained. The organic phase was further washed with water (130 L). The organic layer was filtered through a very short Celite pad, and the reactor and Celite bed were rinsed with toluene (65 L). The filtrate was placed in a clean reactor, and the toluene was then distilled off under vacuum at 40-50 °C. The crude product was either used directly in the next step, or the product was drained into a container with the aid of a minimal amount of toluene (65 L) and stored at 20-23 °C. Typically, 150 kg of A-8a was obtained as a pale yellow oil in 96% yield with an enantiomeric ratio of ≥ 90:10. 11H NMR (500 MHz, CDCl3): δ 5.75 (ddt, J = 14.8, 9.4, 7.5 Hz, 1H), 5.06 - 5.00 (m, 2H), 4.19 (q, J = 7.1 Hz, 2H), 2.61 (dd, J = 13.9, 7.1 Hz, 1H), 2.51 - 2.43 (m, 3H), 2.33 (dd, J = 13.9, 7.9 Hz, 1H), 2.03 - 1.98 (m, 1H), 1.78 - 1.60 (m, 3H), 1.50 - 1.42 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 207.7, 171.6, 133.5, 118.4, 61.3, 61.0, 41.3, 39.4, 35.9, 27.7, 22.6, 14.3. ESI - MS: m / z 211 [M + H] + .
[0382] Process 2 [Chemical formula] To the reactor containing A-8a (150 kg, 713.4 mol) from step 1 (less than 1 V toluene, if used), ethylene glycol was added to give a yellow biphasic mixture. After cooling the mixture to 10-15 °C, TMSCl (193.5 kg, 1783.5 mol, 2.5 equiv.) was added over at least 15 min at a rate that maintained the internal temperature between 20-30 °C (yielding an orange biphasic mixture). Adequate stirring was required to achieve mixing. The batch was held at 20-25 °C for 2 h, after which stirring was stopped and the mixture was held at 20-25 °C for at least 15 min. The batch was cooled to 0-5 °C. NaOH (96 kg, 1854.8 mol, 2.6 equiv.) in water (600 L) was added at a rate that maintained the internal temperature below 20 °C (yielding a pale yellow, cloudy biphasic mixture). Toluene (300 L) was added, and the batch was then stirred for 10 min. After cutting the phases to remove the bottom aqueous layer (note: a precipitate may form in the interphase), the organic layer was washed twice with water (300 L). The organic phase was filtered through a short Celite pad to remove insoluble solids / interphase. The organic solution was placed in a clean, dry reactor, and the solvent was then distilled off to a minimum volume that allowed stirring at 40-50 °C. The crude product A-9a (189 kg, 95.2 wt%, 100% yield) was discharged into a vessel with the aid of a minimum amount of toluene. 1 H NMR (500 MHz, CDCl3): δ 5.65 (ddt, J = 14.7, 8.1, 6.6 Hz, 1H), 5.07-4.98 (m, 2H), 4.20-4.10 (m, 2H), 3.97-3.88 (m, 4H), 2.81 (dd, J = 13.9, 6.6 Hz, 1H), 2.35 (dd, J = 13.9, 8.1 Hz, 1H), 2.04-1.98 (m, 1H), 1.75-1.35 (m, 7H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ173.7, 134.3, 117.6, 110.9, 65.0, 64.7, 60.5, 54.6, 36.2, 32.3, 30.3, 23.3, 20.9, 14.4. ESI-MS: m / z 255 [M+H]+ .
[0383] Process 3 [ka] To a dry, clean reactor was added 9-BBN (688.5 kg, 401 mol, 1.2 equiv.) under nitrogen. The solution was cooled to 0–5°C to give a slurry. A-9a (85.0 kg, 334.2 mol) from step 2 was added at 0–5°C, followed by a THF (40 L) rinse. The mixture was warmed to 20–23°C over 1 h and held at 20–23°C for at least 1 h. After the mixture was cooled to −45–−40°C, methyl chloroacetate (69.6 kg, 1.3 equiv.) was added in one portion, followed by the dropwise addition of LiHMDS (909.5 kg, 1102.9 mol), maintaining the temperature below −35°C. The batch was then warmed to 20–23°C over 1 h and then held at 20–23°C for at least 18 h. Approximately 12-13 V of solvent was removed by distillation under vacuum with heating (35 °C). EtOH (255 kg) was added, followed by a solution of NaOH (13.4 kg) in HO (212.5 L). The mixture was heated at reflux (66-70 °C) for at least 14 h.
[0384] Approximately 5-6 V of solvent was then removed by distillation under reflux, the batch was cooled to 20-25 °C, and then filtered through a short Celite pad to remove insoluble material and rinsed with heptane (160 L). Approximately 5-6 V of solvent (or most of the residual THF and ethanol) was distilled off under reduced pressure at 40-50 °C. The batch was cooled to 20-25 °C. Water (255 L) was then added, and the crude product was extracted twice with heptane (2364.8 kg). The combined heptane layers were washed once with water (85 L). After removal of the solvent by distillation under vacuum at 40-50 °C, the crude product (52.7 kg, 87.5 wt %) was obtained as a yellow oil in an assay yield of 52.6%. The crude product A-6b was used directly in the next step. 1H NMR (500 MHz, CDCl3): δ 4.01-3.82 (m, 4H), 2.50-2.44 (m, 1H), 2.382.34 (m, 1H), 2.28-2.22 (m, 1H), 2.11-2.05 (m, 1H), 2.01-1.95 (m, 1H), 1.92-1.86 (m, 1H), 1.81-1.58 (m, 6H), 1.54-1.43 (m, 3H), 1.27-1.18 (m, 1H). ESI-MS: m / z 225 [M+H] + .
[0385] Synthesis of Alcohol-, Pyrazole-, and Tosylate-Intermediates B Experimental procedure for the synthesis of B-2a [ka] B-1a (4.92 g, 19.1 mmol, 1.00 equiv.), N,N'-carbonyldiimidazole (5.14 g, 28.6 mmol, 1.50 equiv.), and molecular sieves (3A, 500 mg) were dissolved in DCM (29.5 mL) and stirred at room temperature for 40 min. After complete activation, N,O-dimethylhydroxylamine hydrochloride (2.79 g, 28.6 mmol, 1.50 equiv.) was added, and the reaction was stirred at room temperature for 2 h. After complete conversion, water (100 mL) and DCM (150 mL) were added, and the phases were separated. The aqueous phase was extracted with DCM (2x). The combined organic phases were washed with brine and concentrated under reduced pressure. The residue was purified by NP chromatography to give product B-2a.
[0386] The following intermediate B-2 (Table 1) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 2]
[0387] Experimental procedure for the synthesis of B-3a [ka] B-2a (4.88 g, 16.9 mmol, 1.00 equiv) was dissolved in THF (15 mL) under an argon atmosphere and cooled to −10° C. Bromo(methyl)magnesium (3.4 M in MeTHF, 6.46 mL, 22.0 mmol, 1.3 equiv) was added and stirred at −10° C. for 1 h. After complete conversion, the reaction mixture was cooled to −20° C. and quenched by the addition of brine. The resulting mixture was extracted with DCM (3×). The combined organic phase was concentrated under reduced pressure to give B-3a.
[0388] The following intermediate B-3 (Table 2) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 3]
[0389] Experimental procedure for the synthesis of B-4a [ka] (R)-Methyl oxazaborolidine (0.99 g, 3.3 mmol, 0.20 equiv.) was dissolved in THF (2 mL) under an argon atmosphere and cooled to -5 °C. Borane-dimethyl sulfide complex (1.0 M, 22 mL, 22.0 mmol, 1.3 equiv.) was added. The mixture was stirred at room temperature for 30 min. The mixture was cooled to -5 °C, and B-3a (4.1 g, 17 mmol, 1 equiv.) was added dropwise slowly. The reaction was stirred at room temperature for 1 h. After complete conversion of the starting material, the reaction was cooled to -10 °C and quenched by the addition of MeOH. The mixture was concentrated under reduced pressure. The residue was dissolved in water (150 mL) and formic acid (0.5 mL) and extracted with DCM (3x). The combined organic phase was concentrated under reduced pressure and purified by NP chromatography to give product B-4a.
[0390] The following intermediate B-4 (Table 3) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 4]
[0391] Experimental procedure for the synthesis of B-5a [ka] B-4a (306 mg, 12.5 mmol, 1.00 equiv) was dissolved in THF (30.6 mL) under an argon atmosphere. Lithium aluminum hydride (1 M in THF, 24.9 mL, 25.0 mmol, 2.00 equiv) was added slowly. The reaction was stirred at 60 °C for 1 h. After complete conversion, the reaction was cooled to room temperature, Rochelle's salt solution and KOH were added, and the mixture was stirred for 1 h. The existing suspension was extracted with DCM (3x), and the combined organic phases were concentrated under reduced pressure to yield B-5a.
[0392] The following intermediate B-5 (Table 4) can be obtained in a similar manner. The deuterated intermediate B-5 was obtained in a similar manner, but lithium aluminum hydride was replaced by lithium aluminum deuteride. The crude product was purified by chromatography if necessary. [Table 5]
[0393] Experimental procedure for the synthesis of B-7a [ka] B-6a (502 mg, 4.22 mmol, 1.00 equiv) was dissolved in ACN (6 mL), cesium carbonate (2.04 g, 6.24 mmol, 1.49 equiv), and (2S)-2-methyloxirane (420 μL, 5.93 mmol, 1.41 equiv) was added. The reaction was stirred at 80° C. under a nitrogen atmosphere for 18 h. After complete conversion, the reaction mixture was filtered, washed with ACN, and the filtrate was concentrated under reduced pressure. The mixture was purified by RP chromatography to yield B-7a.
[0394] Intermediate B-7 (Table 5) can be accessed in a similar manner using the corresponding epoxide or alkyl halide. The crude product is purified by chromatography if necessary. [Table 6]
[0395] Experimental procedure for the synthesis of B-8a [ka] B-7a (545 mg, 3.18 mmol, 1.00 equiv) was dissolved in EtOH (40 mL) and palladium (10% on carbon, 40.0 mg, 0.04 mmol, 0.01 equiv) was added. The reaction was stirred at room temperature under a hydrogen atmosphere (3 bar) for 4 h. After complete conversion, the reaction mixture was filtered, washed with EtOH, and concentrated under reduced pressure to give B-8a, which was used in the next step without purification.
[0396] Intermediate B-8 (Table 6) is accessible in a similar manner. The crude product is purified by chromatography if necessary. [Table 7]
[0397] Experimental procedure for the synthesis of B-9a [ka] B-8a (222 mg, 1.57 mmol, 1.00 equiv) and bis(pinacolato)diboron (450 mg, 1.73 mmol, 1.10 equiv) were dissolved in ACN (5 mL). tert-Butyl nitrite (504 μL, 4.25 mmol, 2.70 equiv) was added, and the reaction was stirred at 80° C. under a nitrogen atmosphere for 2 h. After complete conversion, the reaction mixture was concentrated under reduced pressure to produce B-9a, which was used in the next step without purification.
[0398] Intermediate B-9 (Table 7) is accessible in a similar manner. The crude product is purified by chromatography if necessary. [Table 8]
[0399] Experimental procedure for the synthesis of B-11a [ka] 1H-Pyrazole-3-carboxylic acid (500 mg, 4.46 mmol, 1.00 equiv.) was dissolved in ACN (4.5 mL). Pyrrolidine (745 μL, 8.92 mmol, 2.00 equiv.), DIPEA (1.50 mL, 8.92 mmol, 2.00 equiv.), and 1-propanephosphonic anhydride (2.00 mL, 6.69 mmol, 1.50 equiv.) were added, and the reaction mixture was stirred at room temperature for 1 h until complete conversion. The reaction mixture was diluted with saturated NaHCO3 and extracted with DCM. The organic phase was dried, filtered, and the solvent was removed under reduced pressure. The crude product was purified by NP chromatography to give B-11a (HPLC method: C, t ret =0.14 minutes; [M+H] + =166).
[0400] Experimental procedure for the synthesis of B-13a [ka] To a solution of B-12a (5.00 g, 4.90 mmol, 1.00 equiv) and pyridine (7.75 g, 9.79 mmol, 2.00 equiv) in DCM (50 mL) was added p-toluenesulfonyl chloride (14.0 g, 73.4 mol, 1.5 equiv) at 0 °C. The reaction mixture was allowed to warm to room temperature. After 16 h, the reaction mixture was diluted with water and extracted with DCM (2x). The combined organic layers were washed with HCl (1 M), dried over NaSO, and then concentrated under reduced pressure to give product B-13a.
[0401] Intermediate B-13 (Table 8) is accessible in a similar manner. The crude product is purified by chromatography if necessary. [Table 9]
[0402] Experimental procedure for the synthesis of B-15a [ka] 3-Ethynyloxetan-3-ol (120 mg, 1.16 mmol, 1.00 equiv.) and (trimethylsilyl)diazomethane (2 M solution in hexanes, 2.00 mL, 4.00 mmol, 3.46 equiv.) were combined and stirred at 50 °C in a sealed vial for 3 h until complete conversion. The reaction mixture was cooled to room temperature, diluted with MeOH, and the solvent was removed under reduced pressure to give crude B-15a (HPLC method: C, t ret =0.08 minutes; [M+H] + = 141). The crude product was used in the next step without purification.
[0403] Synthesis of pyrimidine derivatives C Experimental procedure for the synthesis of intermediate C-2a: [ka] To a solution of 2,4,6-trichloro-5-fluoropyrimidine (1.00 g, 4.87 mmol, 1.00 equiv.) and B-5b (739 mg, 487 mmol, 1.00 equiv.) in THF (10 mL) at −78 °C, sodium bis(trimethylsilyl)amide (1 M, 5.00 mL, 5.00 mmol, 1.03 equiv.) was added dropwise, and the mixture was stirred for 10 min. After complete conversion, the reaction mixture was quenched with water, extracted with DCM, and the organic phase was dried, filtered, and concentrated. The crude product was purified by NP chromatography to yield C-2a (HPLC method: B, t ret =1.00 minutes; [M+H] + =312).
[0404] Experimental procedure for the synthesis of intermediate C-3a: [ka] To a solution of C-2a (445 mg, 1.43 mmol, 1.00 equiv) in DMSO (1 mL) was added DIPEA (996 μL, 5.70 mmol, 4.00 equiv) and (S)-5-methyl,4-7-diazaspiro[2.5]octane dihydrochloride (300 mg, 1.43 mmol, 1.00 equiv). After 72 h at room temperature, complete conversion was observed. The crude product was purified by RP chromatography to afford C-3a.
[0405] The following intermediates C-3 (Table 9) are accessible in an analogous manner using the corresponding amines: The crude products are purified by chromatography if necessary. [Table 10]
[0406] Experimental procedure for the synthesis of C-5a: [ka] To a stirred solution of 2-methoxy-malonic acid dimethyl ester (36.0 g, 222 mmol, 1.00 equiv.) and thiourea (25.4 g, 333 mmol, 1.50 equiv.) in MeOH (360 mL), sodium methoxide (27.8 g, 555 mmol, 2.5 equiv.) was added at room temperature, and the mixture was stirred at 80 °C for 24 h. After complete conversion, iodomethane (41.0 g, 289 mmol, 1.30 equiv.) was added slowly at room temperature, and the mixture was stirred at room temperature for 16 h. After complete conversion, the reaction mixture was concentrated, water was added, and the reaction mixture was stirred for 30 min. The product was collected by filtration, washed with water, and dried under vacuum. The crude product C-5a was used in the next step without purification (HPLC method: H, t ret =0.89 minutes; [M+H] + =189).
[0407] Experimental procedure for the synthesis of intermediate C-6a: [ka] To a stirred mixture of C-5a (3.1 g, 16 mmol, 1.0 equiv.) and N,N-diethylaniline (0.4 mL) at 0 °C, POCl (13 g, 81 mmol, 5.0 equiv.) was slowly added, and the resulting mixture was stirred at 90 °C for 16 h. After complete conversion, the mixture was cooled to room temperature, excess POCl was evaporated, water was added, and the product was isolated by extraction with EtOAc. The crude product was purified by NP chromatography to give C-6a (HPLC method: H, t ret =2.12 minutes; [M+H] + =225).
[0408] Experimental procedure for the synthesis of intermediate C-7a: [ka] To a stirred solution of C-6a (24.0 g, 107 mmol, 1.00 equiv.) in DCM (240 mL) at 0 °C was added m-CPBA (55.0 g, 321 mmol, 3.0 equiv.), the mixture was allowed to reach room temperature, and stirred for an additional 16 h. After complete conversion, the mixture was diluted with DCM, washed with saturated NaHCO3, and the organic layer was dried, filtered, and concentrated to yield C-7a, which was used in the next step without purification (HPLC method: H, t ret =1.68 minutes; [M+H] + =257).
[0409] Experimental procedure for the synthesis of C-9a: [ka] 6-Hydroxy-2-methylsulfanyl-3H-pyrimidin-4-one (120 g, 0.759 mol, 1.00 equiv.) and sodium carbonate (80.4 g, 0.759 mol, 1.00 equiv.) were dissolved in water (1898 mL). (Diacetoxyiodo)benzene (244.3 g, 0.759 mol, 1.00 equiv.) and sodium carbonate (80.4 g, 0.759 mol, 1.00 equiv.) were dissolved in water (1898 mL). The two solutions were combined and stirred at 40° C. for 2 hours. The precipitate was filtered, washed with water, and dried to give C-8a, which was used in the next step without purification.
[0410] HCl (2.8 M, 140 mL, 0.389 mol, 0.70 equiv.) was added to a suspension of crude C-8a (200 g, 0.555 mol, 1.00 equiv.) in ethanol (1000 mL). The reaction mixture was heated to reflux for 20 min, concentrated under reduced pressure, and the resulting residue was washed with petroleum ether to give C-9a (HPLC method: H, t ret =0.98 minutes; [M+H] + =193) was obtained and used in the next step without purification.
[0411] Experimental procedure for the synthesis of intermediate C-10a: [ka] Crude C-9a (98.0 g, 0.509 mol, 1.00 equiv.) was added to a solution of freshly distilled POCl3 (356 mL, 3.816 mol, 7.50 equiv.). The resulting mixture was heated to reflux for 16 h. After complete conversion, the mixture was allowed to reach room temperature. The mixture was slowly added to ice-cold water, extracted with EtOAc, and the organic layer was dried, filtered, and concentrated under reduced pressure. The crude product was purified by NP chromatography to give C-10a (HPLC method: G, t ret =2.49 minutes; [M+H] + =229).
[0412] Experimental procedure for the synthesis of intermediate C-11a: [ka] To a stirred solution of C-10a (60.0 g, 261 mmol, 1.00 equiv.) in DCM (1200 mL) at 0 °C, m-CPBA (157.4 g, 915 mmol, 3.50 equiv.) was added, the mixture was allowed to reach room temperature, and stirred for an additional 16 h. After complete conversion, the mixture was diluted with DCM and washed with saturated aqueous NaHCO3, and the organic layer was dried, filtered, and concentrated to yield C-11a, which was used in the next step without purification (HPLC method: V, t ret =10.91 minutes; [M+H] + =260).
[0413] Synthesis of Nitrile Intermediate D Experimental procedure for the synthesis of D-2a: [ka] To a stirred solution of C-7a (24.0 g, 93.4 mmol, 1.0 equiv) in ACN (216 mL) and water (24 mL) under nitrogen at 0° C., NaCN (5.49 g, 112 mmol, 1.2 equiv) was added, the mixture was allowed to warm to room temperature, and stirred for an additional 1 h. After complete conversion, water and EtOAc were added, the organic layer was separated, washed with water, dried, filtered, concentrated, and the crude product was purified by NP chromatography to afford D-2a.
[0414] The following intermediate D-2 (Table 10) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 11]
[0415] Experimental procedure for the synthesis of D-6a [ka] To a solution of 4,6-dichloropyrimidine-2-carbonitrile D-3a (2000 mg, 10.356 mmol, 90% purity, 1.0 equiv.) in anhydrous DMSO (5 mL) was added cesium fluoride (6.286 g, 41.382 mmol, 4 equiv.), and the resulting mixture was stirred at 60 °C for 1 h until complete conversion of the starting material was observed to give 4,6-difluoropyrimidine-2-carbonitrile D-4a. The resulting suspension was filtered, and the remaining solid was washed with anhydrous ACN (2 mL). Next, tert-butyl-(2S)-2-[(1S)-1-hydroxyethyl]pyrrolidine-1-carboxylate (2449 mg, 11.376 mmol, 1.1 equiv.) and DIPEA (3.517 mL, 20.684 mmol, 2 equiv.) were added to the filtrate (8 mL), which was stirred at 60 °C for 1 h. After complete conversion of the starting material was observed, N-methylpiperazine (1.262 mL, 11.376 mmol, 1.1 equiv.) was also added to the mixture. The mixture was then stirred at 60 °C for 30 min. After complete conversion to D-5a was observed, the reaction was filtered, and the crude product was purified by RP chromatography to yield D-6a.
[0416] The following intermediate D-6 (Table 11) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 12]
[0417] Experimental procedure for the synthesis of D-8a [ka] To a solution of D-2b (100 mg, 0.478 mmol, 1.00 equiv.) in anhydrous THF (0.5 mL) were added B-5b (80 mg, 0.527 mmol, 1.10 equiv.) and DIPEA (0.10 mL, 0.569 mmol, 1.19 equiv.), and the mixture was stirred at 70 °C for 2 h. After complete conversion to intermediate D-7a was observed, 4-Boc-4,7-diazaspiro[2.5]octane (115 mg, 0.525 mmol, 1.10 equiv.) and additional DIPEA (0.10 mL, 0.569 mmol, 1.19 equiv.) were added to the mixture. The mixture was then stirred at 70 °C for 12 h. After complete conversion was observed, the reaction mixture was concentrated and purified by RP chromatography to give the desired product D-8a (HPLC method: A, t ret =1.74 minutes; [M+H] + =495).
[0418] Experimental procedure for the synthesis of D-10a [ka] 2,6-Dichloropyrimidine-4-carbonitrile D-9a (3.0 g, 0.02 mol, 1.00 equiv.) was dissolved in DCM (21.4 mL), DIPEA (5.69 mL, 33.5 mmol, 2.00 equiv.) was added, and cooled to 0 °C. 4-Boc-4,7-diazaspiro[2.5]octane (3.55 g, 0.02 mol, 1.00 equiv.) was added dropwise. The reaction was stirred at room temperature until complete conversion of the starting material was observed. The mixture was concentrated under reduced pressure and purified by NP chromatography to give D-10a (HPLC method: A, t ret =1.47 minutes; [M+H] + =350).
[0419] Experimental procedure for the synthesis of D-11a [ka] D-10a (4.7 g, 0.01 mol, 1.00 equiv.) was dissolved in DMSO (10 mL) and (S)-tert-butyl-3-methyl-1,4-diazepane-1-carboxylate (6.30 g, 0.03 mol, 2.10 equiv.) and DIPEA (4.69 mL, 0.03 mol, 2.00 equiv.) were added. The reaction was stirred at 80 °C overnight. After complete conversion of the starting material was observed, the reaction was concentrated under reduced pressure and purified by RP chromatography to give D-11a (HPLC method: A, t ret =1.72 minutes; [M+H] + =528).
[0420] Experimental procedure for the synthesis of D-13a [ka] 4,6-Dichloropyrimidine-2-carbonitrile D-3a (1.00 g, 5.74 mmol, 1.00 equiv.) and (1S)-1-[(2S)-1-methylpyrrolin-2-yl]ethanol (656 mg, 0.01 mol, 1.10 equiv.) were dissolved in DMSO (1 mL) and ACN (1 mL). DIPEA (1.62 mL, 0.01 mol, 2.00 equiv.) was added and the reaction was stirred at 60 °C for 2 h. After complete conversion of the starting material was observed, the reaction mixture was concentrated under reduced pressure and extracted with DCM / NaHCO3. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to yield D-13a (HPLC method: A, t ret =1.31 minutes; [M+H] + =267).
[0421] Synthesis of esters and acids
[0422] Experimental procedure for the synthesis of intermediate E-1a: [ka] D-2a (7.00 g, 34.3 mmol, 1.0 equiv) was added to a stirred solution of HCl (4 M in MeOH, 105 mL, 420 mmol, 12.4 equiv) at 0 °C. The mixture was allowed to reach room temperature and stirred for an additional 16 h. After complete conversion, the reaction mixture was concentrated and the crude product was purified by NP chromatography to give the desired product E-1a (HPLC method: H, t ret =1.48 minutes; [M+H] + =237).
[0423] Experimental Procedure for the Synthesis of Intermediate E-2a: [ka] To a solution of D-6a (1.37 g, 3.29 mmol, 1.00 equiv) in MeOH (5 mL) was added a solution of sodium hydroxide (4 M in water, 4.93 mL, 19.7 mmol, 6.00 equiv), and the resulting mixture was stirred for 2 h at 65° C. After complete conversion, the solvent was removed under reduced pressure, and the mixture was neutralized and purified by RP chromatography to give the desired product E-2a.
[0424] The following intermediate E-2 (Table 12) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 13]
[0425] Experimental Procedure for the Synthesis of Intermediate E-3a: [ka] To a solution of D-11a (4.00 g, 7.58 mmol, 1.00 equiv) in MeOH (15 mL) was added a solution of sodium hydroxide (10 M in water, 0.758 mL, 7.58 mmol, 1.00 equiv), and the resulting mixture was stirred at room temperature for 2 h. After complete conversion, HCl (8 M in water, 3.79 mL, 30.3 mmol, 4.00 equiv) was added, and the mixture was stirred at room temperature for 1 h. After complete conversion to the ester, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with DCM (3x). The organic phase was dried, filtered, and concentrated under reduced pressure to yield E-3a.
[0426] The following intermediate E-3 (Table 13) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 14]
[0427] Experimental procedure for the synthesis of E-4a [ka] D-13a (400 mg, 1.49 mmol, 1.00 equiv) was dissolved in MeOH (2 mL) and cooled to 0 °C. Thionyl chloride (0.13 mL, 0.2 mmol, 1.20 equiv) was added dropwise and stirred at room temperature until complete conversion of the starting material was observed. The reaction mixture was cooled to 0 °C, quenched with NaHCO3, and then extracted with EtOAc. The combined organic phases were concentrated under reduced pressure and purified by NP chromatography to yield E-4a (HPLC method: K, t ret =1.69 minutes; [M+H] + =300).
[0428] Experimental procedure for the synthesis of E-5a: [ka] To a solution of C-3c (980 mg, 2.01 mmol, 1.00 equiv) in MeOH (15 mL) was added TEA (0.835 mL, 6.03 mmol, 3.0 equiv) and Pd(dppf)Cl2CH2Cl2 (166 mg, 0.201 mmol, 0.10 equiv). The mixture was stirred in a pressure reactor under CO pressure (150 psi) at 90 °C for 22 h. After complete conversion, the reaction mixture was diluted with saturated aqueous NaHCO3 and extracted with DCM. The organic phase was dried, filtered, and concentrated, and the crude product was purified by RP chromatography to afford E-5a.
[0429] The following intermediate E-5 (Table 14) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 15]
[0430] Experimental procedure for the synthesis of intermediate E-7a: [ka] 2-Chloro-6-(trifluoromethyl)pyrimidine-4-carboxylic acid E-6a (1.00 g, 4.19 mmol, 1.00 equiv.) was dissolved in DMSO (2 mL), (S)-tert-butyl-3-methyl-1,4-diazepane-1-carboxylate (1.97 g, 8.81 mmol, 2.1 equiv.), and DIPEA (1.83 mL, 0.01 mmol, 2.50 equiv.) was added. The reaction was stirred at 80 °C overnight. After complete conversion of the starting material was observed, the mixture was purified by RP chromatography.
[0431] The following intermediate E-7 (Table 15) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 16]
[0432] Experimental Procedure for the Synthesis of Intermediate E-9a: [ka] 4,6-Dichloropyrimidine-2-carboxylic acid E-8a (900 mg, 4.66 mmol, 1.00 equiv.) was dissolved in DMSO (2 mL) and DIPEA (1.5 mL, 8.8 mmol, 2.0 equiv.), and (S)-tert-butyl 3-methyl-1,4-diazepane-1-carboxylate (1.04 g, 4.896 mmol, 95% purity, 1.05 equiv.) was added dropwise. The reaction mixture was then stirred at 40° C. for 18 h. The mixture was diluted with ACN and purified by RP chromatography to give the desired product E-9a (HPLC method: A, t ret =0.82 minutes; [M+H] + =371).
[0433] Experimental procedure for the synthesis of intermediate E-11a: [ka] E-10a (3.00 g, 14.5 mmol, 1.00 equiv.) was dissolved in DCM (30 mL) and DIPEA (5.34 mL, 29 mmol, 2.0 equiv.), and B-5b (3.20 g, 21.8 mmol, 1.5 equiv.) was added. The reaction mixture was then stirred at room temperature for 18 h. After complete conversion, the mixture was concentrated, water was added, the mixture was extracted with EtOAc, and the organic phase was washed with brine, dried, filtered, and concentrated. The crude product was purified by NP chromatography to yield E-11a.
[0434] The following intermediate E-11 (Table 16) is accessible in a similar manner: The crude product E-11 is purified by chromatography if necessary. [Table 17]
[0435] Experimental procedure for the synthesis of E-11e: [ka] B-5a (100 mg, 0.48 mmol, 1.00 equiv.) was dissolved in THF (500 μL) and LiHMDS (591 μL, 0.59 mmol, 1.10 equiv.) was added and stirred for 5 min. Meanwhile, methyl 4,6-dichloropyrimidine-2-carboxylate (170 mg, 0.81 mmol, 1.5 equiv.) was dissolved in THF (500 μL). The solution of B-5a was added dropwise over 5 min to the methyl 4,6-dichloropyrimidine-2-carboxylate solution. The reaction was stirred for 25 min. After complete conversion of the starting material was observed, the reaction was filtered and purified by RP chromatography to give E-11e (HPLC method: A, t ret =1.08 minutes; [M+H] + =330).
[0436] Experimental procedure for the synthesis of intermediate E-12a: [ka] Methyl 4,6-dichloropyrimidine-2-carboxylate (450 mg, 21.4 mmol, 1 equiv.) was dissolved in THF (18 mL). In a second flask, imidazole (1.42 mg, 20.7 mmol, 0.97 equiv.) was dissolved in THF (18 mL), cooled to 0 °C, and LiHMDS (20.1 mL, 20.1 mmol, 0.94 equiv.) was added dropwise. At -30 °C, the LiHMDS / imidazole solution was added dropwise to the solution of E-10a. The reaction was stirred at room temperature for 30 min. After complete conversion was observed, the reaction was concentrated under reduced pressure and purified by NP chromatography to give E-12a (HPLC method: C, t ret =0.23 minutes; [M+H] + =239).
[0437] Experimental procedure for the synthesis of E-13a [ka] To a stirred mixture of E-11c (50.0 mg, 0.166 mmol, 1.00 equiv.), 2-furan-3-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaboroloane (0.04 g, 0.206 mmol, 1.2 equiv.), and cesium carbonate (81.5 mg, 0.25 mmol, 1.50 equiv.) in dioxane (4.5 mL) in a sealed tube was purged with argon gas for 10 min, then Pd(dppf)Cl (36.6 mg, 0.05 mmol, 0.30 equiv.) was added at room temperature, and the reaction was heated to 90 °C for 18 h. After complete conversion of the starting material was observed, the mixture was filtered through Celite and washed with DCM. The filtrate was concentrated under reduced pressure and purified by NP chromatography to give the desired product E-13a.
[0438] Intermediate E-13 (Table 17) is accessible in a similar manner. The crude product is purified by chromatography if necessary. [Table 18]
[0439] Experimental procedures for the synthesis of E-14a and E-14b [ka] E-13a (6.10 g, 0.02 mol, 1.00 equiv.) was dissolved in MeOH, palladium (10% on carbon, 5.88 mg, 0.06 mmol, 3.00 equiv.) was added, and the reaction was stirred under a hydrogen atmosphere at room temperature for 48 h. After complete conversion of the starting material was observed, the mixture was filtered and washed with 10% MeOH in DCM. The filtrate was concentrated under reduced pressure to give the crude product.
[0440] Intermediate E-14 (Table 18) is accessible in a similar manner. The crude product is purified by chromatography if necessary.
[0441] The diastereomeric mixture E-14a / b was purified by chiral HPLC (column / dimensions: Lux Amylose-2 (250 × 30) mm, 5 μm; solvent: n-hexane / ethanol (75:25); column temperature: ambient temperature) to give both diastereomers E-14a and E-14b (E-14a elutes as peak 1, followed by E-14b as peak 2). [Table 19]
[0442] Experimental Procedure for the Synthesis of Intermediate E-15a [ka] To a solution of E-3a (4.20 g, 7.49 mmol, 1.00 equiv.) in ACN (5 mL) was added a solution of sodium hydroxide (1 M in water, 10.5 mL, 10.5 mmol, 1.40 equiv.), and the resulting reaction mixture was stirred at room temperature for 1.5 h. After complete conversion, the solvent was removed under reduced pressure, and the remaining aqueous solution was carefully neutralized with aqueous HCl (8 M). The mixture was diluted with ACN and purified by acidic RP chromatography to give the desired product E-15a.
[0443] The following intermediate E-15 (Table 19) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 20]
[0444] Experimental procedure for the synthesis of E-16a [ka] To a solution of methyl 4,6-dichloropyrimidine-2-carboxylate E-10a (2.50, 11.8 mmol, 1.00 equiv.) in DMSO (2.00 mL) was added a solution of imidazole (885 mg, 13.0 mmol, 1.10 equiv.) in DIPEA (4.02 mL, 23.6 mmol, 2.00 equiv.) and ACN (2.00 mL). After 2 h at 45 °C, complete conversion was observed, and (S)-tert-butyl 3-methyl-1,4-diazepane-1-carboxylate (2.90 g, 13.0 mmol, 1.10 equiv.) was added. The resulting reaction mixture was stirred overnight at 45 °C. The reaction mixture was diluted with brine and extracted with DCM. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give the desired product E-16a (HPLC method: A, t ret =1.16 minutes; [M+H] + =417).
[0445] Synthesis of diketones F When multiple HPLC retention times are reported, it indicates that different tautomers exist.
[0446] Experimental procedure for the synthesis of F-1a [ka] Under an argon atmosphere, E-2a (832 mg, 1.91 mmol, 1.0 equiv.) and 1-(1H-imidazole-1-carbonyl)-1H-imidazole (620 mg, 3.82 mmol, 2.0 equiv.) were dissolved in THF (5 mL) and stirred at room temperature for 1 h. After complete activation of the acid, a solution of A-6b (473 mg, 2.01 mmol, 1.1 equiv.) and LiHMDS (1.0 M in THF, 4 mL, 4.01 mmol, 2.1 equiv.) was added to the reaction mixture and washed with THF (5 mL). The resulting mixture was stirred at 60 °C overnight. After complete conversion, the reaction was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give the crude product. The crude product was dissolved in ACN and water, filtered and purified by basic RP chromatography to give the desired product F-1a.
[0447] Intermediate F-1 (Table 20) is accessible in a similar manner. The crude product F-1 is purified by chromatography if necessary. [Table 21] TIFF2024543967000126.tif197165
[0448] Experimental procedure for the synthesis of F-2a [ka] E-14a (203 mg, 0.58 mmol, 1.00 equiv.) was dissolved in THF (10 mL), activated molecular sieves (3 Å) were added, and the mixture was stirred at 50° C. for 20 min under an argon atmosphere. Next, magnesium bromide ethyl etherate (225 mg, 0.87 mmol, 1.5 equiv.) was added, and the mixture was further stirred at 50° C. for 30 min.
[0449] Separately, a second solution was prepared using A-6b (152 mg, 0.67 mmol, 1.17 equiv.), also pre-dried over activated 3Å molecular sieves in THF (5 mL) at 50 °C for 20 min. LiHMDS (1 M in THF, 1.6 mL, 1.6 mmol, 2.77 equiv.) was then added and stirred for 15 min. The second solution was then added to the first solution and stirred at 50 °C for 1 h until complete conversion to the product was observed.
[0450] The mixture was carefully quenched with NaHCO3, concentrated under reduced pressure, and extracted with DCM / water. The combined organic phase was concentrated under reduced pressure and purified by RP chromatography to give F-2a.
[0451] The following intermediate F-2 (Table 21) is accessible in an analogous manner: The crude product is purified by chromatography if necessary. [Table 22] TIFF2024543967000129.tif202165
[0452] Experimental procedure for the synthesis of F-4a [ka] A-6b (1.4 g, 5.31 mmol, 1.1 equiv.) and magnesium bromide diethyl etherate (2.5 g, 9.66 mmol, 2.0 equiv.) were dissolved in DCM (10.0 mL). F-3a (1.0 g, 4.83 mmol, 1.0 equiv.) dissolved in DCM (10 mL) was added dropwise. DIPEA (2.1 mL, 12.08 mmol, 2.5 equiv.) was added and the reaction mixture was stirred at room temperature for 7 h. The reaction was quenched with 1 M HCl and diluted with DCM and water. The organic phase was separated and evaporated, and the resulting residue was purified by RP chromatography to give F-4a (HPLC method: C, t ret =0.633 minutes; [M+H] + =399).
[0453] Experimental procedure for the synthesis of F-5a [ka] 4,6-Dichloropyrimidine-2-carboxylic acid methyl ester (2.00 g, 9.67 mmol, 1.00 equiv.) was dissolved in dry ACN (5 mL) under a nitrogen atmosphere. A solution of magnesium bromide diethyl etherate (2.99 g, 11.6 mmol, 1.20 equiv.), A-6b (2.38 g, 10.6 mmol, 1.10 equiv.), and DIPEA (2.67 mL, 14.5 mmol, 1.50 equiv.) in ACN (5 mL) was added, and the reaction mixture was stirred at 50 °C for 20 h. After complete conversion, the reaction mixture was carefully quenched with HCl (1 M), diluted with water, extracted with DCM, and the organic phase was dried, filtered, and concentrated to give crude F-5a. The crude compound was purified by normal phase chromatography (HPLC-method: H, t ret = 2.50 min; [M+H] = 399 / 401).
[0454] Experimental procedure for the synthesis of F-6a [ka] A-6b (3.71 g, 0.02 mol, 1.05 equiv.) was dissolved in THF (10 mL), and LiHMDS (1 M in THF, 31.3 mL, 31.3 mmol, 2 equiv.) was added at room temperature and stirred for 10 minutes. E-12a (3.73 g, 0.02 mol, 1 equiv.) and magnesium bromide diethyl etherate (1.63 g, 6.25 mmol, 0.4 equiv.) were dissolved in THF (40 mL) and stirred at 50° C. under an argon atmosphere. The solution from A-6b was added at 50° C.
[0455] The reaction mixture was stirred at 50° C. for 1 hour. After complete conversion, the reaction mixture was concentrated under reduced pressure. Water was added, acidified with formic acid, filtered through Celite, and extracted with DCM. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give F-6a (HPLC method: C, t ret =0.45, 0.62, 0.71 minutes; [M+H] + =431).
[0456] Experimental procedure for the synthesis of F-7a [ka] F-4a (2.8 g, 7.01 mmol, 1 equiv.) was dissolved in DMSO (10 mL), (2S,6S)-tert-butyl 2,6-dimethylpiperazine-1-carboxylate (1.7 g, 7.71 mmol, 1.1 equiv.) and DIPEA (3.6 mL, 21.0 mmol, 3.0 equiv.) were added, and the solution was stirred at 60 °C for 1 h. After cooling to room temperature, the reaction mixture was diluted with DCM and water. The organic phase was separated and evaporated, and the resulting residue was purified by NP chromatography to give F-7a.
[0457] The following intermediate F-7 (Table 22) is available in an analogous manner using different starting materials. [Table 23]
[0458] Experimental procedure for the synthesis of F-8a [ka] F-4a (1.27 g, 2.77 mmol, 1.0 equiv.) was dissolved in dioxane (10 mL), and aqueous cesium carbonate (2 M, 3.46 mL, 6.93 mmol, 2.5 equiv.) was added and stirred at 80 °C for 15 min. Then, pyridine-4-boronic acid (357 mg, 2.91 mmol, 1.1 equiv.) and Pd(dppf)Cl2CH2Cl2 (238 mg, 0.28 mmol, 0.1 equiv.) were added to the reaction mixture, which was stirred at 90 °C for 30 min until complete conversion of the starting material was observed. The reaction mixture was filtered, diluted with water, and extracted three times with DCM. The organic phase was evaporated, and the residue was dissolved in DMF and purified by RP chromatography to give the desired product F-8a (HPLC-method: C, t ret =0.80 / 86 minutes; [M+H]=440).
[0459] Experimental procedure for the synthesis of F-9a [ka] F-5a (10.0 g, 19.4 mmol, 1.00 equiv.) was dissolved in DMSO (10 mL), (1S)-1-[(2S)-1-methylpyrrolidinepyrorolidin-2-yl]ethanol (2.76 g, 21.4 mmol, 1.10 equiv.) and DIPEA (6.78 mL, 38.8 mmol, 2.0 equiv.) were added, and the solution was stirred at room temperature overnight. The reaction mixture was diluted with DCM and water. The organic phase was separated and evaporated, and the resulting residue was purified by RP chromatography to give F-9a (HPLC-Method: A, t ret =1.58 / 1.66 minutes; [M+H]=492).
[0460] Experimental procedure for the synthesis of F-10a [ka] (1S)-1-[(2S)-1-Methylpyrrolidin-2-yl]ethanol (245 mg, 1.71 mmol, 1.10 equiv.) was dissolved in DMSO (2 mL) and DIPEA (542 μL, 3.11 mmol, 2.00 equiv.) was added. F-5a (1.00 g, 2.50 mmol, 1.00 equiv.) dissolved in DMSO (2 mL) was added dropwise. The reaction mixture was stirred overnight.
[0461] 4-Oxo-7-azaspiro[2.5]octane (281 mg, 2.48 mmol, 1.60 equiv) and DIPEA (271 μL, 1.55 mmol, 1.00 equiv) were added and the reaction was stirred at 50 °C for 2 days. After complete conversion of the starting material was observed, the mixture was concentrated under reduced pressure and purified by RP chromatography to give F-10a (HPLC method: C, t ret =0.82 / 0.89 minutes; [M+H]=569).
[0462] Experimental procedure for the synthesis of F-11a [ka] Under an argon atmosphere, E-9a (1.05 g, 2.83 mmol, 1.00 equiv.) and 1-(1H-imidazole-1-carbonyl)-1H-imidazole (918 mg, 5.66 mmol, 2.00 equiv.) were dissolved in THF (5 mL) and stirred at room temperature for 1 h. After complete activation of the acid, a solution of A-6b (1.34 mg, 5.98 mmol, 2.00 equiv.) and LiHMDS (1.0 M in THF, 5.95 mL, 5.95 mmol, 2.10 equiv.) was added to the reaction mixture and washed with THF (5 mL). The resulting mixture was stirred at 60 °C overnight. After complete conversion, the reaction mixture was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in ACN and water, filtered and purified by basic RP chromatography to give the desired product F-11a (HPLC method: C, t ret =0.888 / 0.936 / 0.978 minutes; [M+H]=557).
[0463] Experimental procedure for the synthesis of F-12a [ka] E-11e (1.80 g, 0.01 mol, 1 equiv.) was dissolved in THF (18 mL) and activated 3Å molecular sieves were added (200 mg protons per mL of solvent). The mixture was stirred at 50 °C for 20 min under an argon atmosphere. Next, magnesium bromide ethyl etherate (2.11 g, 0.01 mol, 1.5 equiv.) was added and stirred at 50 °C for an additional 30 min. Meanwhile, a second solution was prepared using A-6b (1.47 g, 0.01 mol, 1.5 equiv.), also predried with activated 3Å molecular sieves in THF (8 mL) at 50 °C for 20 min. Next, LiHMDS (1 M in THF, 13.7 mL, 0.01 mol, 2.5 equiv.) was added and stirred for 15 min. The second solution was then added to the first solution and stirred at 50 °C for 1 h. After complete conversion, the reaction mixture was carefully quenched with water and the THF was removed under reduced pressure. The residual pH was adjusted to 7-8 with 1N HCl and extracted with 5% MeOH in DCM (2x). The combined organic layers were washed with brine solution, dried over Na2SO4, filtered, and concentrated to give crude F-12a. The crude compound was purified by NP chromatography.
[0464] The following intermediate F-12 (Table 23) is available in an analogous manner: The crude product is purified by chromatography if necessary. [Table 24]
[0465] Synthesis of Isoxazole Intermediate G Experimental procedure for the synthesis of G-4a [ka] F-1h (944 mg, 1.25 mmol, 1.00 equiv) was dissolved in dioxane (5 mL) and a hydroxylamine solution (50% in water, 0.15 mL, 2.51 mmol, 2.00 equiv) was added. The reaction was stirred overnight at 80 °C under a N atmosphere. After complete conversion, the reaction mixture was concentrated under reduced pressure and purified by RP chromatography to give a mixture of G-1a and G-2a.
[0466] A mixture of G-1a and G-2a (522 mg, 0.679 mmol, 1.00 equiv.) was dissolved in DCM (5 mL), and DIPEA (260 μL, 1.5 mmol, 2.20 equiv.) and methanesulfonyl chloride (54.2 μL, 0.71 mmol, 1.04 equiv.) were added. The resulting solution was stirred at room temperature until complete conversion was observed. The reaction was evaporated and extracted with DCM / water. The organic solvent was evaporated, and the resulting residue was purified by RP chromatography to give G-3a and G-4a.
[0467] The following intermediates G-3 and G-4 (Table 24) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 25]
[0468] Experimental procedures for the synthesis of G-7a and G-8a [ka] F-1a (541 mg, 0.843 mmol, 1.0 equiv) was dissolved in dioxane (5 mL) and hydroxylamine was added (50% in water, 103 μL, 1.69 mmol, 2.0 equiv). The reaction mixture was stirred at 80° C. overnight. After complete conversion of the starting material, the reaction was diluted with saturated aqueous NaHCO and extracted with DCM (3×). The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give the crude product.
[0469] A mixture of crude G-5a and G-6a (116 mg, 0.18 mmol, 1 equiv.) was dissolved in dioxane (1.5 mL) and HCl (4 M in dioxane, 177 μL, 0.71 mmol, 4.00 equiv.) was added. The reaction was stirred at 60° C. for 4 h. After complete conversion, the mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by RP chromatography to give G-7a and G-8a.
[0470] The following intermediates G-7 and G-8 (Table 25) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 26] TIFF2024543967000145.tif103165
[0471] Experimental procedures for the synthesis of G-9a and G-10a [ka] F-11a (1.10 g, 1.91 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (3 mL) and hydroxylamine was added (50% in water, 140 μL, 2.29 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature overnight. After complete conversion, the reaction mixture was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give the crude product.
[0472] The crude mixture of G-9a and G-10a (1.0 g, 1.68 mmol, 1.0 equiv.) was dissolved in 1,4-dioxane (6 mL), and HCl (4 M in water, 2.11 mL, 8.44 mmol, 5.0 equiv.) was added. The reaction mixture was stirred at room temperature for 3 h. After complete conversion, the reaction was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give the crude product. The crude product was dissolved in ACN and water, filtered, and purified by basic RP chromatography to give the desired products G-11a and G-12a.
[0473] The following intermediates G-11 and G-12 (Table 26) are accessible in an analogous manner. The crude product is purified by chromatography if necessary. [Table 27]
[0474] Experimental procedure for the synthesis of A-10a [ka] A dry, clean reactor was charged with 9-BBN (387 mL, 193.5 mmol, 1.2 equiv., 0.5 M in THF) under nitrogen. The solution was cooled to 0–5 °C to give a slurry. A-9a (41.0 g, 161.2 mmol) was added at 0–5 °C, followed by a THF (20.5 mL) rinse. The mixture was warmed to 20–23 °C over 1 h and held at 20–23 °C for at least 1 h. After the mixture was cooled to -45–-40 °C, methyl chloroacetate was added in one portion, followed by the dropwise addition of LiHMDS (355 mL, 532.0 mmol, 3.3 equiv.) while maintaining the temperature below -35 °C. The batch was then warmed to 20–23 °C over 1 h and then held at 20–23 °C for at least 18 h. The batch was cooled to 5-10°C, and AcOH (30.4 mL, 3.3 equiv.) was added below 20°C, followed by water (41 mL) at below 20°C. AcOH (30.4 mL, 3.3 equiv.) was added below 20°C to achieve a pH of approximately 6-7. Approximately 15-16 V of THF was removed under reduced pressure below 35°C. MTBE (246 mL) and water (205 mL) were added. After cutting the phases and removing the bottom aqueous layer, the mixture was cooled to 0-5°C, and a solution of sodium percarbonate (37.2 g, 322.4 mmol, 2.0 equiv.) in water (320 mL) was added below 20°C. After 1 h at 20-23°C, 20 wt% sodium sulfite solution (31 mL) was added. After 15 min at 20-23°C, the bottom aqueous layer was separated and discarded. The organic layer was washed with 5 wt% ammonium chloride solution (123 mL) and water (328 mL). The organic layer was treated with 5% activated carbon for 30 min before filtering. After removing approximately 4-5 V of solvent under vacuum at below 35 °C, crude product A-10a (80% yield, HPLC method: C, t ret =0.84 minutes; [M+H] + = 283) was obtained as an orange-red oil.
[0475] Experimental procedure for the synthesis of G-70a [ka] A reactor was charged with A-10a (45.5 g, 161.2 mmol), ethanol (91.0 mL), NaOAc (39.7 g, 483.6 mmol, 3.0 equiv.), water (45.5 mL), and NHOH·HCl (33.6 g, 483.6 mmol, 3.0 equiv.). The mixture was heated at 73–78 °C for at least 16 h. After the batch was cooled to 20–23 °C, water (227.6 mL) was added over 0.5 h. Next, MTBE (136.5 mL) was added over 0.5 h, followed by heptane (113.8 mL) over 1 h. After 0.5 h at 20–23 °C, the solid was collected by filtration. The solid was washed successively with MTBE (45 mL) and water (91.0 mL). The solid was dried under vacuum to give the product G-70a as an off-white solid (18.27 g, 93.2 wt%) in 40% yield. 1 H NMR (500 MHz, DMSO-d6): δ 11.48 (br s, 1H), 4.04 (q, J = 6.0 Hz, 1H), 3.89-3.80 (m, 2H), 3.60 (q, J = 6.8 Hz, 1H), 2.10-1.95 (m, 2H), 1.92-1.76 (m, 4H), 1.69-1.39 (m, 8H). ESI-MS: m / z 266 [M+H] + .
[0476] Experimental procedure for the synthesis of G-71a [ka] A clean reactor was charged with G-70a (100.0 g, 376.9 mmol, 1.0 equiv.) and KPO (240.0 g, 1130.8 mmol, 3.0 equiv.) in water (499.0 g, 500.0 mL) and toluene (432.5 g, 500.0 mL). The biphasic mixture was stirred until well mixed. After cooling the mixture to 0-5 °C, TfO (186.0 g, 110.9 mL, 659.6 mmol, 1.750 equiv.) was added over 2 h below 5 °C using a syringe pump. After cutting the phases, the organic layer was filtered through a Celite bed with NaSO. After rinsing with toluene (50 mL), the crude product G-71a (149.8 g, 100% yield) was used directly in the next step. 1 H NMR (500 MHz, CDCl3): δ 3.95-3.91(m, 3H), 3.77-3.74 (m, 1H), 2.51-2.44 (m, 2H), 2.16-1.80 (m, 4H), 1.77-1.48 (m, 8H). ESI-MS: m / z 398 [M+H] + .
[0477] Experimental procedure for the synthesis of G-72a [ka] A dry, clean autoclave reactor was charged with G-71a (750 g, 1.89 mol, 1 equiv.), Pd(OAc)2 (8.48 g, 37.7 mmol, 0.02 equiv.), rac-BINAP (23.5 g, 37.7 mmol, 0.02 equiv.), 2-MeTHF (3 L), EtOH (870 g, 18.9 mol, 10 equiv.), and DIPEA (293 g, 2.26 mol, 1.2 equiv.). The reactor was purged twice with nitrogen (100 psi) and then twice with CO2 (100 psi). The reactor was pressurized to 200 psi CO2 and heated to 55–60 °C for at least 12 h. The mixture was transferred to the reactor, and the autoclave reactor was rinsed with 2-MeTHF (0.75 L). The mixture was washed with water (3.75 L). After filtration through a short Celite pad, the solvent was removed by vacuum distillation to give crude product G-72a (531.9 g, 87.7% yield), which was used in the next step without purification. 1 H NMR (400 MHz, CDCl3): δ 4.38 (q, J = 7.1 Hz, 2H), 3.95-3.85 (m, 3H), 3.76-3.73 (m, 1H), 2.85 (dt, J = 17.5, 5.5 Hz, 1H), 2.64 (ddd, J = 17.5, 9.6, 6.0 Hz, 1H), 2.22-2.14 (m, 1H), 2.04-1.88 (m, 3H), 1.78-1.45 (m, 8H), 1.37 (t, J = 7.1 Hz, 3H). ESI-MS: m / z 322 [M+H] + .
[0478] Experimental procedure for the synthesis of G-73a [ka] A dry, clean reactor was charged with G-72a (482.0 g, 1.5 mol, 1 equiv.) and EtOH (3 V) and vacuum distilled to approximately 3 V to remove residual 2-MeTHF from the previous carbonylation step. EtOH (1.45 L) and NH4OH (1.93 L) were added. The mixture was held at 20-25 °C for at least 15 h. Water (1.69 L) was added over 30 min. After 30 min at 20-25 °C, the solid was collected and washed with 1:2 EtOH / water (0.96 L) and water (0.48 L). The solid was slurried in 1:1 MTBE / hexane (0.96 L) for 1 h. The solid was collected by filtration and dried under reduced pressure at 40-45°C overnight to give the product G-73a (332.4 g, 75.8% yield, water content ≤ 0.5% based on Karl Fischer titration) as a tan solid. 1 H NMR (500 MHz, DMSO-d6): δ 8.05 (s, 1H), 7.78 (s, 1H), 3.94-3.72 (m, 4H), 2.78 (dt, J = 17.1, 5.0 Hz, 1H), 2.54-2.48 (m, 1H), 2.20-2.14 (m, 1H), 1.93-1.78 (m, 3H), 1.70-1.42 (m, 8H). ESI-MS: m / z 293 [M+H] + .
[0479] Experimental procedure for the synthesis of G-74a [ka] A dry, clean reactor was charged with G-73a (383 g, 86.7 wt%, 1.137 mol, 1 equiv.), MeCN (1.15 L), and pyridine (216 g, 0.19 L, 2.4 equiv.). After cooling the mixture to 0-5 °C, trifluoroacetic anhydride (287 g, 1.36 mol, 1.2 equiv.) was added below 5 °C. After 5 min at 0-5 °C, water (1.54 L) was added below 15 °C. The product was extracted with MTBE (1.92 L) and washed with 5% sodium bicarbonate solution (1.15 L). The organic layer was filtered through a silica gel pad (380 g) and rinsed with MTBE (0.58 L). After removal of the solvent by distillation under vacuum, the product G-74a (421.8 g, 97.8% yield) was obtained as an orange-brown oil. 1 H NMR (500 MHz, CDCl3): δ 3.98-3.85 (m, 3H), 3.80-3.75 (m, 1H), 2.72 (dt, J = 17.0, 5.2 Hz, 1H), 2.60 (ddd, J = 17.0, 9.5, 5.8 Hz, 1H), 2.20-2.12 (m, 1H), 2.07-1.94 (m, 3H), 1.82-1.48 (m, 8H). ESI-MS: m / z 275 [M+H] + .
[0480] Experimental procedure for the synthesis of G-76a [ka] A dry flask was charged with crude G-74a (265 g, 72.3 wt %, 698.4 mmol) in MeOH (1590 mL) and catalytic NaOMe (8.0 mL, 25% in MeOH, 34.9 mmol). The mixture was stirred at room temperature for 1 h to achieve >99% conversion. Solid NH4Cl (52.0 g, 977.8 mmol, 1.4 equiv.) was added, and the resulting mixture was stirred at room temperature to achieve >95% conversion (if not, additional NH4Cl was added). Dimethyl dimalonate (168 g, 1047.7 mmol, 1.5 equiv.) was added at room temperature, followed by NaOMe (377 g, 25% in MeOH, 2.5 equiv.). The resulting mixture was heated at reflux for 4 h to achieve >95% conversion. After the mixture was cooled to 23° C., water (795 mL) was added, followed by the slow addition of 6 N HCl (349 mL) below 20° C. to reach a pH of about 3. MTBE (530 mL) was added to the slurry. After 1 h at room temperature, the solid was collected by filtration and washed with 3 V water (796 mL) and MTBE (530 mL) to give the product G-76a (178 g) as an off-white solid in 71% crude yield. The crude product was used directly in the next step. 1 H NMR (500 MHz, CDCl3): δ 5.82 (s, 1H), 3.96-3.74 (m, 4H), 2.74-2.70 (m, 1H), 2.62-2.59 (m, 1H), 2.22-2.10 (m, 1H), 2.12-1.90 (m, 3H), 1.80-1.48 (m, 8H). ESI-MS: m / z 360 [M+H] + .
[0481] Experimental procedure for the synthesis of G-77a [ka] A dry flask was charged with G-76a (80.0 g, 253.7 mmol), DMAP (4.0 g), tetramethylammonium chloride (4.0 g), and POCl (400 mL). The mixture was heated at 80 °C for 1.5 h to achieve >99% conversion. POCl was removed under reduced pressure to give a thick, pale yellow slurry. MTBE (160 mL) was added. The mixture was then cooled to 5 °C. Water (800 mL) was slowly added. The resulting white slurry was stirred at 23 °C for 1 h. The solid was collected by filtration and then washed successively with water (480 mL) and MTBE (160 mL). After drying overnight under reduced pressure at 60 °C, 84.3 g of product G-77a was isolated as a white solid with a purity of >99% and a yield of approximately 93%. 1 H NMR (600 MHz, DMSO-d6): δ 8.05 (s, 1H), 2.96-2.91 (m, 1H), 2.76-2.69 (m, 2H), 2.53-2.48 (m, 2H), 2.37-2.34 (m, 1H), 1.97-1.96 (m, 2H), 1.88-1.82 (m, 4H), 1.70-1.61 (m,1H), 1.52-1.41 (m, 1H). 13C NMR (125 MHz, DMSO-d6): δ 209.8, 164.3, 161.4, 157.3, 155.7, 120.8, 120.2, 50.3, 38.1, 37.5, 31.0, 26.6, 20.7,19.9, 18.0. ESI-MS: m / z 353 [M+H] + .
[0482] Experimental procedure for the synthesis of G-78a [ka] A dry, clean reactor was charged with LiHMDS (1 M in THF) (406.4 kg, 456.1 mol, 1.1 equiv.). The solution was cooled to 0–5 °C, and crude A-6b (93.0 kg, 414.6 mol) was added below 5 °C, rinsing with THF (46.5 kg) to aid transfer. After 30 min at 0–5 °C, diethyl oxalate (72.5 kg, 497.5 mol, 1.2 equiv.) was added below 5 °C. The mixture was warmed to 20–25 °C for 1 h, after which the mixture was held at 20–25 °C for at least 3 h. After cooling the batch to 10–15 °C, a chilled HCl solution [prepared by adding acetyl chloride (73.6 kg, 932.9 mol, 2.25 equiv.) to EtOH (293.9 kg) at 0–5 °C] was added to the batch below 25 °C to achieve a final pH of approximately 6–7. Solid NHOH·HCl (28.8 kg, 414.4 mol, 1.05 equiv.) was added in one portion, and the resulting mixture was heated to reflux at 66–70 °C for 6–10 h. The 5V solvent was then removed by distillation at reflux at 66–70 °C. EtOH (73.5 kg) was used to remove residual THF. Water (372.0 kg) and EtOH (293.9 kg) were added. After 3–6 h at 70–75 °C, the mixture was cooled to 30–35 °C and seeded with 0.5–1% G-78a crystals. After 2-4 hours at 30-35°C, heptane (63.2 kg) was added over at least 1 hour. After 60 minutes at 20-25°C, water (279.0 kg) was added over 4-6 hours. After 1 hour at 20-25°C, the solid was collected and washed twice with 1:2 EtOH / water (51.2 kg EtOH and 130.2 kg water), followed by heptane (63.2 kg). The solid was dried under vacuum under a stream of nitrogen to give the product G-78a (93.0 kg) in 65% yield. 1H NMR (500 MHz, CDCl3): δ 4.42 (q, J = 7.1 Hz, 2H), 2.73 (dt, J = 16.8, 5.1 Hz, 1H), 2.64 (dt, J = 14.3, 6.0 Hz, 1H), 2.60-2.51 (m, 2H), 2.43-2.30 (m, 2H), 2.09-1.96 (m, 3H), 1.91-1.81 (m, 3H), 1.76-1.67 (m, 1H), 1.65-1.58 (m, 1H), 1.40 (t, J = 7.1 Hz, 3H). ESI-MS: m / z 278 [M+H] + .
[0483] Experimental procedure for the synthesis of G-79a [ka] A dry, clean reactor was charged with G-78a (72.0 kg, 259.6 mol), EtOH (56.9 kg), and NH4OH (aq) (280.8 kg). The mixture was held at 20-25 °C for at least 16 hours. Water (144.0 kg) was added over 30 minutes, and the slurry was then held at 20-25 °C for 30 minutes. The solid was collected by filtration and washed with 1:3 EtOH / water (28.5 kg EtOH and 108 kg water) followed by heptane (97.9 kg). After drying under vacuum at 23 °C for 1 hour, the solid was dried under vacuum at 50-55 °C overnight to give product G-79a (61.4 kg, 87.2% yield, enantiomeric ratio ≥ 95:5 (at 254 nm), water content ≤ 0.5% by Karl Fischer titration).
[0484] A dry, clean reactor was charged with crude G-79a (60.0 kg, 1.0 equiv.), 1,4-dioxane (240.0 kg), and activated carbon (3.0 kg, 5 wt%). The mixture was stirred at 55-65°C for 2-4 hours. After filtration at elevated temperature (55-65°C), the filter cake was washed with 1,4-dioxane (33.0 kg). The filtrate was transferred to a clean reactor. The temperature was adjusted to 45-55°C and stirred at 45-55°C for 1-2 hours. Water (240.0 kg) was added over 2 hours. The temperature was adjusted to 45-55°C and stirred at 45-55°C for 1-2 hours. The mixture was cooled to 35-45°C and stirred at 35-45°C for 2-4 hours. Water (87.0 kg) was added over 4 hours. The mixture was cooled to 15-25°C and stirred at 15-25°C for 12-14 hours. The solid was collected by centrifugation, washed with water (120.0 kg), and dried under vacuum at 50-55°C overnight to give product G-79a (44.8 kg, 71% yield) as a pale yellow to off-white solid. The undesired isomer should be less than 0.5%. 1 H NMR (500 MHz, DMSO-d6): δ 7.99 (s, 1H), 7.71 (s, 1H), 2.80-2.69 (m, 1H), 2.60-2.53 (m, 1H), 2.50-2.42 (m, 1H), 2.40-2.28 (m, 2H), 2.26-2.18 (m, 1H), 2.05-1.70 (m, 7H), 1.48-1.39 (m, 1H). ESI-MS: m / z 249 [M+H] + .
[0485] Experimental procedure for the synthesis of G-80a [ka] A dry, clean reactor was charged with G-79a (40.0 kg, 161.1 mol), MeCN (96.0 kg), and pyridine (30.8 kg, 386.6 mol, 2.4 equiv.). After cooling the mixture to 0-5 °C, TFAA (40.8 kg, 193.3 mol, 1.2 equiv.) was added slowly below 5 °C. After 5 min at 0-5 °C, water (120.0 kg) was added over 30 min at 0-5 °C and seeded with 0.5% G-80a crystals. After 15 min at 0-5 °C, water (120.0 kg) was added over 30 min. After 30 min at 0-5 °C, the solid was collected by filtration and washed with 1:3 MeCN / water (15.6 g acetonitrile and 60.0 kg water) and then with water (80.0 kg). The solid was dried under vacuum to give the crude product (33.0 kg, 93.6% yield) as a tan solid.
[0486] A dry, clean reactor was charged with crude G-80a (32.5 kg, 1.0 equiv.) and MTBE (48.1 kg), and the slurry was stirred at 20-25 °C for 30 min. Heptane (132.6 kg) was added over 1 h. After 30 min at 20-25 °C, the solid was collected and dried under vacuum to give the product G-80a (26.6 kg, 82.0% yield) as a white solid with a >99:1 enantiomeric ratio (254 nm) and a purity of >98% (220 nm). 1 H NMR (500 MHz, DMSO-d6): δ 2.83-2.73 (m, 1H), 2.60-2.40 (m, 3H), 2.34-2.20 (m, 2H), 2.06-1.75 (m, 7H), 1.53-1.43 (m, 1H). ESI-MS: m / z 231 [M+H] + .
[0487] Experimental procedure for the synthesis of G-82a [ka] To a stirred solution of G-80a (25.0 g, 108.6 mmol, 1.0 equiv) in MeOH (150 mL), NaOMe (30% in MeOH, 4.89 g, 27.1 mmol, 0.25 equiv) was added, and the resulting mixture was stirred at room temperature for 2 h. Next, NHCl (6.39 g, 119.4 mmol, 1.1 equiv) was added, and the mixture was stirred at room temperature for 16 h. After complete conversion to the desired amidine, the mixture was filtered through a Celite bed and concentrated. The residue was dissolved in DMF (125 mL), and 1,8-diazabicyclo[5.4.0]undec-7-ene (32.3 g, 212.3 mmol, 2.1 equiv) and diethyl malonate (13.4 g, 101.1 mmol, 1.0 equiv) were added at 0 °C, and the resulting mixture was stirred at 90 °C for 16 h. After complete conversion, ice-cold water was added, the mixture was acidified with 1N HCl and the precipitate was collected by filtration. The precipitate was dried under reduced pressure to give crude G-82a (HPLC-method: H, t ret = 1.51 min; [M+H] = 316) which was used in the next step without purification.
[0488] Experimental procedure for the synthesis of G-83a [ka] G-82a (10.0 g, 30.1 mmol, 1.0 equiv.) and POCl3 (48.0 g, 310.0 mmol, 10.3 equiv.) were combined at 0 °C and stirred for 5 min. DIPEA (8.2 g, 63.2 mmol, 2.1 equiv.) was added, and the resulting mixture was stirred at 80 °C for 3 h. After complete conversion, ice-cold water (1 L) was slowly added to the mixture at 0 °C, after which the mixture was allowed to warm to room temperature and stirred for 1 h. The precipitate was collected by filtration, washed with water and hexane, and dried under vacuum to yield G-83a (HPLC method: H, t ret = 2.22 min; [M+H] = 352 / 354). The crude product was used in the next step without purification.
[0489] Experimental procedure for the synthesis of G-84a [ka] B-5d (694 mg, 4.09 mmol, 1.2 equiv) was dissolved in dry THF (13 mL) and cooled to 0 °C. LiHMDS (1.0 M in THF, 5.11 mL, 5.11 mmol, 1.5 equiv) was added dropwise at 0 °C, and the mixture was stirred for an additional 15 min. G-77a (1.20 g, 3.41 mmol, 1.0 equiv) was dissolved in dry THF (13 mL) and added dropwise at 0 °C. The mixture was stirred at 65 °C for 1.5 h. After complete conversion, the mixture was diluted with saturated aqueous NaHCO and extracted three times with DCM. The organic phases were combined, filtered, and concentrated under reduced pressure to give G-84a. The crude product was used in the next step without purification.
[0490] The following intermediate G-84 (Table 27) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 28]
[0491] Experimental procedure for the synthesis of G-15a [ka] F-8a (356 mg, 0.804 mmol, 1.0 equiv) was dissolved in dioxane (2 mL) and hydroxylamine solution (50% in water, 98.6 μL, 1.61 mmol, 2.0 equiv) was added. The resulting solution was stirred at 40 °C until complete conversion was observed. The solvent was evaporated, and the resulting residue was purified by RP chromatography to give G-13a (G-14a was observed as a by-product and separated by chromatography). G-13a (136.0 mg, 0.29 mmol, 1.0 equiv) was dissolved in DCM (2 mL) and DIPEA (114.38 μL, 0.65 mmol, 2.2 equiv) and methanesulfonyl chloride (34.2 μL, 0.45 mmol, 1.5 equiv) was added. The resulting solution was stirred at room temperature until complete conversion was observed. The reaction mixture was concentrated under reduced pressure and extracted with DCM (3×) and water. The organic solvent was evaporated and the resulting residue was purified by RP chromatography to give G-15a.
[0492] The following intermediate G-15 (Table 28) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 29]
[0493] Experimental procedure for the synthesis of G-18a [ka] F-7a (740 mg, 1.28 mmol, 1.00 equiv) was dissolved in pyridine (5.0 mL), hydroxylamine hydrochloride (135 mg, 1.92 mmol, 1.5 equiv) was added, and the solution was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was acidified with 2 M HCl and extracted with DCM (2x). The combined organic phases were washed with 1 M HCl, the solvent was evaporated, and the resulting residue was purified by NP chromatography to give G-16a. G-17a was observed as a by-product but was not isolated.
[0494] G-16a (425 mg, 0.65 mmol, 1.00 equiv) was dissolved in acetic acid (1.0 mL) and stirred at 50 °C overnight. The reaction mixture was quenched with saturated Na2CO3. The suspension was extracted with DCM, the organic phase was separated and evaporated, and the resulting residue was purified by NP chromatography to give G-18a.
[0495] The following intermediate G-18 (Table 29) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 30]
[0496] Experimental procedure for the synthesis of G-21a [ka] F-6a (1.98 g, 4.60 mmol, 1 equiv.) was dissolved in dioxane (40 mL) and MeOH (10 mL), and formic acid (250 μL, 6.63 mmol, 1.44 mmol) and hydroxylamine solution (50% in water, 310 μL, 5.05 mmol, 1.44 equiv.) were added and stirred overnight. After complete conversion, the reaction was concentrated under reduced pressure and purified by NP chromatography to give products G-19a and G-20a.
[0497] G-19a (350 mg, 0.78 mmol, 1.00 equiv) was dissolved in HCl (4 M in dioxane, 2.5 mL) and stirred at room temperature for 5 min. Then, HCl (4 M, 2.5 mL) was added, and the reaction was stirred at room temperature for 30 min. After complete conversion, the reaction mixture was basified with NaHCO and extracted with DCM. The combined organic phase was concentrated under reduced pressure to give product G-21a.
[0498] The following intermediates G-21 and G-22 (Table 30) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 31]
[0499] Experimental procedure for the synthesis of G-25a [ka] F-1e (350 mg, 0.54 mmol, 1.00 equiv.) was dissolved in pyridine (3 mL) and hydroxylamine hydrochloride (56.9 mg, 0.81 mmol, 1.5 equiv.) was added. The reaction was stirred at 90 °C for 3 days. After complete conversion of the starting material was observed, the reaction was concentrated under reduced pressure and extracted with NaHCO3 / DCM. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give G-25a. G-26a was observed as a minor by-product but was not isolated (HPLC method: C, t ret =1.01 min; [M+H]=639).
[0500] Experimental procedure for the synthesis of G-27a [ka] (1S)-1-[(2S)-1-methylpyrrolidin-2-yl]ethan-1-ol (1.78 g, 10.5 mmol, 3.0 equiv.) and potassium tert-butoxide (1.17 g, 10.5 mmol, 3.0 equiv.) were dissolved in 1-4 dioxane (500 mL) and stirred at 50 °C for 30 min. G-18a (2.0 g, 3.48 mmol, 1 equiv.) was added and the solution was stirred at 85 °C for 3 h. The solvent was evaporated and the resulting residue was purified by NP chromatography to give G-27a (HPLC method: A, t ret =1.92 minutes; [M+H]=667).
[0501] Experimental procedure for the synthesis of G-28a [ka] G-15a (114 mg, 0.260 mmol, 1.0 equiv.) was dissolved in DMSO (1 mL) and DIPEA (90.4 μL, 0.519 mmol, 2.0 equiv.) was added. Next, (S)-tert-butyl 3-methyl-1,4-diazepane-1-carboxylate (121 mg, 0.545 mmol, 2.1 equiv.) was added to the reaction mixture, which was then stirred at 70 °C for 17 h until complete conversion of the starting material was observed. The reaction mixture was diluted with water and extracted three times with DCM. The organic solvent was evaporated, and the resulting residue was purified by RP chromatography to give G-28a (HPLC method: C, t ret =1.06 minutes; [M+H]=617).
[0502] Experimental procedure for the synthesis of G-29a [ka] (1S)-1-[(2S)-1-Methylpyrrolidin-2-yl]ethan-1-ol (122 μL mg, 0.865 mmol, 3.0 equiv.) and potassium tert.-butoxide (97.0 mg, 0.865 mmol, 3.0 equiv.) were dissolved in THF (2 mL) and stirred at 50° C. for 30 min. G-15b (165 mg, 0.28 mmol, 1 equiv.) was added and the solution was stirred at 85° C. for 3 h. The solvent was evaporated and the resulting residue was purified by RP chromatography to give G-29a (HPLC method: C, t ret =1.12 minutes; [M+H]=665).
[0503] Experimental procedure for the synthesis of G-30a [ka] G-29a (183 mg, 275 μmol, 1.0 equiv) and HCl (8 M, 172 μL, 1.38 mmol, 5.0 equiv) were dissolved in MeOH (2.0 mL) and stirred at 60° C. until complete conversion. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc / NaHCO. The combined organic phase was concentrated under reduced pressure to give G-30a (HPLC method: A, t ret=1.41 minutes; [M+H]=521).
[0504] Experimental procedure for the synthesis of G-31a [ka] G-11b (3.00 g, 6.45 mmol, 1.0 equiv) was dissolved in DMF (7 mL), sodium azide (504 mg, 7.74 mmol, 1.2 equiv) was added, and the reaction was stirred at 50 °C for 18 h. After complete conversion of the starting material, the reaction was cooled to room temperature and extracted with DCM / water. The combined organic phases were concentrated under reduced pressure to give G-31a (HPLC method: C, t ret =0.88 minutes; [M+H]=452).
[0505] Experimental procedure for the synthesis of G-32a [ka] G-15c (80.0 mg, 0.139 mmol, 1.0 equiv.) was dissolved in DMSO (1 mL) and DIPEA (47.4 μL, 0.279 mmol, 2.0 equiv.), and N-methylpiperazine (20.9 mg, 0.209 mmol, 1.5 equiv.) was added. The reaction mixture was stirred at 90 °C until complete conversion was observed. The mixture was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in ACN and purified by basic RP chromatography (gradient elution: 40% to 98% ACN in water) to give the desired product 32a (HPLC method: C, t ret =0.953 minutes; [M+H] + =638).
[0506] Experimental procedure for the synthesis of G-33a [ka] G-32a (139 mg, 0.225 mmol, 1.0 equiv) was dissolved in dioxane (1 mL) and HCl solution (2 M in water, 0.79 mL, 1.58 mmol, 7.0 equiv) was added. The resulting solution was stirred at 60 °C for 2 h until complete conversion of the starting material was observed. The reaction mixture was diluted with saturated aqueous NaHCO and extracted three times with DCM. The organic solvent was evaporated and the resulting residue was purified by RP chromatography to give G-33a.
[0507] The following intermediate G-33 (Table 31) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 32]
[0508] Experimental procedure for the synthesis of G-34a [ka] G-12b (100 mg, 0.22 mmol, 1.0 equiv), (S)-5-methyl-4,7-diazaspiro[2.5]octane dihydrochloride (141 mg, 0.67 mmol, 3.0 equiv), and DIPEA (230 μL, 0.67 mmol, 6.0 equiv) were dissolved in DMSO (1 mL). The reaction was stirred at 90 °C for 18 h. After completion of the reaction, the solvent was removed under reduced pressure, and the residue was purified by basic RP chromatography to give the desired product G-34a.
[0509] The following intermediate G-34 (Table 32) is available in a similar manner: The crude product is purified by chromatography if necessary.
[0510] The diastereomeric mixture G-34c could be separated by chiral HPLC (Chiralpack IE, 250 × 20 mm, 5 μm; solvent: ethanol / heptane 60:40 + 0.1% diethylamine) to give G-34c1 (eluting first as peak 1) and G-34c2 (eluting later as peak 2). [Table 33] TIFF2024543967000180.tif224165 TIFF2024543967000181.tif218165
[0511] Experimental procedure for the synthesis of G-35a [ka] G-12b (140 mg, 0.31 mmol, 1.0 equiv.) was dissolved in dioxane (2 mL). [1-(oxetan-3-yl)-1H-pyrazol-3-yl]boronic acid (B-9c) (66.3 mg, 0.38 mmol, 1.19 equiv.), XPHOS PD G3 (29.9 mg, 0.03 mmol, 0.1 equiv.), and cesium carbonate (400 μL, 0.80 mmol, 2.54 equiv.) were added. The reaction was stirred at 80° C. under an argon atmosphere for 10 min. After complete conversion was observed, the reaction was extracted with DCM / water. The combined organic phase was concentrated under reduced pressure, dissolved in ACN / water, and purified by RP chromatography to give the desired product G-35a.
[0512] The following intermediate G-35 (Table 33) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 34] TIFF2024543967000184.tif247165 TIFF2024543967000185.tif86165
[0513] Experimental procedure for the synthesis of G-35n [ka] G-12b (118 mg, 0.27 mmol, 1.0 equiv.), 1-methyl-1H-1,2,3-triazole-4-boronic acid, ate complex with 1,1,1-tris(hydroxymethyl)ethane lithium salt (69.0 mg, 0.32 mmol, 1.20 equiv.). Pd(dppf)Cl DCM (45.6 mg, 0.05 mol, 0.20 equiv.) was dissolved in dioxane (1.5 ml), and cesium carbonate (190 mg, 0.58 mol, 2.2 equiv.) dissolved in water (165 μl) was added to the reaction mixture. The reaction mixture was stirred at 90 °C for 18 h. After complete conversion, the reaction mixture was filtered and extracted with DCM (3x). The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give G-35n (HPLC method: A, t ret =1.41 minutes; [M+H]=492).
[0514] Experimental procedure for the synthesis of G-36a [ka] G-35l (61.0 mg, 0.1 mmol, 1.0 equiv) was dissolved in dioxane (1 mL) and HCl (4 M, 101 μL, 0.4 mmol, 4.0 equiv) was added. The reaction was stirred at 50° C. for 3 h. After complete consumption of the starting material, the reaction was quenched by the addition of NaHCO and extracted with DCM (3×). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in ACN and purified by RP chromatography to give the desired product G-36a (HPLC method: C, t ret =0.72 minutes; [M+H]=503).
[0515] Experimental procedure for the synthesis of G-37a [ka] G-34f (157 mg, 0.25 mmol, 1.0 equiv.) was dissolved in MeOH (2 mL) and palladium (10% on charcoal, 26.7 mg, 0.1 equiv.) was added. The reaction was stirred at room temperature under 5 bar of hydrogen for 17 hours. After complete conversion, the reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved in DMF and purified by RP chromatography to give product G-37a (HPLC method: C, t ret =0.67 minutes; [M+H]=537).
[0516] Experimental procedure for the synthesis of G-38a [ka] G-34g (185 mg, 0.29 mmol, 1.0 equiv) was dissolved in DCM (3 mL) and TFA (110 μL, 1.48 mmol, 5.07 equiv) was added. The reaction was stirred at 40° C. for 20 h. After complete conversion of the starting material, the reaction was concentrated under reduced pressure, basified, dissolved in DMSO, and purified by RP chromatography to give product G-38a (HPLC method C, t ret =0.80 minutes; [M+H]=535).
[0517] Experimental procedure for the synthesis of G-39a [ka] G-33a (52.0 mg, 0.105 mmol, 1.0 equiv) was dissolved in DCM (2 mL) under argon and cooled to 0 °C. Formaldehyde (9.47 μL, 0.126 mmol, 1.2 equiv) was added, followed by sodium triacetoxyborohydride (94.0 mg, 0.443 mmol, 4 equiv). The solution was stirred at 0 °C for 30 min. After complete consumption of the starting material, the reaction was quenched by the addition of water. The aqueous phase was extracted with DCM (3x). The combined organic phases were filtered and concentrated under reduced pressure. The residue was purified by RP chromatography to give the desired product G-39a (HPLC method: C, t ret =0.72 minutes; [M+H] +=508).
[0518] Experimental procedure for the synthesis of G-40a [ka] G-11a (500 mg, 1.07 mmol, 1.00 equiv) was dissolved in MeOH (10 mL) and formaldehyde (403 μL, 5.36 mmol, 5 equiv), and acetic acid (27 μL, 0.54 mmol, 0.50 equiv) was added, followed by sodium cyanoborohydride (142 mg, 2.14 mmol, 2.00 equiv). The solution was stirred at room temperature for 1 h. After complete consumption of the starting material, the reaction was quenched by the addition of water and saturated NaHCO3. The aqueous phase was extracted with DCM (3x). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in ACN and purified by RP chromatography to give the desired product G-40a (HPLC method: A, t ret =1.39 minutes; [M+H] + =444).
[0519] Experimental procedure for the synthesis of G-41a [ka] G-27a (1.00 g, 1.50 mmol, 1.00 equiv) was dissolved in DCM (3.0 mL), TFA (500 μL, 6.48 mmol, 4.32 equiv) was added, and the solution was stirred at 50° C. for 1 h. The solvent was evaporated, and the resulting residue was dissolved in DCM and saturated aqueous NaCO solution. The organic phase was separated, and the remaining aqueous phase was extracted with DCM (2×). The combined organic phases were dried over magnesium sulfate, the solvent was evaporated, and the resulting residue was purified by RP chromatography to give G-41a (HPLC method: A, t ret =1.34 minutes; [M+H] + =523).
[0520] Experimental procedure for the synthesis of G-42a [ka] G-4a (114 mg, 0.152 mmol, 1.0 equiv) was dissolved in dioxane (2 mL) and 2 M aqueous HCl (0.38 mL, 0.76 mmol, 5.0 equiv) was added. The resulting solution was stirred at 60 °C for 2 h until complete conversion of the starting material was observed. The reaction mixture was diluted with saturated aqueous NaHCO and extracted three times with DCM. The organic solvent was evaporated and the resulting residue was purified by RP chromatography to give G-42a.
[0521] The following intermediate G-42 (Table 34) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 35]
[0522] Experimental procedure for the synthesis of G-43a [ka] G-18b (1.15 g, 1.64 mmol, 1.0 equiv) was treated with HCl (4N in 1,4-dioxane, 15 mL, 60.0 mmol, 36.6 equiv), and the mixture was stirred at 80 °C for 1 h. After complete conversion, the reaction mixture was diluted with saturated aqueous NaHCO and extracted three times with DCM. The organic phase was dried, filtered, and evaporated. The resulting residue was purified by RP chromatography to give G-43a.
[0523] The following intermediate G-43 (Table 35) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 36]
[0524] Experimental procedure for the synthesis of G-44a [ka] G-12b (120 mg, 0.269 mmol, 1.0 equiv), 1H-1,2,3-triazole (37.3 mg, 0.539 mmol, 2.0 equiv), and cesium carbonate (220 mg, 0.67 mmol, 2.5 equiv) were dissolved in DMSO (1 mL) and stirred at 80 °C for 1 h. After complete conversion, DCM was added, and the reaction was washed with water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-44a.
[0525] The following intermediate G-44 (Table 36) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 37]
[0526] Experimental procedure for the synthesis of G-45a [ka] G-11a (217 mg, 0.505 mmol, 1.0 equiv) was dissolved in DMSO (2 mL) and DIPEA (172 μL, 1.01 mmol, 2.0 equiv), and N-methylpiperazine (75.8 mg, 0.757 mmol, 1.5 equiv) was added. The reaction mixture was stirred at 90 °C until complete conversion was observed. The mixture was diluted with saturated aqueous NaHCO and extracted three times with DCM. The organic phases were combined, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in ACN and purified by basic RP chromatography to give the desired product G-45a.
[0527] The following intermediate G-45 (Table 37) is available in a similar manner: The crude product is purified by chromatography if necessary.
[0528] The diastereomeric mixture G-45l was separated by chiral HPLC (column: Chiralpack IE, 250 × 20 mm, 5 μm; solvent: ethanol / heptane 1:1 + 0.1% diethylamine) to give G-45I1 (eluting first as peak 1) and G-45I2 (eluting later as peak 2). [Table 38] TIFF2024543967000201.tif236165 TIFF2024543967000202.tif215165 TIFF2024543967000203.tif240165 TIFF2024543967000204.tif248165 TIFF2024543967000205.tif242165 TIFF2024543967000206.tif50165
[0529] Experimental procedure for the synthesis of G-46a [ka] 4-(1H-pyrazol-3-yl)pyridine (73.4 mg, 0.51 mmol, 1.50 equiv) was dissolved in DMF (1 mL) and NaH (51.7 mg, 1.35 mmol, 4.0 equiv) was added and stirred at room temperature for 20 min. G-11b (150 mg, 0.34 mmol, 1.0 equiv) was added and the reaction was stirred at 40 °C for 1 h. After complete conversion, the reaction was extracted with EtOAc / water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-46a.
[0530] The following intermediate G-46 (Table 38) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 39] TIFF2024543967000209.tif239165 TIFF2024543967000210.tif38165
[0531] Experimental procedure for the synthesis of G-47a [ka] G-11b (150 mg, 271.7 μmol, 1.0 equiv.), 2-hydroxypyrazine (31.3 mg, 326.1 μmol, 1.2 equiv.), and t-BuONa (2 M in THF, 190.20 μL, 0.38 mmol, 1.4 equiv.) were dissolved in THF (2 mL) and stirred at 65° C. for 18 h. After complete conversion, the reaction was extracted with DCM / water. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give the desired product G-47a (HPLC method: A, t ret =1.39 minutes; [M+H]=505).
[0532] Experimental procedure for the synthesis of G-48a [ka] G-11d (150 mg, 0.32 mmol, 1.0 equiv.) was dissolved in dioxane (1.5 mL). 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (82.7 mg, 0.39 mmol, 1.2 equiv.), XPHOS PD G3 (26.0 mg, 0.03 mmol, 0.09 equiv.), and cesium carbonate (0.4 mL, 0.80 mmol, 2.46 equiv.) were added. The reaction was stirred at 80 °C for 2 h. After complete conversion was observed, the reaction was extracted with DCM / water. The combined organic phase was concentrated under reduced pressure, dissolved in ACN / water, and purified by RP chromatography to give the desired product G-48a.
[0533] The following intermediate G-48 (Table 39) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 40] TIFF2024543967000214.tif226165 TIFF2024543967000215.tif204165 TIFF2024543967000216.tif234165 TIFF2024543967000217.tif231165 TIFF2024543967000218.tif242165
[0534] Experimental procedure for the synthesis of G-49a [ka] G-11b (50 mg, 0.10 mmol, 1.0 equiv.), 2-(4,4,5,5-tetramethyl-1,3,4 dioxaborolan-2-yl)pyridine (41.39 mg, 0.19 mmol, 2.0 equiv.), Pd(dppf)Cl (7 mg, 0.01 mmol, 0.1 equiv.), copper(I) chloride (9.68 mg, 0.10 mmol, 1.0 equiv.), and cesium carbonate (128 mg, 0.38 mmol, 4.0 equiv.) were dissolved in DMF (1 mL) and stirred at 90 °C under argon for 18 h. The reaction was extracted with DCM / water, and the organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-49a (HPLC method: A, t ret =1.56 minutes; [M+H]=488).
[0535] Experimental procedure for the synthesis of G-50a [ka] G-11b (148 mg, 0.30 mmol, 1 equiv.), 5-bromothiazole (50 mg, 0.30 mmol, 1.0 equiv.), bis(pinacolato)diboron (163 mg, 0.63 mmol, 2.10 equiv.), APhos PD G3 methanesulfonate (10.4 mg, 0.02 mmol, 0.06 equiv.), potassium acetate (60.3 mg, 0.61 mmol, 2.06 equiv.), and potassium triphosphate (4 M in water, 161 μL, 0.64 mmol, 2.15 equiv.) were dissolved in dioxane (1 mL) and stirred under nitrogen at 90 °C for 18 h. After complete conversion, the reaction mixture was extracted with EtOAc / water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-50a (HPLC method: C, t ret =0.79 minutes; [M+H]=494).
[0536] Experimental procedure for the synthesis of G-51a [ka] G-11b (150 mg, 0.34 mmol, 1.0 equiv.) was dissolved in dioxane (18 mL) and 2-oxazolidone (59.9 mg, 0.67 mmol, 2.0 equiv.), Pd(dppf)Cl2 (24.7 mg, 0.03 mmol, 0.1 equiv.) and NaOtBu (2.0 M in THF, 185 μL, 0.37 mmol, 1.1 equiv.) were added. The reaction was stirred at 60 °C for 3 days. After complete conversion was observed, the reaction was filtered and concentrated under reduced pressure. The residue was extracted with DCM / water. The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give G-51a (HPLC method: C, t ret =0.78 minutes; [M+H]=496).
[0537] Experimental procedure for the synthesis of G-52a [ka] G-11b (120 mg, 0.27 mmol, 1.0 equiv), 1-methylimidazolin-2-one (81.0 mg, 0.81 mmol, 3.0 equiv), Xantphos PD G3 (16.15 mg, 0.02 mmol, 0.06 equiv), and cesium carbonate (131 mg, 0.40 mmol, 1.5 equiv) were dissolved in dioxane (960 μL) and stirred at 110 °C under argon atmosphere for 16 h. After complete conversion, the reaction mixture was filtered and purified by RP chromatography to give the desired product G-52a.
[0538] The following intermediate G-52 (Table 40) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 41]
[0539] Experimental procedure for the synthesis of G-53a [ka] G-11b (300 mg, 617 μmol, 1 equiv.), 2-hydroxythiazole (125 mg, 1.23 mmol, 2 equiv.), and cesium carbonate (402 mg, 1.23 mmol, 2 equiv.) were dissolved in DMSO (3 mL). The reaction was stirred at 85 °C for 2 h. After complete conversion, DCM was added, and the solution was washed with water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give G-53a.
[0540] The following intermediate G-53 (Table 41) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 42] TIFF2024543967000226.tif233165 TIFF2024543967000227.tif160165
[0541] Experimental procedure for the synthesis of G-54a [ka] G-11b (200 mg, 449 μmol, 1.0 equiv.), tert-butyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (148 mg, 629 μmol, 1.4 equiv.), cesium carbonate (293 mg, 0.899 mmol, 2.0 equiv.), CuI (17.1 mg, 90 μmol, 0.20 equiv.), and 4,7-dimethoxy-1,10-phenanthroline were dissolved in DMF (1 mL). The mixture was purged with argon and stirred at 80 °C for 24 h. After complete conversion, the reaction mixture was treated with a few drops of aqueous ammonia, and the product was isolated by RP chromatography to give G-54a.
[0542] The following intermediate G-54 (Table 42) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 43]
[0543] Experimental procedure for the synthesis of G-55a [ka] To a stirred solution of G-11b (700 mg, 1.57 mmol, 1.0 equiv.) in ACN (14.0 mL) under argon at 0 °C, tetraethylammonium cyanide (368.1 mg, 2.36 mmol, 1.50 equiv.) was added, followed by 1,4-diazabicyclo[2.2.2]octane (52.9 mg, 0.47 mmol, 0.3 equiv.). The reaction mixture was stirred overnight at room temperature until TLC showed complete conversion. The solvent was removed under reduced pressure. The crude product was purified by NP chromatography to give G-55a (HPLC method: A; t ret =1.48 minutes; [M+H] + =436).
[0544] Experimental procedure for the synthesis of G-56a [ka] To a stirred solution of G-55a (300 mg, 0.69 mmol, 1.0 equiv.) in THF (2.0 mL) and water (2.0 mL), NaOH (83 mg, 2.1 mmol, 3.0 equiv.) was added at room temperature, and the reaction mixture was then stirred at 50° C. for 90 min until TLC showed complete conversion. The solvent was removed under reduced pressure. The crude product was purified by NP chromatography to give G-56a (HPLC method: A; t ret =0.97 minutes; [M+H] + =455).
[0545] Experimental procedure for the synthesis of G-57a [ka] To a stirred mixture of G-56a (100 mg, 0.22 mmol, 1.0 equiv.) and HATU (126 mg, 0.33 mmol, 1.50 equiv.) in dioxane (2.0 mL), DIPEA (112 μL, 0.66 mmol, 3.0 equiv.) was added at room temperature, and the reaction mixture was then stirred at room temperature for 30 min. Morpholine (21.1 μL, 0.242 mmol, 1.10 equiv.) was added, and the mixture was stirred at room temperature overnight until complete conversion. The crude product was purified by RP chromatography to give product G-57a (HPLC method: D; t ret =0.67 minutes; [M+H] + =524).
[0546] Experimental procedure for the synthesis of G-58a [ka] G-31a (150 mg, 0.28 mol, 1.0 equiv) was dissolved in DCM (2 mL) and N,N-dimethylprop-2-ynamide (30.2 mg, 0.31 mmol, 1.1 equiv), copper(I) iodide (10.8 mg, 0.06 mol, 0.2 equiv), and DIPEA (98.9 μL, 0.56 mmol, 2 equiv) were added. The reaction was stirred at room temperature for 20 min. After complete conversion, the reaction was extracted with DCM / NaHCO. The organic phase was concentrated under reduced pressure and purified by RP chromatography to afford G-58a.
[0547] The following intermediate G-58 (Table 43) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 44] TIFF2024543967000235.tif119165
[0548] Experimental procedure for the synthesis of G-59a [ka] G-21a (144 mg, 0.36 mmol, 1.0 equiv.) and B-5b (80.0 mg, 0.49 mmol, 1.37 equiv.) were dissolved in dioxane (1.4 mL) and degassed with argon. [BrettPhos Pd(crotyl)]OTf (24 mg, 0.03 mmol, 0.08 equiv.) was added, followed by NaOtBu (222 μL, 0.44 mmol, 1.25 equiv.) at room temperature. The reaction was stirred at 60 °C for 30 min. After complete conversion, the solution was filtered and purified by RP chromatography to give the desired product G-59a.
[0549] The following intermediate G-59 (Table 44) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 45]
[0550] Experimental procedure for the synthesis of G-60a [ka] G-8f (2.4 g, 0.01 mol, 1 equiv.) was dissolved in THF (100 mL), triethylamine (2.09 mL, 0.02 mol, 3.0 equiv.) and dimethylaminopyridine (122 mg, 1.0 mmol, 0.2 equiv.) were added, and the reaction was stirred at room temperature for 5 min. The reaction was cooled to 0 °C, and Boc-anhydride (2.18 g, 0.01 mol, 2.0 equiv.) was added. The reaction was stirred at room temperature for 16 h. After complete conversion, water was added, and the reaction was extracted with DCM. The combined organic phase was concentrated under reduced pressure and purified by NP chromatography to yield the desired product G-60a as a mixture of diastereomers. The diastereomeric mixture G-60a was separated by SFC (column: (R,R) Whelk-01 (250 x 30, 5μ); 55% CO2, 45% cosolvent = 0.5% i-propylamine in isopropanol, flow rate: 100 g / min, temperature: 30°C) to yield G-60a1 and G-60a2 (Table 45). [Table 46]
[0551] Experimental procedure for the synthesis of G-61a [ka] G-45b (204 mg, 0.335 mmol, 1.0 equiv) was dissolved in MeOH (1 mL) and 4 M HCl (0.42 mL, 1.67 mmol, 5.0 equiv) was added. The reaction was stirred at 60 °C for 3 h. After complete conversion, the reaction mixture was quenched by the addition of NaHCO and extracted with DCM. The combined organic phases were filtered and concentrated under reduced pressure. The residue was purified by RP chromatography to give the desired product G-61a.
[0552] The following intermediate G-61 (Table 46) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 47] TIFF2024543967000242.tif218165 TIFF2024543967000243.tif230165
[0553] Experimental procedure for the synthesis of G-62a [ka] G-45w (135 mg, 217 μmol, 1.0 equiv) was dissolved in DCM (1.0 mL) and trifluoroacetic acid (0.50 mL, 6.49 mmol, 30 equiv). The reaction was stirred at room temperature for 1 h. After complete conversion, the solvent was removed under reduced pressure. The residue was dissolved in DCM and extracted with saturated aqueous Na2CO3. The combined organic phases were dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by RP chromatography to give G-62a (HPLC method: B; t ret =0.93 minutes; [M+H] + =521).
[0554] Experimental procedure for the synthesis of G-63a [ka] G-45a (124 mg, 0.251 mmol, 1.0 equiv) was dissolved in DCM (1 mL) under argon and cooled to 0 °C. Formaldehyde (22.5 μL, 0.301 mmol, 1.2 equiv) was added, followed by sodium triacetoxyborohydride (224 mg, 1.01 mmol, 4.0 equiv). The solution was stirred at 0 °C for 30 min. After complete consumption of the starting material, the reaction was quenched by the addition of water. The aqueous phase was extracted with DCM. The combined organic phases were dried, filtered, and concentrated under reduced pressure. The residue was purified by RP chromatography to give the desired product G-63a.
[0555] The following intermediate G-63 (Table 47) can be obtained in a similar manner. The deuterated intermediate G-63 was obtained in a similar manner, but replacing sodium triacetoxyborohydride with sodium triacetoxyborodeuteride. The crude product was purified by chromatography if necessary. [Table 48]
[0556] Experimental procedure for the synthesis of G-64a [ka] G-48af (272 mg, 0.48 mmol, 1 equiv.) was dissolved in MeOH (2 mL) and HCl (4 M in dioxane, 363 μL 1.45 mmol, 3.0 equiv.) was added. The reaction was stirred at room temperature for 1.5 h. After complete conversion, the reaction was filtered and extracted with NaHCO3 / DCM (3x). The combined organic phases were concentrated under reduced pressure and purified by RP chromatography to give product G-64a (HPLC method: A; t ret =1.10 minutes; [M+H] + =478).
[0557] Experimental procedure for the synthesis of G-65a [ka] G-45p (150 mg, 0.24 mmol, 1 equiv.) was dissolved in ACN (2 mL). The reaction was stirred in a microwave at 150° C. for 4 h. After complete conversion, the reaction was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-65a (HPLC method: C, t ret =0.659; [M+H] + =537).
[0558] Experimental procedure for the synthesis of G-66a [ka] G-8a (87.0 mg, 0.176 mmol, 1.0 equiv.) was dissolved in ACN (1 mL) and DIPEA (121.0 μL, 0.704 mmol, 4.0 equiv.), and [(3S)-tetrahydrofuran-3-yl] 4-methylbenzenesulfonate (139 mg, 0.528 mmol, 3.0 equiv.) was added. The reaction mixture was stirred at 70° C. until complete conversion was observed. The mixture was diluted with saturated aqueous NaHCO3 and extracted with DCM. The organic phases were combined, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in DMF and purified by RP chromatography to give the desired product G-66a (HPLC method: A, t ret =1.48 minutes; [M+H] + =565).
[0559] Experimental procedure for the synthesis of G-67a [ka] G-61c (60.0 mg, 0.13 mmol, 1.0 equiv) was dissolved in ACN (0.5 mL), cesium carbonate (82.0 mg, 0.25 mmol, 2.0 equiv) was added, and the mixture was stirred at room temperature for 30 min. B-13a (65.9 mg, 0.25 mmol, 2.0 equiv) was added. The reaction mixture was stirred at 85 °C for 2 h. After complete conversion, the reaction was extracted with DCM / water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-67a.
[0560] The following intermediate G-67 (Table 48) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 49]
[0561] Experimental procedure for the synthesis of G-68a [ka] G-61c (60 mg, 0.13 mmol, 1 equiv), 2-(chloromethyl)oxazole (23.4 mg, 0.19 mmol, 1.5 equiv), and KCO (34.8 mg, 0.25 mmol, 2.0 equiv) were dissolved in DMF (0.5 mL) and stirred at 60 °C for 30 min. After complete conversion, the reaction mixture was extracted with DCM / water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-68a.
[0562] The following intermediate G-68 (Table 49) is accessible in an analogous manner using the appropriate alkyl halide. The crude product is purified by chromatography if necessary. [Table 50]
[0563] Experimental procedure for the synthesis of G-69a [ka] G-48ac (152 mg, 0.31 mmol, 1.0 equiv) was dissolved in DCM (6 mL) and palladium (10% on carbon, 60 mg) was added. The reaction was stirred under 7 bar of H at room temperature for 4 h. After complete conversion, the reaction was filtered and concentrated under reduced pressure. The residue was purified by RP chromatography to give the desired product G-69a.
[0564] The following intermediate G-69 (Table 50) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 51]
[0565] Experimental procedure for the synthesis of G-85a [ka] G-53k (600 mg, 1.10 mmol, 1.0 equiv) was dissolved in DMSO (4.0 mL) and cesium carbonate (539 mg, 1.66 mmol, 1.5 equiv), B-13c (269 mg, 1.10 mmol, 1.0 equiv) was added, and the reaction mixture was stirred at 65° C. for 12 h. After complete conversion, the desired product was isolated by RP chromatography to give G-85a.
[0566] The following intermediate G-85 (Table 51) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 52]
[0567] Experimental procedure for the synthesis of G-86a [ka] G-12b (2.00 g, 4.23 mmol, 1 equiv.), ethyl 1H-pyrazole-5-carboxylate (936 mg, 6.34 mmol, 1.5 equiv.), and cesium carbonate (4.59 g, 8.46 mmol, 2 equiv.) were dissolved in THF (20 mL). The reaction was stirred at 70 °C for 2 h. After complete conversion, DCM was added and the solution was washed with water. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give G-86a.
[0568] The following intermediate G-86 (Table 52) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 53]
[0569] Experimental procedure for the synthesis of G-88a [ka] G-11b (4.00 g, 8.99 mmol, 1 equiv.), 2-(1H-pyrazol-3-yl)acetic acid hydrochloride (1.73 g, 10.34 mmol, 1.15 equiv.), and cesium carbonate (8.79 g, 26.97 mmol, 3 equiv.) were dissolved in DMSO (20 mL). The reaction was stirred at 90 °C for 1.5 h. After complete conversion to the desired intermediate, the reaction mixture was cooled to room temperature, and isopropylamine (1.55 mL, 17.98 mmol, 2.0 equiv.), 1-methylimidazole (1.43 mL, 17.98 mmol, 2.0 equiv.), and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (5.15 g, 17.98 mmol, 2.0 equiv.) were added, and the mixture was stirred at room temperature for 15 min. After complete conversion, DCM was added and the solution was washed with water and brine. The organic phase was concentrated under reduced pressure and purified by RP chromatography to give G-88a.
[0570] The following intermediate G-88 (Table 53) is available in a similar manner: The crude product is purified by chromatography if necessary. [Table 54]
[0571] Synthesis of aminocyanothiophenes I and II.
[0572] Experimental procedure for the synthesis of I-1 [ka] To a solution of G-12b (76.1 mg, 0.157 mmol, 1.00 equiv.) and molecular sieves (3 Å) in MeOH (2 mL) under an argon atmosphere, malononitrile (14.5 mg, 0.209 mmol, 1.33 equiv.), sulfur (10.1 mg, 0.312 mmol, 2.00 equiv.), and β-alanine (19.4 mg, 0.218 mmol, 1.40 equiv.) were added. The reaction mixture was stirred at 80 °C overnight. After complete conversion, the reaction mixture was cooled to room temperature, filtered, and extracted with DCM and saturated aqueous NaHCO3. The organic phases were combined and concentrated under reduced pressure. The residue was dissolved in ACN and water and purified by basic RP chromatography to give the desired product I-1 (HPLC method: A, t ret =2.16 minutes; [M+H] + =525).
[0573] Experimental procedure for the synthesis of I-2 [ka] G-30a (80.0 mg, 154 μmol, 1.00 equiv.), malononitrile (64.2 mg, 953 μmol, 6.20 equiv.), sulfur (23.1 mg, 791 μmol, 4.70 equiv.), β-alanine (60.9 mg, 684 μmol, 4.50 equiv.), and magnesium sulfate (23.5 mg, 195 μmol, 1.30 equiv.) were suspended in EtOH (2.0 mL) and stirred at 80 °C for 18 h. The reaction mixture was diluted with EtOAc, filtered, and washed with saturated aqueous NaHCO. The organic phase was separated, and the remaining aqueous phase was extracted with EtOAc (2x). The combined organic phases were dried over magnesium sulfate and evaporated, and the resulting residue was purified by RP chromatography to give I-2.
[0574] The following final compounds I (Table 54) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 55] TIFF2024543967000265.tif241165 TIFF2024543967000266.tif250165 TIFF2024543967000267.tif244165 TIFF2024543967000268.tif247165 TIFF2024543967000269.tif241165 TIFF2024543967000270.tif157165
[0575] Experimental procedure for the synthesis of I-37 [ka] G-34h (91.0 mg, 0.160 mmol, 1.00 equiv), ammonium acetate (26.3 mg, 0.320 mmol, 2.00 equiv), and sulfur (10.3 mg, 0.320 mmol, 2.00 equiv) were suspended in EtOH (1.0 mL) and stirred at 60 °C for 15 min. Malonitrile (22.3 mg, 0.320 mmol, 2.00 equiv) was added. The reaction was stirred at 80 °C for 5 h. After complete conversion, the mixture was diluted with DMSO, filtered, and purified by RP chromatography to give I-37.
[0576] The following final compounds I (Table 55) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 56] TIFF2024543967000273.tif130165
[0577] Experimental procedure for the synthesis of I-40 [ka] I-2 (52 mg, 87 μmol, 1.0 equiv) was dissolved in DCM (1.0 mL) and formaldehyde (6.2 μL, 82 μmol, 1.0 equiv) was added. The solution was stirred at room temperature for 4 h, then sodium triacetoxyborohydride (23 mg, 0.10 mmol, 1.2 equiv) was added, and the suspension was stirred for 2 h. The reaction mixture was quenched with water, diluted with DCM, and washed with water. The organic phase was separated, and the remaining aqueous phase was extracted with DCM (2×). The combined organic phases were washed with brine, dried over magnesium sulfate, and evaporated, and the resulting residue was purified by RP chromatography to give I-40.
[0578] The following final compounds I (Table 56) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 57]
[0579] Experimental procedure for the synthesis of I-44 [ka] I-3 (51 mg, 83 μmol, 1.0 equiv) was dissolved in THF and cooled in an ice / water bath for 15 min, then NaH (60% in mineral oil, 6.5 mg, 0.16 mmol, 2.0 equiv) was added and stirred for 10 min. Methyl iodide (5.7 μL, 9.2 μmol, 1.1 equiv) was added, the reaction was warmed to room temperature, and stirred at room temperature for 18 h. After complete conversion, the reaction mixture was extracted with EtOAc (3×). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in DMSO and purified by RP chromatography to give the desired product I-44 (HPLC method: A, t ret =1.69 minutes; [M+H]=629).
[0580] Experimental procedure for the synthesis of I-45 [ka] I-38 (225 mg, 0.31 mmol, 1.0 equiv) was dissolved in DCM / TFA (1:1, 2.0 mL) and the reaction was stirred at room temperature for 3 h. After complete conversion, the reaction mixture was concentrated under reduced pressure and purified by RP chromatography to give I-45 (HPLC method: A, t ret =1.47 minutes; [M+H]=619).
[0581] Experimental procedure for the synthesis of I-51 [ka] To a suspension of I-46 (2.73 g, 4.14 mmol, 1.0 equiv) in ethanol (47 mL) was added potassium hydroxide (1.91 g, 29.0 mmol, 7.0 equiv) dissolved in water (53 mL), and the mixture was stirred at room temperature for 2 h. After complete conversion, the mixture was acidified to pH 6, the ethanol was removed under reduced pressure, and the resulting precipitate was collected by repeated centrifugation, washed with water, and dried under reduced pressure to give the desired product I-51. The crude product was used without further purification.
[0582] The following final compounds I (Table 57) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 58]
[0583] Experimental procedure for the synthesis of I-53 [ka] To a solution of I-51 (90.1 mg, 0.14 mmol, 1.0 equiv.) in DMSO (0.7 mL) was added (R)-tetrahydrofuran-3-amine hydrochloride (21.9 mg, 0.17 mmol, 1.2 equiv.), 1-methylimidazole (45.6 μL, 0.57 mmol, 4.0 equiv.), and chloro-N,N,N',N'-tetramethylformidinium hexafluorophosphate (57.3 mg, 0.20 mmol, 1.4 equiv.), and the mixture was stirred at room temperature for 1 h. After complete conversion, the mixture was diluted with ACN, and the product was isolated by RP chromatography to give the desired product I-53.
[0584] The following final compounds I (Table 58) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 59] TIFF2024543967000282.tif242165 TIFF2024543967000283.tif110165
[0585] Experimental procedure for the synthesis of II-1 [ka] G-11c (1.20 g, 2.59 mmol, 1.00 equiv), ammonium acetate (319 mg, 4.15 mmol, 1.60 equiv), and sulfur (133 mg, 4.15 mmol, 1.60 equiv) were dissolved in EtOH (12 mL) and stirred at 60 °C for 15 min. Malonitrile (3.77 mL, 4.28 mmol, 1.65 equiv) as a solution in EtOH was added dropwise slowly (mL / h). The reaction was stirred at 80 °C for 5 h. After complete conversion, the reaction was concentrated and purified by NP chromatography. The product fractions were concentrated and extracted with DCM and saturated NaHCO. The organic phase was concentrated under reduced pressure to give II-1.
[0586] The following final compounds II (Table 59) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 60] TIFF2024543967000286.tif99165
[0587] Experimental procedure for the synthesis of II-5 [ka] II-3 (100 mg, 0.152 mmol, 1.00 equiv) was dissolved in DMF (1 mL), sodium azide (17.8 mg 0.274 mmol, 1.80 equiv) was added, and the reaction was stirred at 50 °C for 16 h. After complete conversion, the reaction was extracted with DCM / water. The organic phase was concentrated under reduced pressure to give II-5 (HPLC method: A, t ret =1.63 minutes; [M+H] + =532).
[0588] Experimental procedure for the synthesis of II-6 [ka] II-5 (40 mg, 0.068 mmol, 1.0 equiv.), 3-ethynyl-4-methylpyridine (10 mg, 0.088 mmol, 1.3 equiv.), and copper(I) iodide (2.6 mg, 0.01 mmol, 0.20 equiv.) were dissolved in DCM (500 μL), and DIPEA (24 μL, 0.14 mmol, 2.0 equiv.) was added. The brown solution was stirred at room temperature. After 30 min, additional 3-ethynyl-4-methylpyridine (10 mg, 0.088 mmol, 1.3 equiv.) was added. The reaction mixture was stirred at room temperature for 18 h. After complete conversion, the reaction mixture was extracted with DCM and ammonium chloride solution, dried, filtered, and concentrated. The resulting residue was purified by RP chromatography to give the desired final product II-6 (HPLC method: A, t ret =1.56 minutes; [M+H] + =649).
[0589] Experimental procedure for the synthesis of II-7 [ka] II-3 (100 mg, 0.190 mmol, 1.00 equiv) was suspended in EtOH (700 μL). DIPEA (116 μL, 0.667 mmol, 3.00 equiv) and N,N-dimethylazetidin-3-amine dihydrochloride (41.6 mg, 0.229 mmol, 1.20 equiv) were added, and the reaction mixture was stirred at 80 °C overnight. After complete conversion, the reaction mixture was filtered and purified by RP chromatography to give the desired final product II-7.
[0590] The following final compounds II (Table 60) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 61] TIFF2024543967000291.tif241165 TIFF2024543967000292.tif84165
[0591] Experimental procedure for the synthesis of II-17 [ka] II-1 (0.10 g, 0.18 mmol, 1.0 equiv.) was suspended in DMSO (0.50 mL). DIPEA (0.11 mL, 0.57 mmol, 3.1 equiv.) and (R)-5-methyl-4,7-diazaspiro[2.5]octane dihydrochloride (42 mg, 0.20 mmol, 1.1 equiv.) were added, and the reaction mixture was stirred at 80 °C for 2 h. After complete conversion, the reaction mixture was purified by RP chromatography.
[0592] The following final compounds II (Table 61) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 62]
[0593] Experimental procedure for the synthesis of II-19 [ka] II-3 (80 mg, 0.15 mmol, 1.0 equiv) and B-11a (50.3 mg, 0.31 mmol, 2.0 equiv) were dissolved in THF (1.0 mL), cesium carbonate (123 mg, 0.38 mmol, 2.5 equiv) was added, and the mixture was stirred at 65 °C for 3 h. After complete conversion, saturated NaHCO solution was added, and the product was extracted with DCM. The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was purified by RP chromatography to give the desired final product II-19.
[0594] The following final compounds II (Table 62) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 63] TIFF2024543967000297.tif126165
[0595] Experimental procedure for the synthesis of II-24 [ka] To a solution of II-23 (100 mg, 0.159 mmol, 1.0 equiv) in 1-propanol (1 mL) was added sodium hydroxide (4 M in water, 99.4 μL, 0.40 mmol, 2.5 equiv), and the mixture was stirred at room temperature for 30 min. After complete conversion, saturated NaHCO was added, the mixture was washed with DCM, and the aqueous phase was then acidified with HCl and extracted with DCM. The organic phase was dried, filtered, and concentrated, and the crude product was purified by RP chromatography to give the desired product II-24.
[0596] The following final compounds II (Table 63) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 64]
[0597] Experimental procedure for the synthesis of II-25 [ka] To a solution of II-24 (40 mg, 0.067 mmol, 1.0 equiv) in DMF (0.4 mL) were added oxetan-3-amine hydrochloride (15 mg, 0.133 mmol, 2.0 equiv), DIPEA (22.3 μL, 0.166 mmol, 2.5 equiv), and 1-propanephosphonic anhydride (29.7 μL, 1.00 mmol, 1.5 equiv), and the mixture was stirred at room temperature for 3 h. After complete conversion, saturated NaHCO was added, and the mixture was extracted with DCM. The organic phase was dried, filtered, and concentrated, and the crude product was purified by RP chromatography to give the desired product II-25.
[0598] The following final compounds II (Table 64) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 65] TIFF2024543967000302.tif234165 TIFF2024543967000303.tif147165
[0599] Experimental procedure for the synthesis of II-27 [ka] II-1 (70 mg, 0.1 mmol, 1.0 equiv) was dissolved in dioxane (1 mL), cesium carbonate (2 M, 131 μL, 0.26 mmol, 2.5 equiv) was added, and the resulting suspension was stirred at 80° C. for 10 min. 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (32.7 mg, 0.16 mmol, 1.5 equiv) and XPhos-Pd-G3 (9.34 mg, 0.01 mmol, 0.1 equiv) were added. The reaction was stirred under argon for 10 min, after which the reaction mixture was heated at 80° C. for 18 h. After complete conversion, the reaction mixture was extracted with NaHCO3 and DCM. The organic phase was concentrated under reduced pressure, dissolved in DMSO, and purified by RP chromatography to give the desired product II-27.
[0600] The following final compounds II (Table 65) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 66]
[0601] Experimental procedure for the synthesis of II-30 [ka] To a solution of G-63a (94.0 mg, 0.18 mmol, 1.0 equiv.) and molecular sieves (3 Å) in anhydrous EtOH (2 mL) under an argon atmosphere, malononitrile (64.4 mg, 0.97 mmol, 5.0 equiv.), sulfur (23.8 mg, 0.74 mmol, 4.0 equiv.), and β-alanine (69.5 mg, 0.78 mmol, 4.0 equiv.) were added. The reaction mixture was stirred at 80 °C overnight. After complete conversion, the mixture was cooled to room temperature, filtered, and extracted with DCM and saturated aqueous NaHCO3. The organic phases were combined and concentrated under reduced pressure. The residue was dissolved in ACN and water and purified by basic RP chromatography to give the desired product II-30.
[0602] The following final compounds II (Table 66) can be obtained in a similar manner. The crude product is purified by chromatography if necessary. In the case of II-87, Boc-deprotection was observed during the reaction using G-48r as the starting material. [Table 67] TIFF2024543967000308.tif222165 TIFF2024543967000309.tif246165 TIFF2024543967000310.tif224165 TIFF2024543967000311.tif222165 TIFF2024543967000312.tif224165 TIFF2024543967000313.tif230165 TIFF2024543967000314.tif231165 TIFF2024543967000315.tif213165 TIFF2024543967000316.tif248165 TIFF2024543967000317.tif242165 TIFF2024543967000318.tif218165 TIFF2024543967000319.tif218165 TIFF2024543967000320.tif224165 TIFF2024543967000321.tif250165 TIFF2024543967000322.tif241165 TIFF2024543967000323.tif229165 TIFF2024543967000324.tif236165 TIFF2024543967000325.tif114165
[0603] Experimental procedure for the synthesis of II-143 [ka] G-51a (90 mg, 0.18 mmol, 1.0 equiv), ammonium acetate (22.4 mg, 0.29 mmol, 1.6 equiv), and sulfur (9.32 mg, 0.29 mmol, 1.6 equiv) were dissolved in EtOH (1.20 mL) and stirred at 60 °C for 15 min. Malonitrile (0.26 mL, 0.3 mmol, 1.65 equiv) was added dropwise slowly as a solution in EtOH. The reaction was stirred at 80 °C for 5 h. After complete conversion, DCM was added and extracted three times with water. The combined organic phase was concentrated under reduced pressure, dissolved in DMF / ACN / water, and purified by RP chromatography to give II-143.
[0604] The following final compounds II (Table 67) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 68] TIFF2024543967000328.tif225165 TIFF2024543967000329.tif240165 TIFF2024543967000330.tif204165 TIFF2024543967000331.tif169165
[0605] Experimental procedure for the synthesis of II-160 [ka] To a solution of II-146 (210 mg, 0.29 mmol, 1.0 equiv) in dioxane (3 mL), HCl (4 M in dioxane, 0.29 mL, 1.17 mmol, 4.0 equiv) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was heated to 50° C. and stirred for 6 h. The solvent was removed and the residue was purified by RP chromatography to give II-160.
[0606] The following final compounds II (Table 68) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 69]
[0607] Experimental procedure for the synthesis of II-166 [ka] II-137 (148 mg, 0.21 mmol, 1.0 equiv) was dissolved in DCM (1 mL). TFA (60 μL, 0.83 mmol, 4 equiv) was added, and the reaction was stirred at room temperature for 3 h. After complete conversion, the reaction mixture was concentrated under reduced pressure and purified by RP chromatography to give II-166.
[0608] The following final compounds II (Table 69) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 70]
[0609] Experimental procedure for the synthesis of II-169 [ka] II-142 (70 mg, 0.129 mmol, 1.0 equiv) was dissolved in DCM (1.0 mL), and acetone (100 μL, 1.36 mmol, 10.5 equiv) and acetic acid (1.48 μL, 0.03 mmol, 0.2 equiv) were added. The resulting solution was cooled to 0 °C and stirred for 10 min. Sodium triacetoxyborohydride (115 mg, 0.52 mmol, 4.0 equiv) was then added, and the suspension was stirred for 1 h. The reaction mixture was quenched with water, and the aqueous phase was extracted with DCM. The combined organic phases were evaporated, and the resulting residue was purified by RP chromatography to give II-169.
[0610] Intermediate II (Table 70) is accessible in a similar manner. The crude product is purified by chromatography if necessary. [Table 71]
[0611] Experimental procedure for the synthesis of II-171 [ka] II-54 (50.0 mg, 0.083 mmol, 1.0 equiv) was dissolved in DCM (1 mL) under argon and cooled to -30 °C. Formaldehyde (7.48 μL, 0.100 mmol, 1.3 equiv) was added, followed by sodium triacetoxyborohydride (74.2 mg, 0.333 mmol, 4.0 equiv). The solution was stirred at -30 °C for 30 min. After complete conversion of the starting material, the reaction was quenched by the addition of water. The aqueous phase was extracted with DCM (3x). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in ACN and purified by RP chromatography (gradient elution: 60% to 98% ACN in water) to give the desired product II-171.
[0612] The following final products II (Table 71) are available in a similar manner: The crude products are purified by chromatography if necessary. [Table 72] TIFF2024543967000340.tif134165
[0613] Experimental procedure for the synthesis of II-177 [ka] II-6 (40 mg, 0.07 mmol, 1 equiv.) was dissolved in acetone (720 μL) and an aqueous solution of potassium carbonate (27.5 mg, 0.2 mmol, 3.0 equiv.) in water (280 μL) was added. Acetyl chloride (1 M in acetone, 51.8 mg, 0.07 mmol, 1 equiv.) was added to the reaction, and the reaction mixture was stirred at room temperature for 3 h. After complete conversion, the reaction mixture was concentrated under reduced pressure, dissolved in DMF / water, and purified by RP chromatography to yield II-177.
[0614] The following final compounds II (Table 72) are accessible in a similar manner: The crude product is purified by chromatography if necessary. [Table 73]
[0615] Experimental procedure for the synthesis of II-210 [ka] II-188 (76 mg, 0.13 mmol, 1 equiv.), 4-azidoxane (19.8 mg, 0.15 mmol, 1.1 equiv.), and CuI (2.6 mg, 0.013 mmol, 0.1 equiv.) were suspended in DCM (2.0 mL). DIPEA (53.2 mg, 0.27 mmol, 2.0 equiv.) was added, and the reaction mixture was stirred at 40 °C for 12 h. After complete conversion, the reaction mixture was concentrated under reduced pressure, dissolved in DMF, filtered, and purified by RP chromatography to yield II-210.
[0616] The following final compounds II (Table 73) are available in a similar manner: The crude product is purified by chromatography if necessary. [Table 74]
[0617] The following examples describe the biological activities of the compounds of the present invention without limiting the invention to these examples.
[0618] KRAS::SOS1 AlphaScreen binding assay This assay can be used to determine the efficacy of compounds of the present invention that bind to (mutant) KRAS to inhibit the protein-protein interaction between SOS1 and (mutant) KRAS, e.g., KRAS WT, KRAS G12C, KRAS G12D, KRAS G12V, and KRAS G13D. This inhibits the GEF function of SOS1 and locks the corresponding (mutant) KRAS protein in its inactive GDP-bound state. A low IC in this assay setting 50 The values indicate a strong inhibition of the protein-protein interaction between SOS1 and KRAS.
[0619] Assay description These assays use AlphaScreen technology by Perkin Elmer to measure the inhibitory effect of compounds on KRAS mutant protein-protein interactions.
[0620] These assays use the following (mutated) enzymatic forms of KRAS and interacting proteins at given concentrations:
[0621] KRAS(G12D)1–169, N-terminal 6His tag, C-terminal avi tag (Xtal BioStructures, Inc); final assay concentration 10 nM and SOS1 564–1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 5 nM;
[0622] KRAS (G12C) 1–169, N-terminal 6His tag for purification, cleaved and removed, C-terminal avi tag, biotinylated, mutations: C51S, C80L, C118S (in-house); final assay concentration 7.5 nM and SOS1 564–1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 5 nM;
[0623] KRAS (G12V) 1–169, N-terminal 6His tag for purification, cleaved and removed, C-terminal avi tag, biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM and SOS1 564–1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM;
[0624] KRAS (G13D) 1–169, N-terminal 6His tag for purification, cleaved and removed, C-terminal avi tag, biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM and SOS1 564–1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM;
[0625] KRAS (WT) 1-169, N-terminal 6His tag for purification, cleaved off, C-terminal Avi tag, biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM; and SOS1 564-1049, N-terminal 229GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM.
[0626] Test compounds dissolved in DMSO are dispensed into assay plates (Proxiplate 38 4PLUS, white, PerkinElmer; 6008289) using an Access Labcyte Workstation equipped with a Labcyte Echo55x. For the highest assay concentration selected, 100 μM, 150 nL of compound solution is transferred from a 10 mM DMSO compound stock solution. Eleven 5-fold dilutions per compound are transferred to the assay plate, and compound dilutions are tested in duplicate. DMSO is added as a backfill to a total volume of 150 nL.
[0627] The assay is performed in a dark room under 100 lux using a fully automated robotic system. 150 nl of compound dilution is added to columns 1-24, along with 10 μl of a mixture containing KRAS mutant protein, SOS1 (final assay concentration as described above), and GDP nucleotide (Sigma G7127; final assay concentration 10 μM) in assay buffer (1x PBS, 0.1% BSA, 0.05% Tween 20).
[0628] After 30 minutes of incubation, 5 μl of AlphaScreen bead mix in assay buffer is added to columns 1 to 23. The bead mix consists of AlphaLISA glutathione acceptor beads (PerkinElmer, Cat No AL109) and AlphaScreen streptavidin donor beads (PerkinElmer Cat No 6760002) in assay buffer, each at a final assay concentration of 10 μg / ml.
[0629] The plates are kept at room temperature in a darkened incubator. After a further 60 min incubation, the signal is measured on a PerkinElmer Envision HTS multilabel reader using AlphaScreen specs from PerkinElmer.
[0630] Each plate contains up to 16 wells of negative controls (DMSO instead of test compound; containing KRAS mutant::SOS1 GDP mix and bead mix; column 23) and 16 wells of positive controls (DMSO instead of test compound; containing KRAS mutant::SOS1 GDP mix but no bead mix; column 24), depending on the dilution strategy (plate-wise or serial).
[0631] As an internal control, a known inhibitor of the KRAS mutant::SOS1 interaction can be measured on each compound plate.
[0632] IC50 values are calculated and analyzed using a four-parametric logistic model using the MEGALAB IC50 application from Boehringer Ingelheim.
[0633] The table of example compounds disclosed herein includes the IC determined using the above assay. 50 Contains values (see Table 74).
[0634] [Table 75] TIFF2024543967000346.tif247165 TIFF2024543967000347.tif247165 TIFF2024543967000348.tif246165 TIFF2024543967000349.tif247165 TIFF2024543967000350.tif247165 TIFF2024543967000351.tif114165
[0635] Ba / F3 cell model generation and proliferation assay Ba / F3 cells were obtained from DSMZ (ACC300, Lot 17) and grown in RPMI-1640 (ATCC30-2001) + 10% FCS + 10 ng / mL IL-3 at 37°C in a 5% CO atmosphere. Plasmids containing KRASG12 mutants (i.e., G12D, G12C, G12V) were obtained from GeneScript. To generate a KRASG12-dependent Ba / F3 model, Ba / F3 cells were transduced with retroviruses containing vectors carrying KRASG12 isoforms. Platinum-E cells (Cell Biolabs) were used for retroviral packaging. The retrovirus was added to Ba / F3 cells. To ensure infection, 4 μg / mL polybrene was added and the cells were spinfected. Infection efficiency was confirmed by measuring GFP-positive cells using a cell analyzer. Cells with an infection efficiency of 10%-20% were further cultured and 1 μg / mL puromycin selection was initiated. Parental Ba / F3 cells were used as a control to demonstrate the selection status. Selection was considered successful when the parental Ba / F3 cell culture died. To evaluate the transforming potential of the KRASG12 mutant, the growth medium was no longer supplemented with IL-3. Ba / F3 cells carrying the empty vector were used as a control. Puromycin was removed approximately 10 days before the experiment.
[0636] For the proliferation assay, Ba / F3 cells were cultured in growth medium (RPMI-1640 + 10% FCS) at a concentration of 1.5 × 10 3Cells are seeded into 384-well plates at 60 μL / well. Compounds are added using an Access Labcyte Workstation equipped with a Labcyte Echo 550 or 555 accoustic dispenser. All treatments are performed in technical duplicates. Treated cells are incubated for 72 hours at 37°C in 5% CO2. The viability stain AlamarBlue™ (ThermoFisher) is added and fluorescence is measured using a PerkinElmer Envision HTS MultilabelReader. Raw data are imported into Boehringer Ingelheim's proprietary software, MegaLab, and analyzed (curve fitting based on the PRISM program (GraphPad Inc.)).
[0637] IC of representative compounds of the present invention measured in this assay 50 The values are shown in Table 75.
[0638] [Table 76] TIFF2024543967000353.tif247165 TIFF2024543967000354.tif246165 TIFF2024543967000355.tif247165 TIFF2024543967000356.tif245165 TIFF2024543967000357.tif236165
[0639] Additional proliferation assays using mutant cancer cell lines NCI-H358 CTG proliferation assay (120 hours) (NSCLC, G12C) NCI-H358 cells (ATCC No. CRL-5807) are dispensed into white-bottom opaque 96-well plates (PerkinElmer cat. no. 5680) at a density of 2000 cells per well in 100 μL of RPMI-1640 ATCC-Formulation (Gibco #A10491) + 10% FCS (fetal bovine serum) (Assay 1) or into flat-bottom black clear 384-well plates (Greiner, PNr. 781091) at a density of 200 cells per well in 60 μL of RPMI-1640 ATCC-Formulation (Gibco #A10491) + 10% FCS (fetal bovine serum) (Assay 2). Cells are incubated overnight at 37°C in a humidified tissue culture incubator with 5% CO2. Compounds (10 mM stock in DMSO), including a DMSO control, are added in a logarithmic dose series using an HP Digital Dispenser D300 (Tecan) (Assay 1) or an ECHO acoustic liquid handler system (Beckman Coulter) (Assay 2) and normalized to the added DMSO. For the TO time point measurement, untreated cells are analyzed at the time of compound addition. Plates are incubated for 120 hours, and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (listed as % control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of the DMSO control cells. IC 50 Values are determined from viability measurements by nonlinear regression using a four-parameter model.
[0640] NCI-H2122 CTG Proliferation Assay (120 hours) (NSCLC, G12C) The CTG assay was designed to quantitatively measure the proliferation of NCI-H2122 cells (ATCC CRL-5985) using the CellTiter Glow assay kit (Promega G7571). Cells were grown in RPMI medium (ATCC) supplemented with fetal bovine serum (Life Technologies, Gibco BRL, Cat. No. 10270-106). On day 0, 200 NCI-H2122 cells were seeded in 60 μL of RPMI ATCC + 10% FCS + Penstrep in a clear, flat-bottom, black 384-well plate (Greiner, PNr. 781091). The cells were then incubated in the plate overnight at 37°C in a CO2 incubator. On day 1, compounds (10 mM stock in DMSO), including a DMSO control, were added using an ECHO acoustic liquid handler system (Beckman Coulter). Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (listed as % control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of the DMSO control cells. IC 50 Values are determined from viability measurements by nonlinear regression using a four-parameter model.
[0641] AsPC-1 CTG proliferation assay (120 hours) (pancreatic cancer, G12D) The CTG assay was designed to quantitatively measure the proliferation of AsPC-1 cells (ATCC RL-5985) using the CellTiter Glow assay kit (Promega G7571). Cells were grown in RPMI medium (ATCC) supplemented with fetal bovine serum (Life Technologies, Gibco BRL, Cat. No. 10270-106). On day 0, 2000 AsPC-1 cells were seeded in 60 μL of RPMI ATCC + 10% FCS + Penstrep in a flat-bottom, clear 384-well plate (Greiner, PN r. 781091). The cells were then incubated in the plate overnight at 37°C in a CO2 incubator. On day 1, compounds (10 mM stock in DMSO), including a DMSO control, were added using an ECHO acoustic liquid handler system (Beckman Coulter). Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (listed as % control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of the DMSO control cells. IC 50 Values can be determined from viability measurements by non-linear regression using a four-parameter model.
[0642] GP2D proliferation assay (120 hours) (colon cancer, G12D) GP2D cells (ATCC No. CRL-5807) are dispensed into white flat-bottom 384-well pla...
Claims
1. Formula (I) [C194] [In the formula, R 1a and R 1b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; R 2a and R 2b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 and / or selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; In some cases, R 1a Or R 1b and R 2a Or R 2b are taken together with the carbon atom to which they are attached to form a cyclopropane ring, Z is -(CR 6a R 6b ) n - and Each R 6a and R 6b is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; R 6a and R 6b together with the carbon atom to which they are attached form a cyclopropane ring, n is selected from the group consisting of 0, 1 and 2; R 3 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -N 3 , C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 All aryls and 5- to 10-membered heteroaryls may be one or more of the same or different R 7 and / or R 8 and is optionally and independently substituted by Each R 7 is -OR 8 , -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and the divalent substituent =O; Each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10All aryls and 5- to 10-membered heteroaryls may be one or more of the same or different R 9 and / or R 10 and optionally substituted by Each R 9 is -OR 10 , -NR 10 R 10 and -C(O)NR 10 R 10 are independently selected from the group consisting of Each R 10 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 Alkyl is C 1-6 C optionally substituted with alkyl 1-6 Alkoxy, C 3-10 optionally substituted with a substituent selected from the group consisting of cycloalkyl and 3- to 11-membered heterocyclyl; W is nitrogen (-N=) or -CH=; V is nitrogen (-N=) or -CH=; U is nitrogen (-N=) or -C(R 11 )= R 11 is hydrogen, halogen and C 1-4 alkoxy; Ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and triazole; R 4 If present, each R 4 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, Cyano-C 1-6 Alkyl, halogen, -OH, -NH 2 , -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl) 2, -C.N., C. 3-5 independently selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; p is selected from the group consisting of 0, 1, 2 and 3; R 5 is one or more of the same or different C 1-6 Alkyl, C 1-6 3- to 11-membered heterocyclyl optionally substituted by alkoxy or 5- to 6-membered heterocyclyl, where C 1-6 Alkyl is optionally substituted by cyclopropyl or R 5 is —O—C substituted by 3- to 11-membered heterocyclyl 1-6 alkyl, where the 3- to 11-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted by Each R 12 is C 1-6 Alkyl, C 1-6 alkoxy, halogen and 3- to 11-membered heterocyclyl. or a salt thereof.
2. Formula (Ia) [C195] [In the formula, A, V, U, W, R 3 and R 5 is as defined in claim 1. or a salt thereof.
3. Formula (Ib) [C196] [In the formula, A, V, U, W, R 3 and R 5 is as defined in claim 1. or a salt thereof.
4. Ring A is [C197] The compound or salt thereof according to any one of claims 1 to 3, selected from the following:
5. R 3 3-11 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein 3-11 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryls are each independently selected from one or more of the same or different R 7 and / or R 8 and is optionally and independently substituted by Each R 7 But -OH, C 1-6 Alkoxy, -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and the divalent substituent =O; Each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryls are each independently selected from one or more of the same or different R 9 and / or R 10 and optionally substituted by Each R 9 But, -OR 10 , -NR 10 R 10 and -C(O)NR 10 R 10 are independently selected from the group consisting of Each R 10 is hydrogen, C 1-6 Alkyl, C 3-10independently selected from the group consisting of cycloalkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein C 1-6 Alkyl is C 1-6 C optionally substituted with alkyl 1-6 Alkoxy, C 3-10 The compound or salt thereof according to any one of claims 1 to 4, which is optionally substituted with a substituent selected from the group consisting of cycloalkyl and 3- to 11-membered heterocyclyl.
6. R 3 is selected from the group consisting of 3- to 11-membered heterocyclyl and 5- to 10-membered heteroaryl, wherein the 3- to 11-membered heterocyclyl and the 5- to 10-membered heteroaryl are all selected from the group consisting of one or more of the same or different R 7 and / or R 8 and is optionally and independently substituted by Each R 7 But, -OR 8 , -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8 and the divalent substituent =O; Each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryls are each independently selected from one or more of the same or different R 9 and / or R 10 and optionally substituted by Each R 9 is -OH or C 1-6 is an alkoxy; Each R 10 But, C 1-6 The compound or salt thereof according to any one of claims 1 to 5, wherein each of the compound and the salt is independently selected from the group consisting of alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl.
7. R 5 but, [C198] The compound or salt thereof according to any one of claims 1 to 6, selected from the group consisting of:
8. R 5 but, [C199] The compound according to claim 7, or a salt thereof, selected from the group consisting of:
9. W is nitrogen (-N=); V is nitrogen (-N=); U is -C(R 11 )= R 11 is hydrogen, halogen and C 1-4 The compound or salt thereof according to any one of claims 1 to 8, wherein the aryl group is selected from alkoxy.
10. R 3 but, [chemical 200] is selected from the group consisting of Each of said groups is attached to formula (I) at any ring position by removal of a hydrogen atom, and one or more of the same or different R 7 and / or R 8 and optionally and independently substituted by Each R 7 But, -OR 8 , -NR 8 R 8 , halogen, -CN, -C(=O)R 8 , -C(=O)OR 8 , -C(=O)NR 8 R 8 , -NHC(=O)OR 8and the divalent substituent =O; Each R 8 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 11-membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryls are each independently selected from one or more of the same or different R 9 and / or R 10 and optionally substituted by Each R 9 is -OH or C 1-6 is an alkoxy; Each R 10 But, C 1-6 The compound or salt thereof according to any one of claims 1 to 9, wherein each of the compound and the salt is independently selected from the group consisting of alkyl, 3- to 11-membered heterocyclyl, and 5- to 10-membered heteroaryl.
11. R 3 but, [chemical 201] [ka] [ka] [ka] [ka] [ka] [ka] The compound or salt thereof according to any one of claims 1 to 10, selected from the group consisting of:
12. A compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for use as a medicament.
13. 12. A compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for use in treating and / or preventing cancer.
14. 14. The compound or a pharma- ceutically acceptable salt thereof for use according to claim 13, wherein said compound or salt is administered in combination with one or more other pharmacologically active substances.
15. 15. The compound or a pharmaceutically acceptable salt thereof for use according to claim 13 or 14, wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, colon cancer, bile duct cancer, appendix cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, gastroesophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer and sarcoma.
16. The compound or a pharma- ceutically acceptable salt thereof for use according to any one of claims 13 to 15, wherein the cancer comprises tumor cells having a KRAS mutation or an amplification of KRAS wild type.
17. 17. The compound or a pharma- ceutically acceptable salt thereof for use according to claim 16, wherein the KRAS mutation is selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V and KRAS G13D.
18. A compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, and one or more other pharmacologically active substances. Pharmaceutical compositions.
Citation Information
Patent Citations
Heterocyclic spiro compounds and methods of use for treating cancer
JP2021532157A
Cyclofused 2-amino-3-cyanothiophenes and derivatives for treating cancer
JP2023528623A
KRAS g12c inhibitors
US20210179633A1
Cited By
Fused 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer
JP2024543983A
